<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004315.pub3" GROUP_ID="MOVEMENT" ID="740703050518395759" MERGED_FROM="" MODIFIED="2016-05-12 11:06:52 +0100" MODIFIED_BY="Ema Roque" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2016-05-12 11:02:32 +0100" MODIFIED_BY="Ema Roque">
<TITLE>Botulinum toxin type B for cervical dystonia</TITLE>
<CONTACT>
<PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>João</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Costa</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Co-ordinating Editor</POSITION>
<EMAIL_1>jncosta@medicina.ulisboa.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+351 217802120</PHONE_1>
<PHONE_2/>
<FAX_1>+351 21 7802129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-05-12 11:02:32 +0100" MODIFIED_BY="Ema Roque">
<PERSON ID="z1309131050199323179683584225320" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Raquel</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Marques</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>amarques5@campus.ul.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Av. Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>These authors contributed equally to this work</FOOTNOTE>
</PERSON>
<PERSON ID="z1307091141448665579807736261374" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gonçalo</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Duarte</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>gduarte@campus.ul.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+351914662729</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION>Lisboa</REGION>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+351914662729</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>These authors contributed equally to this work</FOOTNOTE>
</PERSON>
<PERSON ID="z1408111518211702342261129499685" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Filipe</FIRST_NAME>
<MIDDLE_INITIALS>B</MIDDLE_INITIALS>
<LAST_NAME>Rodrigues</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Researcher</POSITION>
<EMAIL_1>filipebrodrigues@gmail.com</EMAIL_1>
<EMAIL_2>f.rodrigues@ucl.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE>00447484169226</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>These authors contributed equally to this work</FOOTNOTE>
</PERSON>
<PERSON ID="z1309131047147899672215461982225" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Mafalda</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Castelão</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>mcastelao@outlook.com</EMAIL_1>
<EMAIL_2/>
<URL>www.medicina.ulisboa.pt</URL>
<MOBILE_PHONE>+351969668033</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>These authors contributed equally to this work</FOOTNOTE>
</PERSON>
<PERSON ID="6005" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Joaquim</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ferreira</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>joaquimjferreira@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 797 3453</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 780 2129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6111" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Cristina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sampaio</LAST_NAME>
<SUFFIX/>
<POSITION>Chief Medical Officer</POSITION>
<EMAIL_1>Cristina.Sampaio@chdifoundation.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>CHDI Foundation</ORGANISATION>
<ADDRESS_1>155 Village Boulevard</ADDRESS_1>
<ADDRESS_2>Suite 200</ADDRESS_2>
<CITY>Princeton</CITY>
<ZIP>08540</ZIP>
<REGION>NJ</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14820" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>A</FIRST_NAME>
<MIDDLE_INITIALS>Peter</MIDDLE_INITIALS>
<LAST_NAME>Moore</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>peter.moore@thewaltoncentre.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Walton Centre NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Lower Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 151 225 3611</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 151 529 4638</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>João</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Costa</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Co-ordinating Editor</POSITION>
<EMAIL_1>jncosta@medicina.ulisboa.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+351 217802120</PHONE_1>
<PHONE_2/>
<FAX_1>+351 21 7802129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-04-21 16:06:02 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="26" MONTH="10" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="10" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="7" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-22 00:09:12 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-04-22 00:09:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>New authorship, accumulation of changes, re-assessment and writing according to new quality standards, addition of a summary of findings table</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-04-22 00:05:34 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="10" YEAR="2015"/>
<DESCRIPTION>
<P>A new trial enrolling 230 participants was included in the meta-analysis and systematic review (Kaji 2013)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-04-22 00:04:40 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-04-22 00:04:40 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="7" MONTH="6" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-04-22 00:07:44 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2016-04-22 00:07:44 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-04-22 00:07:44 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Movement Disorders</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Walton Centre for Neurology and Neurosurgery</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-04-22 18:35:02 +0100" MODIFIED_BY="Ana Raquel Marques">
<SUMMARY MODIFIED="2016-04-22 16:18:34 +0100" MODIFIED_BY="Ana Raquel Marques">
<TITLE MODIFIED="2016-03-02 12:07:07 +0000" MODIFIED_BY="[Empty name]">Botulinum toxin for people with involuntary posturing of the head</TITLE>
<SUMMARY_BODY MODIFIED="2016-04-22 16:18:34 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>Undesired, uncontrollable, and often painful placement of the head, a disease called cervical dystonia or spasmodic torticollis, is a relatively uncommon condition (affecting 57 to 280 people per million) that can be very disabling and can compromise quality of life. Mostly the cause is unknown and no cure exists. As this is typically a chronic disease, it requires long-term treatment.</P>
<P>Botulinum toxin (Bt) is a natural powerful chemical produced by a bacterium called <I>Clostridium botulinum,</I> that can cause severe paralysis in animals and humans<I>. </I>It can also be used to treat many conditions, in particular those with involuntary muscle contractions, such as cervical dystonia, by delivering intra-muscular Bt injections. There are different types of Bt, not all available for therapeutic purposes. Bt type A (BtA) is normally the first-used treatment in cervical dystonia. However, not all patients respond to BtA injections, and in such situations, treatment with Bt type B (BtB) is of special interest.</P>
<P>This update of a previous Cochrane review aimed to assess the effectiveness (reduction in severity, disability and pain) and safety of BtB in cervical dystonia, in comparison to placebo (a pretend medicine).</P>
<P>We performed a literature search in October 2015 for studies that compared BtB with placebo in people with cervical dystonia.</P>
<P>We found four studies comparing a single BtB treatment session with placebo, including 441 participants in total.</P>
<P>There was moderate-quality evidence that a single BtB treatment session is efficacious when compared to placebo, improving cervical dystonia symptoms by between 10% and 20%. This clinical benefit applies to people with both a poor and a good response to previous BtA treatments. Both physicians and patients evaluated BtB positively. BtB-treated patients are, however, at an increased risk of dry mouth and swallowing difficulties.</P>
<P>Further studies are needed to establish the long-term clinical benefit of BtB treatment, including its impact on quality of life, to evaluate the best treatment intervals and doses, as well as to find out which people with cervical dystonia would benefit the most from BtB treatment.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-04-22 17:34:14 +0100" MODIFIED_BY="Ana Raquel Marques">
<ABS_BACKGROUND MODIFIED="2016-04-21 22:57:38 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane review first published in 2004, and previously updated in 2009 (no change in conclusions). Cervical dystonia is a frequent and disabling disorder characterised by painful involuntary head posturing. Botulinum toxin type A (BtA) is usually considered the first line therapy for this condition, although botulinum toxin type B (BtB) is an alternative option.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-04-21 22:57:31 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the efficacy, safety and tolerability of botulinum toxin type B (BtB) versus placebo in people with cervical dystonia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-04-21 22:57:28 +0100" MODIFIED_BY="[Empty name]">
<P>We identified studies for inclusion in the review using the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, reference lists of articles and conference proceedings, last run in October 2015. We ran the search from 1977 to 2015. The search was unrestricted by language.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-04-21 16:49:55 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, parallel, randomised, placebo-controlled trials (RCTs) of BtB versus placebo in adults with cervical dystonia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-04-21 22:57:21 +0100" MODIFIED_BY="[Empty name]">
<P>Two independent authors assessed records, selected included studies, extracted data using a paper pro forma and evaluated the risk of bias. We resolved disagreements by consensus or by consulting a third author. We performed one meta-analysis for the comparison BtB versus placebo. We used random-effects models when there was heterogeneity and fixed-effect models when there was no heterogeneity. In addition, we performed pre-specified subgroup analyses according to BtB doses and BtA previous clinical responsiveness. The primary efficacy outcome was overall improvement on any validated symptomatic rating scale. The primary safety outcome was the number of participants with any adverse event.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-04-22 17:34:14 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>We included four RCTs of moderate overall methodological quality, including 441 participants with cervical dystonia. Three studies excluded participants known to have poorer response to Bt treatment, therefore including an enriched population with a higher probability of benefiting from Bt treatment. None of the trials were independently funded. All RCTs evaluated the effect of a single Bt treatment session using doses between 2500 U and 10,000 U. BtB was associated with an improvement of 14.7% (95% CI 9.8% to 19.5) in the patients' baseline clinical status as assessed by investigators, with reduction of 6.8 points in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS-total score) at week 4 after injection (95% CI 4.54 to 9.01). Mean difference (MD) in TWSTRS-pain score at week 4 was 2.20 (95% CI 1.25 to 3.15). Overall, both participants and clinicians reported an improvement of subjective clinical status. There were no differences between groups in the withdrawals rate due to adverse events or in the proportion of participants with adverse events. However, BtB-treated patients had a 7.65 (95% CI 2.75 to 21.32) and a 6.78 (95% CI 2.42 to 19.05) increased risk of treatment-related dry mouth and dysphagia, respectively. Statistical heterogeneity between studies was low to moderate for most outcomes. All tested dosages were efficacious against placebo without clear-cut evidence of a dose-response gradient. However, duration of effect (time until return to baseline TWSTRS-total score) and risk of dry mouth and dysphagia were greater in the subgroup of participants treated with higher BtB doses. Subgroup analysis showed a higher improvement with BtB among BtA-non-responsive participants, although there were no differences in the effect size between the BtA-responsive and non-responsive subgroups.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-04-21 22:57:06 +0100" MODIFIED_BY="[Empty name]">
<P>A single BtB-treatment session is associated with a significant and clinically relevant reduction of cervical dystonia impairment including severity, disability and pain, and is well tolerated, when compared with placebo. However, BtB-treated patients are at an increased risk of dry mouth and dysphagia. There are no data from RCTs evaluating the effectiveness and safety of repeated BtB injection cycles. There are no RCT data to allow us to draw definitive conclusions on the optimal treatment intervals and doses, usefulness of guidance techniques for injection, and impact on quality of life.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-04-22 18:35:02 +0100" MODIFIED_BY="Ana Raquel Marques">
<BACKGROUND MODIFIED="2016-04-22 18:35:02 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>This review is an update of a previously published review in the Cochrane Database of Systematic Reviews 2004, Issue 4 (<LINK REF="REF-Costa-2004" TYPE="REFERENCE">Costa 2004</LINK>), evaluating the efficacy and safety of Botulinum toxin type B versus placebo in the treatment of cervical dystonia.</P>
<CONDITION MODIFIED="2016-04-22 18:35:02 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for glossary of terms.</P>
<P>Dystonia is the third most common movement disorder, after Parkinson&#8217;s disease and essential tremor, with an overall prevalence of 164 per million (<LINK REF="REF-Steeves-2012" TYPE="REFERENCE">Steeves 2012</LINK>). Dystonia syndromes are a group of disabling, painful disorders characterised by involuntary sustained or intermittent muscle contractions causing abnormal, often repetitive, movements or postures of the face, neck, trunk or limbs (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). Dystonic movements are typically patterned or twisting, and are often initiated or worsened by voluntary action (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). These neurological disorders can be classified based on topographic distribution, including focal dystonia (one body region, e.g. cervical dystonia and blepharospasm), segmental dystonia (two or more adjacent regions, e.g. hemifacial spasm), multifocal dystonia (two or more nonadjacent regions), hemidystonia (ipsilateral regions) and generalised dystonia (trunk and two or more other regions) (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>; Tarsy 2006).</P>
<P>Focal dystonia is a highly disabling movement disorder, with serious functional and social impairment. Close to half of the patient population quits work by the age of 40 or retires early due to dystonia, and 10 years later, only 25% of patients are working compared to 62% of the general population (<LINK REF="REF-Zoons-2012" TYPE="REFERENCE">Zoons 2012</LINK>). Moreover, health-related quality of life is significantly diminished, mainly attributable to depression and anxiety, with scores comparable to people with multiple sclerosis, Parkinson&#8217;s disease or stroke (<LINK REF="REF-Zoons-2012" TYPE="REFERENCE">Zoons 2012</LINK>).</P>
<P>Cervical dystonia, also called spasmodic torticollis, is the most common form of adult-onset focal dystonia, with estimates from population studies ranging from 57 per million in Europe (<LINK REF="REF-ESDE-2000" TYPE="REFERENCE">ESDE 2000</LINK>) to as high as 280 per million in the USA (<LINK REF="STD-Jankovic-2006" TYPE="STUDY">Jankovic 2006</LINK>). It typically has its onset in the fifth decade (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>), and affects more women than men (<LINK REF="REF-Defazio-2013" TYPE="REFERENCE">Defazio 2013</LINK>). This condition is characterised by abnormal movements of head, neck, and shoulder, resulting in posturing of the head away from its normal central position (<LINK REF="REF-Foltz-1959" TYPE="REFERENCE">Foltz 1959</LINK>). It may present predominantly with sustained abnormal posture, spasm, jerks, tremor, or a combination of these features. Neck or shoulder pain, or both, occur in more than 70% of patients (<LINK REF="REF-Chan-1991" TYPE="REFERENCE">Chan 1991</LINK>; Tarsy 2006).</P>
<P>Cervical dystonia can be classified according to the dominant head position, with the most common type involving horizontal turning, the so-called rotatory (or simple) torticollis (<LINK REF="REF-Chan-1991" TYPE="REFERENCE">Chan 1991</LINK>
; 
<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). Other common patterns include laterocollis (tilt to one side), retrocollis (tilt upwards resulting in neck extension) and anterocollis (tilt downwards resulting in neck flexion). Complex torticollis, a combination of these abnormal patterns, is frequently found in clinical practice.</P>
<P>The aetiology of most forms of dystonia is still not fully understood, with the exception of early-onset dystonia, for which a hereditary aetiology is common (<LINK REF="REF-Balint-2015" TYPE="REFERENCE">Balint 2015</LINK>). In most cases of focal adult-onset dystonia, such as cervical dystonia, the pathophysiology is generally considered to result from inhibition of the central nervous system (CNS) at multiple levels (<LINK REF="REF-Hallett-1998" TYPE="REFERENCE">Hallett 1998</LINK>) resulting in abnormal sensorimotor integration. Cervical dystonia can also be secondary to brain injury, infections of the CNS, drugs (such as levodopa or antipsychotics), toxics, vascular or neoplastic disorders, and may also be psychogenic (i.e. functional) (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). Although most cases of cervical dystonia are currently classified as idiopathic, it should be observed that some may come to be reclassified as inherited, since new gene discoveries are under investigation (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>; <LINK REF="REF-Balint-2015" TYPE="REFERENCE">Balint 2015</LINK>).</P>
<P>The natural course of cervical dystonia remains unclear though it typically worsens over time. The clinical presentation is seldom progressive to generalised dystonia, although it often extends to contiguous body regions. For most patients, cervical dystonia is a life-long disorder, with only about 10% undergoing spontaneous remissions (<LINK REF="REF-Jahnanshani-1990" TYPE="REFERENCE">Jahnanshani 1990</LINK>).</P>
<P>To date, no curative or disease-modifying treatments are available for cervical dystonia.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-04-21 22:58:44 +0100" MODIFIED_BY="[Empty name]">
<P>Botulinum toxin (Bt) is a powerful biological toxin produced by <I>Clostridium botulinum</I>. The active form of botulinum toxin is a di-chain polypeptide composed of two chains: a heavy chain (100 kDa) and a light chain (50 kDa), and by associating with certain auxiliary proteins (haemagglutinins and non-haemagglutinins), the toxin forms a non-covalent multimeric complex of variable size (<LINK REF="REF-Simpson-2004" TYPE="REFERENCE">Simpson 2004</LINK>). The nontoxic proteins aid the formation of neutralising antibodies, though beyond this their role is unclear (<LINK REF="REF-Frevert-2010" TYPE="REFERENCE">Frevert 2010</LINK>). Bt binds to peripheral cholinergic nerve terminals of the neuromuscular junction as well as sympathetic ganglionic, parasympathetic ganglionic and postganglionic terminals (<LINK REF="REF-Simpson-2004" TYPE="REFERENCE">Simpson 2004</LINK>). Bt, after binding to an acceptor protein, is endocytosed at the presynaptic membrane of acetylcholine nerve terminals (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>). By action of the N-terminal on the heavy -chain, a pore is formed on the endocytic membrane, which permits the release of the light chain into the cytosol. This light chain, which is a zinc protease, performs the key-action of the botulinum toxin, by cleaving soluble N-ethylmaleimidesensitive factor attachment receptor proteins (SNARE proteins) (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>).</P>
<P>SNAREs are docking proteins for acetylcholine vesicles that allow for the release of acetylcholine into the synaptic cleft (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>). The overall effect of Bt is a local chemodenervation by the temporary blockade of acetylcholine release at cholinergic synapses. Temporary synapses are consequently formed via the process of axonal sprouting (<LINK REF="REF-Duchen-1971" TYPE="REFERENCE">Duchen 1971</LINK>; <LINK REF="REF-Holland-1981" TYPE="REFERENCE">Holland 1981</LINK>; <LINK REF="REF-Juzans-1996" TYPE="REFERENCE">Juzans 1996</LINK>).</P>
<P>There are seven immunologically distinct botulinum toxin serotypes (labelled A to G). These different Bt serotypes cleave specific SNARE proteins. Serotype A cleaves SNARE protein SNAP 25 located on the inner membrane, and serotype B targets synaptobrevin located on the vesicular membrane (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>).</P>
<P>Botulinum toxin is injected into the muscles involved in dystonia, with or without guidance by either electromyography (EMG) or ultrasound. As a general rule, the number of muscles injected and the number of injection sites per muscle are tailored to the severity of the case in question and the mass of the muscle, respectively. Within roughly three months after injection of botulinum toxin into skeletal muscle, the nerve terminal resumes exocytosis, and the muscle returns to its baseline clinical function, showing a wearing off response from the Bt injection (<LINK REF="REF-Jankovic-2004" TYPE="REFERENCE">Jankovic 2004</LINK>). Eventually, the muscle paralysis subsides, and this is associated with the formation of new sprouts capable of neurotransmission. Over time, synaptic activity resumes in the original nerve terminals, leading to sprout regression (<LINK REF="REF-de-Paiva-1999" TYPE="REFERENCE">de Paiva 1999</LINK>).</P>
<P>Currently there are two commercially available Bt serotypes (BtA and BtB). The following products are commonly available (three BtA and one BtB): onabotulinumtoxinA (Botox®, Allergan Inc., Irvine, CA, USA), abobotulinumtoxinA (Dysport®/Reloxin®/Azzalure®, Ipsen Pharma, Boulogne Billancourt, France), incobotulinumtoxinA (Xeomin®/Bocoture® Merz GmbH, Frankfurt, Germany), and rimabotulinumtoxinB (Myobloc®/Neurobloc®, Solstice Neurosciences Inc., Louisville, KY, USA). Other BtA formulations are available in more restricted markets and are yet to receive a generic name: Prosigne®/Lantox® (Lanzhou Institute of Biological Products, China), PurTox® (Mentor Worldwide LLC, Santa Barbara, CA, USA), and Neuronox® (Medy-Tox Inc, South Korea) (<LINK REF="REF-Walker-2014" TYPE="REFERENCE">Walker 2014</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-04-21 22:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>The therapeutic potential of all Bt serotypes derives from their ability to inhibit the release of acetylcholine from the presynaptic nerve terminal into the synaptic cleft, causing local chemodenervation (<LINK REF="REF-Jankovic-2004" TYPE="REFERENCE">Jankovic 2004</LINK>). In addition to this, recent research has also suggested that Bt is active at multiple levels, namely sensory nerve terminals, and muscle spindles, which leads to a reduction in sensory input and fewer muscle contractions (<LINK REF="REF-Filippi-1993" TYPE="REFERENCE">Filippi 1993</LINK>; <LINK REF="REF-Matak-2014" TYPE="REFERENCE">Matak 2014</LINK>; <LINK REF="REF-Rosales-1996" TYPE="REFERENCE">Rosales 1996</LINK>; <LINK REF="REF-Rosales-2010" TYPE="REFERENCE">Rosales 2010</LINK>).</P>
<P>It has also been suggested that cortical reorganisation may result from changes in the spinal cord, brainstem and central nervous pathways (<LINK REF="REF-Palomar-2012" TYPE="REFERENCE">Palomar 2012</LINK>). Animal research has shown the presence of supra-therapeutic levels of Bt by way of retrograde axonal transport and penetration of the central nervous system (<LINK REF="REF-Antonucci-2008" TYPE="REFERENCE">Antonucci 2008</LINK>
; 
<LINK REF="REF-Boroff-1975" TYPE="REFERENCE">Boroff 1975</LINK>). However, Bt has not been shown to penetrate the blood-brain barrier in humans.</P>
<P>Until recently, SNARE proteins were considered the only target molecules of Bt. Thus, it was widely accepted that the therapeutic and toxic actions of Bt were exclusively mediated by SNARE cleavage preventing the release of synaptic neurotransmitters. However, recent studies have suggested that a number of Bt actions might not be mediated by SNARE cleavage, specifically regarding neuroexocytosis, cell cycle and apoptosis, neuritogenesis and gene expression (<LINK REF="REF-Matak-2015" TYPE="REFERENCE">Matak 2015</LINK>). The existence of unknown Bt molecular targets and modulation of unknown signalling pathways is a possibility that may prove to be pharmacologically relevant.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-04-22 18:31:37 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>BtA is the toxin serotype that has been most intensively studied and approved for the treatment of the large number of focal dystonias. BtA is considered the first line therapy for cervical dystonia and has proven to be effective in the symptomatic management of this condition (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). However, not all patients have an adequate clinical response. Primary non-response to botulinum toxin is seen in cases where the first and subsequent treatment cycles do not elicit a response. Cases of secondary non-response, however, respond to initial treatment, but over the course of multiple treatment cycles, this effect wanes and is eventually lost. Secondary non-response is partially explained by the formation of neutralising antibodies, though it is worth noting that there are cases of secondary non-responders without positive antibody titers (<LINK REF="REF-Hanna-1998" TYPE="REFERENCE">Hanna 1998</LINK>; <LINK REF="REF-Lange-2009" TYPE="REFERENCE">Lange 2009</LINK>) as well as cases with positive titers but with an adequate sensitivity to Bt (<LINK REF="REF-Brin-2008" TYPE="REFERENCE">Brin 2008</LINK>; <LINK REF="REF-Muller-2009" TYPE="REFERENCE">Muller 2009</LINK>). An estimated 4% to 20% of patients develop neutralising antibodies to the toxin (<LINK REF="REF-Brashear-2008" TYPE="REFERENCE">Brashear 2008</LINK>; <LINK REF="REF-Fabbri-2015" TYPE="REFERENCE">Fabbri 2015</LINK>), and if secondary non-responsiveness occurs, it is partially related to the protein load, with higher protein load per dose generating higher antibody titers (<LINK REF="REF-Benecke-2012" TYPE="REFERENCE">Benecke 2012</LINK>; <LINK REF="REF-Frevert-2010" TYPE="REFERENCE">Frevert 2010</LINK>).</P>
<P>When clinical non-response occurs, other Bt serotypes are important treatment options for cervical dystonia (<LINK REF="STD-Cullis-2000" TYPE="STUDY">Cullis 2000</LINK>; <LINK REF="REF-Eleopra-1997" TYPE="REFERENCE">Eleopra 1997</LINK>; <LINK REF="REF-Greene-1993" TYPE="REFERENCE">Greene 1993</LINK>). At the present time, BtB is the only approved non-BtA formulation available for the treatment of cervical dystonia in the United States and in the European Union.</P>
<P>A Cochrane systematic review previously assessed the efficacy and safety of BtB in comparison to placebo in people with cervical dystonia (<LINK REF="REF-Costa-2004" TYPE="REFERENCE">Costa 2004</LINK>). This is the second update of that review, having been previously updated in 2009 with no changes to conclusions. The original review concluded that a single injection of BtB was efficacious in comparison to placebo in the treatment of cervical dystonia, with a greater benefit for participants who were BtA non-responders when compared to BtA-responders, as assessed by subgroup analysis. Three studies were included in the original review with a total number of 308 participants enrolled.</P>
<P>Since the release of the original review, a new trial has been published (<LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>). Furthermore, Cochrane&#8217;s criteria for evaluating studies' risk of bias and evidence quality have evolved and been updated. Therefore, the authors consider it important to update this review.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-04-21 22:59:47 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the efficacy, safety and tolerability of botulinum toxin type B (BtB) versus placebo in people with cervical dystonia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-04-22 17:12:28 +0100" MODIFIED_BY="Ana Raquel Marques">
<SELECTION_CRITERIA MODIFIED="2016-04-22 01:01:09 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-04-22 00:10:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs), blinded, single or multiple dose, parallel-designed, of any duration, assessing the efficacy or safety, or both, of BtB treatment versus placebo in people with cervical dystonia were eligible for inclusion in this review. We excluded trials in which allocation was not adequately concealed. We excluded non-parallel study designs, namely cross-over trials, from this updated version of the review, due to uncertainty about whether this type of study design was appropriate to study people with cervical dystonia, as well as methodological concerns with regards to detection and performance bias.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-04-22 00:10:11 +0100" MODIFIED_BY="[Empty name]">
<P>Adults (i.e. &#8805; 18 years of age), in any setting, with a clinical diagnosis made by any physician, specialist or otherwise, of idiopathic cervical dystonia. We allowed trials enrolling participants with any form of cervical dystonia, and additional or more widespread dystonias, for inclusion. Participants could have had prior exposure to BtA or BtB, and could be taking any concomitant medications if on stable regimens.</P>
<P>There were no restrictions regarding the number of participants recruited to trials, or the number of recruitment centres.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-04-22 00:09:39 +0100" MODIFIED_BY="[Empty name]">
<P>Intramuscular injections of BtB compared to placebo. We allowed all administration schedules and injection techniques, performed with or without guidance by either EMG or echography.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-04-22 01:01:09 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-04-22 00:09:55 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Primary efficacy outcome</HEADING>
<P>Overall improvement on any validated symptomatic rating scale, such as Cervical Dystonia Severity Scale (CDSS), Tsui scale, and Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), measured between weeks 3 and 6.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Primary safety outcome</HEADING>
<P>Number of participants with any adverse event, measured at any point during study follow up.</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-04-22 01:01:09 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Change in subjective evaluation of clinical status evaluated by both patients and clinicians, as assessed with validated assessment tools such as Patient Subjective Assessment of Change, Patient Global Assessment of Improvement, Patient Evaluation of Global Response (PEGR), Patient and Physician Global Assessment of Change, Investigator Global Assessment of Efficacy (IGAE), and Physician Global Assessment of Change (PGAC), and Visual analogue scale (VAS) for symptom severity, measured between weeks 3 and 6.</LI>
<LI>Changes in pain scores, as assessed with validated assessment tools such as Patient Assessment of Pain, TWSTRS Pain sub-scale score, and VAS Pain score, measured between weeks 3 and 6.</LI>
<LI>Changes in quality- of- life assessments, as assessed with validated assessment tools such as Short Form 36 (SF-36) Quality-of-Life questionnaire, measured at any point during study follow up.</LI>
<LI>Number of withdrawals due to adverse events, including adverse events caused by the intervention (type A or type B, or both, adverse drug reactions (ADRs)), and failure of therapy (type F ADRs), measured at any point during study follow up.</LI>
<LI>Number of participants with adverse events of special interest, such as dry mouth, neck weakness, dysphagia, pain at the injection site, voice change, and systemic complaints (e.g. diffuse muscle weakness, malaise, dizziness and headache), measured at any point during study follow up.</LI>
<LI>Duration of effect, assessed by the number of days until need for reinjection or effect waning.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-04-22 16:21:46 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>For this update, we expanded the search strategy to capture all the search terms for BtB formulations that were available at the time of the search. We designed the search strategy to include other botulinum toxin formulations and other dystonic disorders that were also under revision by this author team.</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-04-22 16:21:46 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>In October 2015 we searched the following databases.</P>
<OL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2015, Issue 11);</LI>
<LI>MEDLINE (1977 to October 2015)</LI>
<LI>EMBASE (1977 to October 2015)</LI>
</OL>
<P>We assessed non-English language papers equally, translated them as necessary and evaluated them for inclusion.</P>
<P>For the identification of studies considered for inclusion in this review, we developed detailed search strategies for each database searched. Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the CENTRAL search strategy, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for the MEDLINE search strategy, and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for the EMBASE search strategy.</P>
<P>We ran the search for the original version of this review in June 2003, based on the search strategy developed for the Movement Disorders Group to identify all papers from 1977, the first year botulinum toxin was used therapeutically in any condition.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-04-22 00:10:55 +0100" MODIFIED_BY="[Empty name]">
<P>The search strategy also included:</P>
<OL>
<LI>searches through reference lists of located trials and review articles concerning botulinum toxin;</LI>
<LI>handsearch of abstracts of international congresses relevant in the fields of movement disorders and botulinum toxins, i.e. American Academy of Neurology, Movement Disorders Society, International Association of Parkinsonism and Related Disorders, and International Neurotoxin Association (1985 to October 2015);</LI>
<LI>personal communication with other researchers in the field;</LI>
<LI>contact with drug manufacturers;</LI>
<LI>whenever necessary, we contacted authors of published trials for further information and unpublished data.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-04-22 17:12:28 +0100" MODIFIED_BY="Ana Raquel Marques">
<STUDY_SELECTION MODIFIED="2016-04-22 00:11:01 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently screened the studies identified by the search strategy, reading each of the titles and abstracts, excluding studies that were not applicable. If there was no abstract, we opted to retrieve the full text of the study in question.</P>
<P>Two review authors then independently assessed the full-text articles to see if the studies fulfilled the inclusion criteria. We resolved disagreements by discussion or, if necessary, reached consensus with the participation of a third author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-04-22 01:01:32 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted study data onto standardised forms, after which we cross-checked the forms for accuracy. We resolved disagreements by discussion or, if necessary, arbitration by a third author. We extracted the following data from each study.</P>
<OL>
<LI>Participants: inclusion and exclusion criteria, demographics and clinical baseline characteristics, number and reasons for withdrawals, exclusions and loss to follow-up, if any.</LI>
<LI>Interventions: full description of intervention, duration of treatment period and follow-up, providers, and co-interventions, if any.</LI>
<LI>Comparisons: number of randomised participants to each arm, compliance and dropouts, reasons for dropouts, and ability to perform an intention-to-treat analysis.</LI>
<LI>Outcomes: definition of outcomes, use of validated measurement tools, time-point measurements, change from baseline or post-interventional measures, and missing outcomes, if any.</LI>
<LI>Study design: interventional, randomised, controlled, double-blind.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-04-21 23:22:59 +0100" MODIFIED_BY="[Empty name]">
<P>We used the recommended Cochrane tool for assessing risk of bias in this review (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). We added one new criteria, in addition to the seven specific domains of this tool (i.e. random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias). This extra domain, 'enriched population', was created to evaluate bias originating from either the preferential enrolment of known positive responders to BtA (high risk of bias being arbitrarily defined as &gt;30% of participants being non-naive to Bt) or the exclusion of known poor responders to BtA.</P>
<P>We also divided the domain 'blinding of outcome assessment' into two categories: subjective and objective assessment. Because the clinical effect of botulinum toxin treatment is easily perceived by most patients, Bt non-naive patients are likely to recognise the presence or absence of clinical effects, or frequent adverse events, or both, effectively revealing the respective allocation arm. Thus, whenever a study population consisted primarily of non-naive participants, we took this potential source of bias for subjective outcome assessment into account.</P>
<P>Two independent review authors performed critical assessments for each domain of the risk of bias tool. We resolved disagreements by discussion and, if necessary, reached consensus with the participation of a third author.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-04-21 23:19:28 +0100" MODIFIED_BY="[Empty name]">
<P>We compared disease symptoms at baseline to disease symptoms in weeks 3 to 6 between BtB and placebo arms. Whenever possible, we extracted continuous outcomes. Where we extracted adequate data from the studies, we pooled these data and used them for comparison. We opted to preferentially use mean differences. When studies investigating the same outcome used different validated rating scales, we calculated a standardised mean difference (SMD). For interpretation of effect sizes with SMDs, we used a rule of thumb to define absence of effect (SMD &lt; 0.2), a small effect (SMD = 0.2 to 0.49), a moderate effect (SMD = 0.5 to 0.79), or a large effect (SMD &#8805; 0.80) (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>). If necessary for comparison, we dichotomised rating scales using each study author's own criteria for improvement or no improvement. If these criteria were not described, we defined 'improvement' as any beneficial change from baseline, and 'no improvement' as lack of improvement or any deterioration from baseline.</P>
<P>We compared the proportion of participants with adverse events between treatment arms using risk ratios, and performed further analysis for adverse events of special interest reported in the trials.</P>
<P>We planned a meta-analysis for the duration of effect of BtB formulations (using time-to-event data). Where there were no data that could be combined and subjected to such analysis, we undertook a narrative approach to result synthesis.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-04-21 23:19:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Studies with multiple treatment groups</HEADING>
<P>Whenever the included studies had multiple BtB arms with different dosages versus placebo, we combined all the BtB groups to create a single pair-wise comparison, using the Review Manager (RevMan) 5.3 Calculator (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). This avoided the duplication of the placebo group that would happen if multiple comparisons (e.g. BtB dose 1 versus placebo; BtB dose 2 versus placebo) were included in the meta-analysis, as well as the loss of information if one dosage group was chosen in detriment of the others. We analysed the importance of dosage in a subgroup analysis.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-04-22 17:12:28 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>Where insufficient data were presented in the study report to combine information into the meta-analysis, we derived the mean value and standard deviation of the outcome measurements using the methods suggested in the Cochrane Handbook, Section 16.1 (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
<P>We used the generic inverse variance method when an effect estimate and a valid measure of uncertainty (e.g. standard error (SE), 95% confidence interval (CI) or exact P value) were reported in the study. When two reported groups needed to be combined into a single group, we calculated a pooled standard deviation (SD) estimate (<LINK REF="REF-Abrams-2005" TYPE="REFERENCE">Abrams 2005</LINK>; <LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>) and used it as the standard deviation for that group.</P>
<P>When change from baseline SD was not reported or not possible to extract, we used alternative methods for imputing SD, namely, those suggested by Cochrane (Cochrane Handbook, Section 16.1.3.2). If a study in this review uses the same scale, degree of error and time period measurements, and SD was available, SD was appropriated from that study (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). Where not possible to use the aforementioned methods, we used a pooled SD estimate (<LINK REF="REF-Abrams-2005" TYPE="REFERENCE">Abrams 2005</LINK>; <LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>) instead, assuming a lower degree of accuracy.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-04-21 23:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>Heterogeneity between trial results was tested using a standard chi-squared test and an I<SUP>2</SUP> statistic was performed to quantify inconsistency across studies (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). When considerable heterogeneity was present (i.e. P &lt; 0.1 or I<SUP>2</SUP> &gt; 50%), we explored the possible causes of heterogeneity by conducting non-planned subgroup analyses. Where heterogeneity could not readily be explained by the planned and non-planned exploratory analyses, we incorporated it into a random-effects (RE) meta-analysis model.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-04-21 23:19:01 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed publication bias through visual inspection of funnel plot asymmetry (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>) and Peters&#8217; regression tests (<LINK REF="REF-Peters-2006" TYPE="REFERENCE">Peters 2006</LINK>), if more than 10 studies per outcome were available (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-04-21 23:18:54 +0100" MODIFIED_BY="[Empty name]">
<P>We performed statistical analysis with Review Manager (RevMan) version 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
<P>We pooled effect measures by applying the Mantel-Haenszel method for dichotomous outcomes, and applying the inverse-variance method for continuous and generalised inverse variance outcomes. We conducted data synthesis using a fixed-effect model unless considerable heterogeneity was detected, in which case we opted to apply the random-effects model. We presented all results with 95% CI.</P>
<P>We calculated the number of participants needed to treat for an additional beneficial outcome (NNTB) and for an additional harmful outcome (NNTH) from meta-analysis estimates, rather than treating data as if they came from a single trial, as the latter approach is more prone to bias, especially when there are significant imbalances between groups within one or more trials in the meta-analysis (<LINK REF="REF-Altman-2002" TYPE="REFERENCE">Altman 2002</LINK>). However, caution is needed in interpreting these findings since they may be misleading because of variation in the event rates in each trial, differences in the outcomes considered, effects of secular trends on disease risk, and differences in clinical setting (<LINK REF="REF-Smeeth-1999" TYPE="REFERENCE">Smeeth 1999</LINK>).</P>
<P>Where data from the study reports could not be combined into a meta-analysis, we presented a narrative report of result synthesis in the review text.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-04-21 23:18:47 +0100" MODIFIED_BY="[Empty name]">
<P>We planned subgroup analysis for the following areas, independently of the presence or not of significant heterogeneity: high (&#8805; 10000 U) versus medium (&gt; 2500 U to &lt; 10000 U) versus low total treatment dose (&#8804; 2500 U), all defined arbitrarily; EMG-guided versus non-EMG- guided injection; and BtA-responsive versus BtA-non-responsive</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-04-22 17:39:59 +0100" MODIFIED_BY="Ana Raquel Marques">
<STUDY_DESCRIPTION MODIFIED="2016-04-22 16:25:13 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>We included one new study in this update (<LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>, n = 130), adding to the three studies already included in the original review (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>).</P>
<P>Overall, we included four parallel-designed studies comparing BtB (different total treatment doses) with placebo in this update, with a total of 441 participants with cervical dystonia.</P>
<SEARCH_RESULTS MODIFIED="2016-04-21 23:18:39 +0100" MODIFIED_BY="[Empty name]">
<P>The search, last run on 26 October 2015, returned 1667 records (189 through CENTRAL, 436 though MEDLINE, 1042 through EMBASE), resulting in 1450 records after removing all duplicates. After title and abstract screening we retrieved twelve full articles. Of these, we excluded a further eight studies, one due to examining the wrong intervention (<LINK REF="STD-AN072_x002d_008-1995" TYPE="STUDY">AN072-008 1995</LINK>) and seven due to having the wrong study design (<LINK REF="STD-Chinnapongse-2010" TYPE="STUDY">Chinnapongse 2010</LINK>; <LINK REF="STD-Cullis-2000" TYPE="STUDY">Cullis 2000</LINK>; <LINK REF="STD-Dressler-2005" TYPE="STUDY">Dressler 2005</LINK>; <LINK REF="STD-Jacob-2003" TYPE="STUDY">Jacob 2003</LINK>; <LINK REF="STD-Jankovic-2006" TYPE="STUDY">Jankovic 2006</LINK>; <LINK REF="STD-Lew-2002" TYPE="STUDY">Lew 2002</LINK>; <LINK REF="STD-Truong-1997" TYPE="STUDY">Truong 1997</LINK>). We did not retrieve any unpublished trials.</P>
<P>We once again included the three studies that had been included in previous versions of this review (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>) and we included one new study in both the qualitative and quantitative syntheses (<LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>).</P>
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for the Study flow diagram.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-04-22 16:25:13 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>We have listed all the included studies in this review in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<SUBSECTION>
<HEADING LEVEL="5">Study participants</HEADING>
<P>The four included studies enrolled a total of 441 adult (aged above 18 years old) participants (57.6% of whom were female (n = 254)). The mean age was 52.9 years across all studies except <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>, where age distribution was not available. Trial size varied from 77 to 133 participants, with all but one study (<LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>) enrolling above 100 participants. Three of the included RCTs were multi-centre studies conducted in the US and published in the late 1990s (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>), and one was a more recent trial conducted in Japan (<LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>). All trials tested only one injection treatment session and followed participants for 16 weeks.</P>
<P>With respect to baseline characteristics, all studies required participants to have had cervical dystonia for at least one year. The mean duration of cervical dystonia was 7.21 years in the <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK> trial (ranging from 5.58 years in the 5000 U BtB treatment arm to 8.53 years in the 2500 U BtB treatment arm); the remaining studies did not present the mean duration of disease in the population enrolled. The baseline mean cervical dystonia impairment was moderate to severe in all participants, though well matched between study arms, with TWSTRS total scores ranging from 43.4 to 52.0, and TWSTRS Severity scores from 19.6 to 22.4 (baseline scores not available in <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>, and sub-scores not reported in <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>).</P>
<P>Participants&#8217; previous Bt response varied across trials. <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK> and <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK> trials allowed both BtA-responsive and BtA-non-responsive participants to enter the study; the <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK> trial allowed only BtA-non-responders; and the <LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK> trial included only BtA-responsive participants. Only the <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK> trial enrolled BtA-naïve participants (25.4% of total population); in all studies, time since last injection before study entry had to be superior to 16 weeks. All trials except <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK> excluded clinical forms of cervical dystonia known to perform poorly to botulinum toxin injections, such as pure anterocollis or retrocollis.</P>
<P>The number of withdrawals was small and balanced in all trials. Reasons for withdrawals were given, even though <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK> did not describe the reasons for each participant withdrawal in detail.</P>
<P>Overall, within studies, participants were well matched between BtB and placebo arms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Study design and interventions</HEADING>
<P>All studies were designed to evaluate only a single treatment session. Total BtB dosages tested varied between studies. All trials assessed the effect of 10,000 U of BtB (a dose that we have arbitrarily classified as being a high dose). Three studies (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>) also included a group treated with 5000 U of BtB (a dose that we have arbitrarily classified as being a medium dose), and two studies (<LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>) further included a group treated with 2500 U (a dose that we have arbitrarily classified as being a low dose).</P>
<P>Techniques and schema of BtB administration did not vary considerably among the studies. In all the trials, BtB was injected into two to four involved cervical dystonia muscles selected by the investigator, with the use of electromyography left at the discretion of the investigator performing the injection.</P>
<P>All trials were short-term, with an observational period lasting 16 weeks post-injection. No re-injections were allowed.</P>
<P>Three studies (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>) assessed efficacy and other primary outcomes using an intent-to-treat (ITT) analysis, which included all participants randomised to treatment or, in the case of <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>, all those to whom treatment was administered. <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK> assessed efficacy and safety outcomes on the per-protocol (PP) population; this study also used an ITT analysis to assess the duration of effect.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-04-21 23:18:07 +0100" MODIFIED_BY="[Empty name]">
<P>We have listed all the excluded studies in this review, together with reasons for their exclusion, in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
<P>One study had been excluded from the original analysis since it was not fully published and relevant data was lacking (<LINK REF="STD-AN072_x002d_008-1995" TYPE="STUDY">AN072-008 1995</LINK>). It was a dose-finding parallel-designed study comparing a single treatment session of BtB in three different doses (400 U, 1200 U, 2400 U) against placebo, doses currently thought to be insufficient for the great majority of CD patients. The follow-up period was 16 weeks. Both BtA-responsive and non-responsive participants were enrolled, and the primary outcome was change in TWSTRS total score. All three experimental groups had large rates of withdrawals (400 U: 71%, 1200 U: 73%, 2400 U: 48%). For all but two of the participants, who had withdrawn from the study, the reason was the protocol-defined criteria, &#8216;lack of response&#8217;. We asked the drug company for further information, without success. Our research did not find any additional publications on this trial that could shed any light on this problem, and because we could not rule out selective reporting of results, we decided that this study should remain excluded from our review. Two other parallel-designed studies comparing different doses of BtB had been excluded from the original review (<LINK REF="STD-Cullis-2000" TYPE="STUDY">Cullis 2000</LINK>; <LINK REF="STD-Truong-1997" TYPE="STUDY">Truong 1997</LINK>) for lacking a placebo group.</P>
<P>From the updated searches, we excluded a further five studies as one was neither blinded nor placebo-controlled (<LINK REF="STD-Chinnapongse-2010" TYPE="STUDY">Chinnapongse 2010</LINK>); one was not placebo-controlled (<LINK REF="STD-Jacob-2003" TYPE="STUDY">Jacob 2003</LINK>); one was a post-hoc analysis of two trials already included in this review (<LINK REF="STD-Lew-2002" TYPE="STUDY">Lew 2002</LINK>), and two were non-randomised, non-controlled studies focusing on the immunogenicity of BtB (<LINK REF="STD-Dressler-2005" TYPE="STUDY">Dressler 2005</LINK>; <LINK REF="STD-Jankovic-2006" TYPE="STUDY">Jankovic 2006</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-04-22 16:31:54 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>The quality assessment of previously included studies was re-evaluated with the Cochrane Risk of bias tool (current at the time of writing), the results of which can be found in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. These assessments were based on the information available in the primary report data.</P>
<P>Overall, no studies were considered to be at low risk of bias across all domains. High risk of bias was attributed only to "enriched population" and "other bias" domains.</P>
<ALLOCATION MODIFIED="2016-04-21 23:17:56 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>) described the process of random sequence generation, in both controlled by an independent organisation; we assessed the other two studies to be at unclear risk of bias for this criterion.</P>
<P>Three studies (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>: <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>) described an adequate allocation concealment process and were rated as being at a low risk of bias, whereas we assessed the remaining study as being at unclear risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-04-22 16:31:07 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>We evaluated the risk of bias in blinding of participants and personnel involved in the trial to be low for all the studies included in this review, since all trials were described as being double-blinded and all used vials with identical appearance to mask the intervention employed.</P>
<P>We considered two studies to have adequately blinded investigators measuring objective outcomes (Brashear 1999; Brin 1999); the other two studies did not provide sufficient information to permit judgement, so we rated them as having an unclear risk of bias.</P>
<P>For the assessment of subjective outcomes, we considered all studies to have an unclear risk of bias: <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK> did not specify the blinding process, and all the other studies enrolled only participants who had previously been treated with botulinum toxin. We considered that studies including only non-naive participants may introduce bias in patient-reported assessment of subjective outcomes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-04-21 23:17:47 +0100" MODIFIED_BY="[Empty name]">
<P>In <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>, all participants completed the study per protocol. In the remainder, missing outcome data was balanced in numbers across intervention groups and adequate imputation methods were used (ITT). Reasons for missing data were unclear only in <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>, but we considered the reasons for participant attrition to be unlikely to motivate output imbalances.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-04-21 23:17:39 +0100" MODIFIED_BY="[Empty name]">
<P>The more clinically relevant outcomes, which are usually evaluated in intervention trials for this condition, were reported in all studies, so we considered them to be at low risk of bias for reporting data. No trial protocol registry was available for any of the four included studies. However, three of these studies were conducted in the 1990's, before trial registration became standard good practice for clinical investigations.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-04-22 16:31:54 +0100" MODIFIED_BY="Ana Raquel Marques">
<SUBSECTION>
<HEADING LEVEL="5">Enriched population</HEADING>
<P>
<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK> exclusively enrolled BtA-responsive participants, and was classified as having a high risk of bias for enriched population. All the other studies allowed BtA-non-responsive participants.</P>
<P>On the other hand, three studies (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>) excluded forms of cervical dystonia known to have a poorer clinical response to BtA injection, and were considered to be at a high risk of bias for this domain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other Bias</HEADING>
<P>Two trials (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>) declared funding or supply of study vials from industry sources, being rated at a high risk of bias for funding and potential conflicts of interest. <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK> did not provide a description of funding, but members of a pharmaceutical company were authors of the study, so this trial was also classified as high risk of bias for this domain. <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK> was classified at unclear risk of bias for not stating the source of funding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Publication bias</HEADING>
<P>We intended to use funnel plots to explore publication bias. However, due to the small number of included studies, the power of this analysis was considered to be inadequate (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-04-22 17:39:59 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>The key results of this review can be found in '<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>'.</P>
<SUBSECTION>
<HEADING LEVEL="3">Botulinum toxin type B versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Preceding data analysis</HEADING>
<P>Whenever necessary, we used appropriate imputation methods in order to combine the reported data into the meta-analysis with other studies for which full data were available (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>). <LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK> and <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK> reported the primary outcome (mean and SD) as total scores for the time point assessed; we obtained change from baseline SD values using pooled SD estimates.</P>
<P>All studies evaluating different BtB dosages (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>) presented data separately for each dose, reporting sample sizes, means and SD (when available) for each intervention group. When an overall dose was required to compare to other studies, we combined the reported subgroups using RevMan 5.3 (see <LINK TAG="UNIT_OF_ANALYSIS" TYPE="SECTION">Unit of analysis issues</LINK>) (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used the same tool to calculate SD values from SE values presented in <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>. We conducted sensitivity analyses for every study where imputation methods were applied.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Overall improvement on any validated symptomatic rating scale for cervical dystonia</HEADING>
<P>The primary outcome in all trials included in this review was change in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) (<LINK REF="REF-Consky-1994" TYPE="REFERENCE">Consky 1994</LINK>) total or subtotal scores, assessed at week 4 following initial injection of BtB. TWSTRS is currently the most common clinical validated tool to assess and document the status of patients with spasmodic torticollis. The TWSTRS (total score range, 0 to 85) is composite of three sub-scales that evaluate different features of CD, namely severity (range, 0 to 35), disability (range, 0 to 30) and pain (range, 0 to 20). The higher the score, the greater the level of morbidity. In the absence of a validated value for a clinically meaningful change in TWSTRS total score, we have considered a 10% change from patients' baseline status as a clinically meaningful change.</P>
<P>Three trials (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>) reported data as the mean change from baseline in the TWSTRS total-score, and demonstrated an improvement in participants treated with BtB compared to placebo mean difference (MD) 6.78; 95% CI 4.54 to 9.01; I<SUP>2</SUP>= 0%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). This represents an improvement of 14.7% from the participant&#8217;s baseline clinical status (46.3 TWSTRS combined score). <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK> was not included in this primary analysis because SD values were not reported. As the study population was not described in detail, lacking important data such as age distribution, duration and severity of disease, we could not impute SD values from similar studies with an acceptable margin of error. However, data from this trial was used to assess NNTB.</P>
<P>The NNTB in TWSTRS total score was three patients (95% CI 2 to 6).</P>
<P>With respect to TWSTRS sub-scores, BtB was associated with a mean reduction of 2.43 points in TWSTRS Severity (95% CI 1.24 to 3.63; I<SUP>2</SUP>= 0%), and of 2.29 points in TWSTRS Disability (95% CI 1.04 to 3.54; I<SUP>2</SUP>= 0%). <LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK> was not included in this analysis of TWSTRS sub-scales as it did not present objective efficacy data for all groups.</P>
<SUBSECTION>
<HEADING LEVEL="6">1.1. Overall improvement with low vs medium vs high dose of BtB</HEADING>
<P>We carried out a subgroup analysis to assess overall improvement according to BtB dose (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>). All trials tested high BtB dose (10,000 U); three tested medium BtB dose (5000 U), and two tested low BtB dose (2500 U).</P>
<P>All BtB doses were efficacious against placebo (low-dose: MD 6.95; 95% CI 3.70 to 10.21; I<SUP>2</SUP>= 0%; medium-dose: MD 6.10; 95% CI 3.40 to 8.81; I<SUP>2</SUP>= 0%; high-dose: MD 8.72; 95% CI 6.35 to 11.10; I<SUP>2</SUP>= 0%). There was no difference in overall improvement, as assessed with TWSTRS global score, between these dose-defined subgroups (P= 0.34; I<SUP>2 </SUP>= 6.9%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.2 Overall improvement with non-EMG guided vs EMG- guided injections</HEADING>
<P>In all trials, the use of EMG-guidance was left at the discretion of the investigator. No data were reported concerning participants that did or did not undergo EMG-guided injection. Thus, it was not possible to perform this planned subgroup analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.3 Overall improvement in BtA-responsive vs BtA-non-responsive participants</HEADING>
<P>Two trials (<LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>) enrolled both types of patients. However, we did not include these studies in this analysis because they did not present mean TWSTRS values for each subgroup.</P>
<P>
<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK> included only BtA-responsive participants, and <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK> included only BtA-non-responsive participants. Overall, BtA-responsive participants improved by 6.22 points (95% CI 1.83 to 10.60), while BtA-non-responsive participants improved by 9.0 points in TWSTRS total score (95% CI 4.46 to 13.54). This difference (2.78 points on the TWSTRS total score) between BtA-responsive and BtA-non-responsiveparticipants was not significant (P = 0.39; I<SUP>2</SUP>= 0%) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>
<LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>, which included both types of participants, reported a higher rate of participants classified as 'responders' among participants who were non-responsive to BtA in comparison to participants who were responsive to BtA (25% versus 66.7% ).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Number of participants with any adverse event</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.1 Proportion of participants with adverse events</HEADING>
<P>Adverse events were generally transient and either mild to moderate, or intermittent. They were reported by 90.2% of the participants in the BtB groups, compared to 83.8% of participants in the placebo arm (RR 1.09; 95% CI 0.97 to 1.23; I<SUP>2</SUP>= 45%) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). This analysis included only two studies (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>) as the others (<LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>) did not present the total number of participants with adverse events per group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.1.1 Proportion of participants with adverse events with low vs medium vs high dose of BtB</HEADING>
<P>
<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK> and <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK> were the studies included for this subgroup analysis. We excluded <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK> and <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK> because they did not provide data according to the BtB dosages used.</P>
<P>There was no difference in the overall risk of any adverse event between medium (RR 1.07; 95% CI 0.89 to 1.29) or high-dose (RR 1.09; 95% CI 0.89 to 1.33; I<SUP>2</SUP>= 59%) BtB-treated participants and placebo (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.1.2 Proportion of participants with adverse events in BtA-responsive vs BtA-non-responsive participants</HEADING>
<P>The overall risk of adverse events reported by <LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK> (with exclusively BtA-responsive participants) was similar between the BtB and placebo groups (RR 0.97; 95% CI 0.79 to 1.20) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). The overall risk of adverse events reported by <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK> (with exclusively BtA-non-responsive participants) was higher in the BtB group (RR 1.19; 95% CI 1.03 to 1.37).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Change in subjective evaluation of clinical status evaluated by both participants and clinicians</HEADING>
<P>Subjective evaluation of overall improvement by both participants and clinicians was assessed in all trials at week 4 after BtB injection. The trials used two scales to quantify overall improvement: the Global Assessment of Change (GAC) and the Visual Analogue Scale (VAS). GAC ranges from "Very marked worsening" (- 4) to "Complete resolution of CD symptoms" (+ 4). VAS (range, 0 mm to 100 mm) assesses the change from baseline in symptom severity, where 0 mm indicates "Much worse", 50 mm: "No change", and 100 mm: "Symptom-free".</P>
<P>Two of the trials included in quantitative synthesis (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>) reported this outcome using mean change from baseline on the GAC scale whilst the other study (<LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>) reported this outcome as the mean change from baseline on the on the VAS scale, with both dimensions of the outcome (participant and clinician assessments) being reported in all three studies. Overall, both participants and clinicians reported an improvement of subjective clinical status, with a SMD of 0.86 (95% CI 0.61 to 1.10; I<SUP>2</SUP>= 0%) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) and 0.80 (95% CI 0.55 to 1.04; I<SUP>2</SUP>= 0%) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>) , respectively.</P>
<P>
<LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK> reported that there was a significant (P = 0.0001) improvement among BtB-treated participants in both Patient and Investigator Global Assessment ratings. However, since these data were not fully reported, we could not include this trial in the meta-analysis for this outcome.</P>
<P>All three trials (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>) reporting extractable data for subjective assessments were meta-analysed according to the doses of BtB used, and all doses were associated with a significant benefit when compared to placebo in both participant and clinician subjective assessments (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> and <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>, respectively). There were no differences between the different dose-based subgroups (low versus medium, versus high-dose BtB).</P>
<P>Two trials (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>) reported subjective assessment data with regards to BtA-responsive and BtA-non-responsive participants. These data were meta-analysed, though we found no differences between the different BtA-responsiveness subgroups (see <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK> and <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Changes in pain scores, as assessed with validated assessment tools</HEADING>
<P>Two trials (<LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>) provided data on TWSTRS pain sub-scores (range, 0 to 20), and reported an improvement in participants treated with BtB compared to placebo with a MD of 2.20 (95% CI 1.25 to 3.15; I<SUP>2</SUP>= 58%) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). We did not include <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK> in this meta-analysis because they did not report SD values for the overall intervention group, although they did report SD values for dose subgroups. As they did not describe the study population in sufficient detail, lacking important data such as age distribution, duration and severity of disease, we decided not to impute SD values from similar studies as the margin of error would be unknown. <LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK> did not report data for this outcome.</P>
<P>We meta-analysed three trials (<LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>) that reported data as mean change from baseline on the TWSTRS pain sub-scale, according to the doses of BtB used. These trials were associated with significant benefit when compared to placebo (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). However, we found no differences between the different dose-based subgroups (low versus medium, versus high-dose BtB).</P>
<P>Two trials (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>) reported pain relief data with regards to BtA-responsive and BtA-non-responsive participants. Subgroup analysis did not identify any differences between the different BtA-responsiveness subgroups (see <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Changes in quality of life assessments</HEADING>
<P>
<LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK> assessed quality of life with the Sickness Impact Profile (SIP), a 136-item questionnaire evaluating quotidian activities, divided into 12 categories: emotional behaviour, social interaction, alertness behaviour, communication, body care and movement, ambulation, mobility, sleep and rest, home management, work, recreation and pastimes, and eating. The results are given in percentages, highest scores representing more disabling status. This trial did not report definitive data , although it does state that scores in the BtB arm did not differ significantly from those in the placebo arm. None of the other studies (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>) reported data on this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Number of withdrawals due to adverse events, including adverse events caused by the intervention (type A or type B, or both, adverse drug reactions (ADRs)), and failure of therapy (type F ADRs)</HEADING>
<P>All the included trials reported the number of withdrawals due to adverse events without differences between BtB and placebo (RR 0.88; 95% CI: 0.19 to 4.06; I<SUP>2</SUP>= 0%) (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>). For the purpose of this analysis we considered that adverse events may be caused by the intervention (i.e. type A and/or type B ADRs), or lack of efficacy of the treatment (i.e., failure of therapy, a type F ADRs) (<LINK REF="REF-Edwards-2000" TYPE="REFERENCE">Edwards 2000</LINK>).</P>
<P>The most frequent reason for withdrawal due to adverse events was failure of therapy, which was reported in two participants in <LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK> (one in the BtB arm and the other in the placebo arm) and in two BtB-treated participants in the <LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK> trial. Withdrawals due to adverse events occurred in one participant in the placebo arm in <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK> and in one BtB-allocated participant in <LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>. The former participant experienced neck pain, headache, urticaria, eye pain, asthenia and nausea, and the latter died after triple-vessel coronary artery bypass surgery performed on study day 67, considered unrelated to CD treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Number of participants with adverse events of special interest</HEADING>
<P>The most frequent adverse events reported were dry mouth (RR 7.65; 95% CI 2.75 to 21.32; I<SUP>2</SUP>= 0%) and dysphagia (RR 6.78; 95% CI 2.42 to 19.05; I<SUP>2</SUP>= 0%), which occurred in 17% of participants in the BtB group versus 3% in the placebo group (<LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>, <LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>). The NNTH for dry mouth and dysphagia was 7 (95% CI 26 to 2) and 8 (95% CI 32 to 3), respectively.</P>
<P>For all the other adverse events no significant differences were found. Nevertheless, the following adverse events were more frequent with BtB than placebo: injection site pain (RR 1.39; 95% CI 0.73 to 2.66; I<SUP>2</SUP>= 0%), nausea (RR 2.06; 95% CI 0.68 to 6.28; I<SUP>2</SUP>= 0%), headache (RR 1.90; 95% CI 0.82 to 4.41; I<SUP>2</SUP>= 0%), pain (RR 1.15; 95% CI 0.51 to 2.62; I<SUP>2</SUP>= 0%), infection (RR 1.14; 95% CI 0.38 to 3.38; I<SUP>2</SUP>= 61%) and flu syndrome (RR 1.44; 95% CI 0.23 to 8.92; I<SUP>2</SUP>= 67%).</P>
<P>We performed subgroup analysis according to BtB dose for the two most common adverse events, dry mouth and dysphagia. In comparison to placebo, dry mouth was significantly higher among high-dose BtB-treated participants (RR 11.47; 95% CI 3.95 to 33.30; I<SUP>2</SUP>= 0%), but not among medium and low-dose BtB-treated participants in comparison to placebo. However, overall risk of dry mouth was no different between the dose-defined subgroups (P = 0.18; I<SUP>2</SUP>= 41%) (<LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>). The risk of dysphagia was significantly higher among high- (RR 9.19; 95% CI 3.38 to 25.01; I<SUP>2</SUP>= 0%) and medium-dose (RR 5.50; 95% CI 1.25 to 24.17; I<SUP>2</SUP>= 0%) BtB-treated participants, but not among low-dose BtB-treated participants in comparison to placebo. However, overall risk of dysphagia was no different between the dose-defined subgroups (P = 0.85; I<SUP>2</SUP>= 0%) (<LINK REF="CMP-001.24" TYPE="ANALYSIS">Analysis 1.24</LINK>).</P>
<P>It is noteworthy that all above mentioned adverse events occurred in more than 10% of BtB-treated participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Duration of effect, or number of days until need for reinjection or effect waning</HEADING>
<P>Three trials (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>; <LINK REF="STD-Lew-1997" TYPE="STUDY">Lew 1997</LINK>) assessed duration of clinical benefit, defined as the time until return to baseline TWSTRS total score. In all trials, the duration of effect thus defined was between 12 and 16 weeks. Data suggested that the change in TWSTRS total score over time was somewhat shorter for the lower doses (2500-5000 U) than for the higher dose (10,000 U). Since the studies performed only one treatment session, no data was available for long-term duration of benefit. The newly included study (<LINK REF="STD-Kaji-2013" TYPE="STUDY">Kaji 2013</LINK>) did not assess duration of effect. We did not conduct meta-analysis due to lack of combinable data (<LINK REF="REF-Michiels-2005" TYPE="REFERENCE">Michiels 2005</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-04-22 01:03:59 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-04-21 23:16:09 +0100" MODIFIED_BY="[Empty name]">
<P>This updated review included four randomised, parallel-designed, placebo-controlled trials, enrolling 441 participants with cervical dystonia, of whom 92.5% had been previously treated with BtA. In comparison to placebo, BtB was effective in reducing overall disease impairment, including disease severity, disability and associated pain. An improvement of 14.7% from the participant&#8217;s baseline clinical status was found among participants treated with BtB four weeks after a single treatment cycle, reducing by nearly 7 points in TWSTRS-total score and yielding an NNTB of 3 (for any improvement in TWSTRS-total score). Subjective assessments by both participants and clinicians also favoured BtB in comparison to placebo. The impact of BtB on other domains of participants' quality of life, such as social functioning or mental health, have not properly been addressed in the included trials.</P>
<P>Overall, there was no difference in rates of adverse events and withdrawals due to adverse events between groups. However, the short duration of the trials, as well as the reduced sample size, precludes strong conclusions with regards to the lack of differences between BtB and placebo. The most common adverse events that were different between the BtB and placebo groups were dry mouth and dysphagia, both considered related to treatment and being about six times more frequent among BtB-treated patients, with an NNTH of 7 and 8, respectively. No fatalities or serious adverse events were considered related to BtB treatment in any of the trials. Data for special subpopulations, such as children and pregnant women, were not available.</P>
<SUBSECTION>
<HEADING LEVEL="5">BtB doses</HEADING>
<P>All dosages were efficacious against placebo, but we found no clear-cut evidence of a dose-response gradient. It is however noteworthy that these trials were not dose-response studies and that this conclusion was based on arbitrarily defined dose-subgroup analyses. On the other hand, higher BtB dosages were associated with a higher risk of dysphagia and dry mouth.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">BtA-responsive versus BtA-non-responsive participants</HEADING>
<P>The percentage improvement of disease impairment reported in one trial enrolling exclusively BtA-non-responders was higher than that reported in another trial enrolling exclusively BtA-responders. The reduced sample size precludes strong conclusions with regards to these results, which could be due to several confounding factors, such as methodological differences and population imbalances between the two trials. One further trial, enrolling both types of participants, also suggested a higher efficacy among BtA-non-responders. As for adverse events, we found no differences between the groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Duration of effect</HEADING>
<P>The effect of BtB lasted approximately 12 to 16 weeks, as assessed by the time needed to return to baseline TWSTRS total scores. Duration of effect thus defined was greater in the subgroup of participants treated with higher BtB doses. Long-term duration of effect could not be evaluated as all trials evaluated only a single treatment session.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-04-21 23:15:42 +0100" MODIFIED_BY="[Empty name]">
<P>All included trials addressed the primary outcome of our review using the same assessment tool. However, some did not fully report all outcome data, and in some cases results could not be pooled and compared across studies. This limits the amount of data available and, consequently, the confidence in overall conclusions.</P>
<P>Four noteworthy factors challenge the implementation of the evidence in this review. First, there was a limited and considerably heterogeneous regional distribution, with one trial being conducted in Japan and three in the United States. Differences in clinical practice, training of experts, and local guidelines in other regions of the world may present an obstacle to the application of the evidence here demonstrated. Second, sample size across included trials was relatively small and many subgroup analyses for the outcomes of interest present only trends in the results. More studies are needed to provide robust evidence for these trends. Third, the enrolment of enriched populations in clinical trials limits applicability of results into clinical practice, as complex and potentially poorer responders are usually excluded in these trials. The fact that these patients are common in clinical practice further complicates issues of generalisation. Fourth, patients frequently have concomitant medications for their condition, such as muscle relaxants and benzodiazepines. In trials, such medications are reasonably required to be on a stable dose for many weeks to avoid confounding factors. As a result, little is currently known about the impact of these drug regimens with regards to implementation of the evidence in this review.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-04-22 01:03:59 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, 'Risk of bias' tables and 'Risk of bias' summary tables (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>Only two of the included studies adequately described their randomisation and allocation methods, with the remaining two trials being assessed at an unclear risk of bias for these items. All studies were considered appropriately blinded in general; however, only two provided satisfactory descriptions of blinding of objective outcome assessment, and all were considered possibly biased regarding subjective outcome assessment, as all studies predominantly enrolled patients with previous treatment with BtA. This represents major methodological limitations that may have resulted in a biased assessment of the intervention effect, particularly with regards to subjective outcomes, which are highly susceptible to biased estimations, namely pain assessment, subjective assessment by participants and clinicians, and quality of life assessments. Finally, statistical heterogeneity was present for pain and adverse events outcomes which could not be clearly explained by the subgroup analysis performed. However, results from individual studies were all in the same direction.</P>
<P>Some outcomes could not be compared across studies, as some studies lacked reporting of relevant data. Imbalances between baseline characteristics of the participants and incomplete description of the variables meant that we could not confidently impute values for missing data, further reducing the amount of combinable data, and therefore the precision of the results.</P>
<P>The included trials enrolled between 77 and 133 participants, and although individually these trials were underpowered, the pooling of the trials permitted an adequate sample size for the majority of efficacy outcomes. Taken together, we consider that there is moderate quality evidence that a single treatment session of BtB, in certain types of cervical dystonia, is efficacious in reducing disease impairment, including severity, pain and disability. However, the quality of the evidence is low and no robust conclusions can be made regarding safety and tolerability, including withdrawals due to adverse events, as well as regarding continued responsiveness and long-term efficacy, which are important aspects in a chronic condition such as cervical dystonia.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-04-21 23:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Although we followed the methods recommended by Cochrane in order to minimise bias in the review process, certain areas are deserving of attention on the part of readers. Despite having contacted experts in the area, not having searched clinical trial registries opens the current review to two potential problems: firstly, possibly having missed trials and also the possibility of introducing publication bias.</P>
<P>The newly added trial was published in Japanese only. Results tables were presented in English, and important information was extracted from the text by a Japanese collaborator (Dr. Masao Kaneshige). Even though we took steps to minimise this potential source of bias, we cannot ignore its existence.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-04-21 23:15:27 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, the results of this updated review are in agreement with the conclusions of earlier versions. However, we now conclude that no claims can be made regarding a clear-cut dose-response relationship for efficacy outcomes. On the other hand, a clear dose-dependent relationship exists for the treatment-related adverse events of special interest, such as dysphagia and dry mouth.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-04-22 01:02:54 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-04-21 23:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>A single treatment session of BtB is effective and well-tolerated in the treatment of both BtA-non-reponsive and BtA-responsive adults with certain types of cervical dystonia. No conclusions can be made regarding people with pure retrocollis or anterocollis as these were predominantly excluded in the clinical trials. Dry mouth and dysphagia are the most frequent treatment-related adverse events, although they were not associated with treatment discontinuation.</P>
<P>Higher doses of BtB are associated with a higher risk of most frequent adverse events, without a clear dose-benefit response. No conclusions can be made from published data about whether EMG guidance of BtB injections improves efficacy or safety outcomes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-04-22 01:02:54 +0100" MODIFIED_BY="[Empty name]">
<P>The qualitative net benefit of a single BtB injection in the treatment of cervical dystonia has been established in published trials. Nonetheless, further studies are needed to establish the relative effectiveness of different doses of BtB, assessing efficacy, safety, duration of effect and quality of life across regimes. Because therapy typically requires optimising a dose for each patient rather than administering fixed units of botulinum toxin, such a line of research would be important to support the physician&#8217;s management of doses and allow for a more solid and safe individualisation of a patient&#8217;s treatment.</P>
<P>New trials should also assess the potential added benefit of EMG-guided botulinum toxin treatments. This would also help to clarify the clinical advantage of training experts in using such techniques. Trial authors should endeavour to fully study and report data on BtA-responsive and BtA-non-responsive participants. Considering that a large number of people who are treated with BtB are BtA-non-responsive, it would be clinically useful to directly compare BtB effectiveness between BtA-non-reponsive and BtA-responsive patients. At the moment there is insufficient evidence to support the claim that a higher benefit due to BtB can be elicited from either group.</P>
<P>Future research concerning all formulations of botulinum toxin should endeavour to establish clinical effectiveness not only based on changes from baseline, but preferably based on validated measures of Minimal Clinically Important Difference/Change (<LINK REF="REF-Brozek-2006" TYPE="REFERENCE">Brozek 2006</LINK>). Research is required in order to establish such a parameter for the TWSTRS, currently the most widely used and disseminated clinical scale in the field. We are, however, aware of an effort to create a new clinical scale in dystonia - the Comprehensive Cervical Dystonia Rating Scale (<LINK REF="REF-Comella-2015" TYPE="REFERENCE">Comella 2015</LINK>), which will include a revision of the TWSTRS, to be named TWSTRS-2, with a Minimal Clinically Important Change validation being planned.</P>
<P>It is currently uncertain whether or not the clinical effectiveness of botulinum toxin decays over time, with repeated treatment sessions, or whether a possible loss of effectiveness occurs in all clinical domains. Another related aspect is the possible development of BtB-non-responsiveness. Future research should address these important prognostic aspects.</P>
<P>Finally, in conducting this systematic review we were faced with the fact that there is no defined Core Outcome Set in cervical dystonia research, as there is in other areas (<LINK REF="REF-Tugwell-2007" TYPE="REFERENCE">Tugwell 2007</LINK>). The definition of a set of core outcome measures to be included in future research, via well-established methodology to determine the inclusion of patient-reported outcomes (<LINK REF="REF-Macefield-2014" TYPE="REFERENCE">Macefield 2014</LINK>) would be relevant to promote research in this field, as well as to support the clinical effectiveness of BtB.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-04-22 00:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to sincerely thank Ema Roque (Cochrane Movement Disorders), Daisy Abreu (Clinical Pharmacology Unit, Faculty of Medicine of Lisbon), Francesca Fiorentino (CEMBE), Nate J. Kosher (American Academy of Neurology) and Masao Kaneshige (Department of Clinical Neuroscience, Tokushima University Graduate School) for their contribution to this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-04-21 16:23:35 +0100" MODIFIED_BY="[Empty name]">
<P>Costa J, Ferreira JJ, Sampaio C have been investigators in clinical trials sponsored by Elan, Allergan, and Ipsen. Ferreira JJ and Sampaio C were speakers in symposia promoted by Elan, Allergan, and Ipsen.<BR/>Moore AP has received fees from various companies marketing botulinum toxin for speaking at meetings and for advice. His unit has received funds for research.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-04-21 23:01:27 +0100" MODIFIED_BY="[Empty name]">
<P>A Peter Moore - APM; Cristina Sampaio - CS; Filipe Brogueira Rodrigues - FBR; Gonçalo S Duarte - GSD; João Costa - JC; Joaquim Ferreira - JJF; Mafalda Castelão - MC; Raquel E Marques - REM.</P>
<P>Conceiving the review - APM, CS, JC, JJF</P>
<P>Designing the review - APM, CS, JC, JJF</P>
<P>Co-ordinating the review - JC</P>
<P>Designing search strategies &#8211; FBR, JC</P>
<P>Undertaking searches &#8211; FBR, GSD</P>
<P>Screening search results &#8211; FRB, GSD, MF, REM</P>
<P>Organising retrieval of papers - FRB, GSD, JC, MF, REM</P>
<P>Screening retrieved papers against eligibility criteria - FRB, GSD, MF, REM</P>
<P>Appraising quality of papers - FRB, GSD, JC, MF, REM</P>
<P>Extracting data from papers - FRB, GSD, JC, MF, REM</P>
<P>Writing to authors of papers for additional information &#8211; GSD, JC, REM</P>
<P>Data management for the review &#8211; FRB, GSD, MF, REM</P>
<P>Entering data into RevMan - FRB, GSD, MF, REM</P>
<P>Analysis of data - FRB, GSD, JC, MF, REM</P>
<P>Interpretation of data - APM, CS, FRB, GSD, JC, JJF, MF, REM</P>
<P>Writing the review - FRB, GSD, JC, MF, REM</P>
<P>Providing general advice on the review &#8211; CS, JC, JJF</P>
<P>Performing previous work that was the foundation of the current review &#8211; Ana Borges, Claudia Espírito Santo, Miguel Coelho.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-02-03 08:22:42 +0000" MODIFIED_BY="[Empty name]">
<P>For this updated review the study designs accepted were restricted to parallel-group. No changes were made in the type of participants included or in the interventions allowed.</P>
<P>Adverse events, which were originally a secondary outcome, were included in this updated review as a primary safety outcome. In this safety analysis we considered also the proportion of participants with the most frequent adverse events, not stated in the original protocol. Assessments of the duration of effect and proportion of withdrawals due to adverse drug reactions were included as new secondary outcomes measures.</P>
<P>The search strategy was prolonged from the inception to October 2015.</P>
<P>New approaches were assumed to deal with missing data and unit of analysis issue.</P>
<P>The latest recommended Cochrane tool for assessing risk of bias was used in this review, which was expanded to include two additional criteria, added by the review authors. Blinding of outcome assessment was analysed in two new subcategories: subjective and objective assessment.</P>
<P>A &#8216;<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>&#8217; table was also added.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-05-12 11:06:52 +0100" MODIFIED_BY="Ema Roque">
<STUDIES MODIFIED="2016-04-22 16:48:32 +0100" MODIFIED_BY="Ana Raquel Marques">
<INCLUDED_STUDIES MODIFIED="2016-04-22 16:47:20 +0100" MODIFIED_BY="Ana Raquel Marques">
<STUDY DATA_SOURCE="PUB" ID="STD-Brashear-1999" MODIFIED="2016-04-22 16:45:53 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Brashear 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-04-22 16:45:24 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al</AU>
<TI>Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-responsive cervical dystonia</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52 (Suppl 2)</VL>
<PG>A292 (S46.003)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954750"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-22 16:45:42 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al</AU>
<TI>Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-responsive cervical dystonia</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53(7)</VL>
<PG>1439-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954751"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-22 16:45:53 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Factor S, Adler CH, Brashear A, Brin MF, Comella CL, Dykstra DD, et al</AU>
<TI>Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 (Suppl 2)</VL>
<PG>7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954752"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-21 19:39:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Factor S</AU>
<TI>Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia</TI>
<SO>Toxins'99 (www.wemove.org)</SO>
<YR>1999</YR>
<PG>9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954753"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koller M, Wallace JD, Willmer-Hulme A, Chiang P, Murray JJ</AU>
<TI>Evaluation of Neurobloc (Botulinum toxin type B) efficacy in patients with cervical dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 (Suppl 2)</VL>
<PG>31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954754"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lew MF, Brashear A, Factor S</AU>
<TI>The safety and efficacy of Botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55 (Suppl 5)</VL>
<PG>S29-S35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954755"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954749"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brin-1999" MODIFIED="2016-04-22 16:46:46 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Brin 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-04-22 16:46:06 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al</AU>
<TI>Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-resistant cervical dystonia</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>22;53(7)</VL>
<PG>1431-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954757"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-22 16:46:18 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al</AU>
<TI>Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-resistant cervical dystonia</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52 (Suppl 2)</VL>
<PG>A293 (S46.004)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954758"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-22 16:46:34 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Factor S, Adler CH, Brashear A, Brin MF, Comella CL, Dykstra DD, et al</AU>
<TI>Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 (Suppl 2)</VL>
<PG>7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954759"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-21 19:42:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Factor S</AU>
<TI>Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>1431-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954760"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-22 16:46:46 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Koller M, Wallace JD, Willmer-Hulme A, Chiang P, Murray JJ</AU>
<TI>Evaluation of Neurobloc (Botulinum toxin type B) efficacy in patients With cervical dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 (Suppl 2)</VL>
<PG>31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954761"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lew MF, Brashear A, Factor S</AU>
<TI>The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55 (Suppl 5)</VL>
<PG>S29-S35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954762"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954756"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaji-2013" MODIFIED="2016-04-22 16:46:59 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Kaji 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-04-22 16:46:59 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaji R, Shimizu H, Takase T, Osawa M, Yanagisawa N</AU>
<TI>A double-blind comparative study to evaluate the efficacy and safety of NerBloc (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia</TI>
<SO>Brain and Nerve</SO>
<YR>2013</YR>
<VL>65</VL>
<NO>2</NO>
<PG>203-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954764"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954763"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lew-1997" MODIFIED="2016-04-22 16:47:20 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Lew 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-04-22 16:47:12 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koller M, Wallace JD, Willmer-Hulme A, Chiang P, Murray JJ</AU>
<TI>Evaluation of Neurobloc (Botulinum toxin type B) efficacy in patients with cervical dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 (Suppl 2)</VL>
<PG>31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954766"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-22 16:47:20 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al</AU>
<TI>Botulinum toxin type B: a double-blind, placebo controlled, safety and efficacy study in cervical dystonia</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>49</VL>
<PG>701-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954767"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lew MF, Brashear A, Factor S</AU>
<TI>The safety and efficacy of Botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55 (Suppl 5)</VL>
<PG>S29-S35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954768"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954765"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-04-22 16:48:32 +0100" MODIFIED_BY="Ana Raquel Marques">
<STUDY DATA_SOURCE="PUB" ID="STD-AN072_x002d_008-1995" MODIFIED="2016-04-22 16:47:40 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="AN072-008 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>American BotB Cervical Dystonia Study Group</AU>
<TI>BotB (Botulinum toxin type B) in the treatment of cervical dystonia (CD) - protocol AN072-008: an interim analysis</TI>
<SO>Movement Disorders</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>2874 (abstract)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954770"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-22 16:47:40 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koller M, Wallace JD, Willmer-Hulme A, Chiang P, Murray JJ</AU>
<TI>Evaluation of Neurobloc (Botulinum toxin type B) efficacy in patients with cervical dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 (Suppl 2)</VL>
<PG>31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954771"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954769"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chinnapongse-2010" MODIFIED="2016-04-22 16:47:53 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Chinnapongse 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-04-22 16:47:53 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chinnapongse R, Pappert EJ, Evatt M, Freeman A, Birmingham W</AU>
<TI>An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinB in subjects with cervical dystonia</TI>
<SO>International Journal of Neuroscience</SO>
<YR>2010</YR>
<VL>120</VL>
<NO>11</NO>
<PG>703-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954773"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954772"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cullis-2000" MODIFIED="2016-04-22 16:47:31 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Cullis 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-04-22 16:47:31 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cullis PA, Barnes M, Duane D, Chen RE, Freeman A, Fross R, et al</AU>
<TI>Safety and tolerability of repeated doses of Neurobloc (Botulinum toxin type B) in patients with cervical dystonia: an open-label, dose-escalation study</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 (Suppl 2)</VL>
<PG>29</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954775"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954774"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dressler-2005" MODIFIED="2016-04-22 16:48:01 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Dressler 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-04-22 16:48:01 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dressler D, Bigalke H</AU>
<TI>Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure
</TI>
<SO>Journal of neurology</SO>
<YR>2005</YR>
<VL>252</VL>
<NO>8</NO>
<PG>904-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954777"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954776"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacob-2003" MODIFIED="2016-04-22 16:48:12 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Jacob 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-04-22 16:48:12 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacob CI</AU>
<TI>Botulinum toxin type B - onset, duration, and efficacy: comparing dilution with preserved versus nonpreserved saline</TI>
<SO>Cosmetic Dermatology</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>7</NO>
<PG>25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954779"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954778"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jankovic-2006" MODIFIED="2016-04-22 16:48:22 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Jankovic 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-04-22 16:48:22 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jankovic J, Hunter C, Dolimbek DZ, Dolimbek GS, Adler CH, Brashear A, et al</AU>
<TI>Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>12</NO>
<PG>2233-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954781"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954780"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lew-2002" MODIFIED="2015-04-26 19:47:23 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Lew 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-04-26 19:47:21 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lew MF</AU>
<TI>Botulinum toxin type B: An effective treatment for alleviating pain associated with cervical dystonia</TI>
<SO>Journal of Back and Musculoskeletal Rehabilitation</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>1</NO>
<PG>3-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954783"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954782"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Truong-1997" MODIFIED="2016-04-22 16:48:32 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Truong 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-04-22 16:48:32 +0100" MODIFIED_BY="Ana Raquel Marques" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD</AU>
<TI>BotB (Botulinum toxin type B): Evaluation of safety and tolerability in Botulinum type A-resistant cervical dystonia patients (preliminary study)</TI>
<SO>Movement Disorders</SO>
<YR>1997</YR>
<VL>12(5)</VL>
<PG>772-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2954785"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2954784"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-04-22 16:52:08 +0100" MODIFIED_BY="Ana Raquel Marques">
<ADDITIONAL_REFERENCES MODIFIED="2016-04-22 16:52:08 +0100" MODIFIED_BY="Ana Raquel Marques">
<REFERENCE ID="REF-Abrams-2005" MODIFIED="2016-04-22 16:48:51 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Abrams 2005" TYPE="JOURNAL_ARTICLE">
<AU>Abrams KR, Gillies CL, Lambert PC</AU>
<TI>Meta-analysis of heterogeneously reported trials assessing change from baseline</TI>
<SO>Statistics in Medicine</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>3823-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Albanese-2013" MODIFIED="2016-04-22 16:48:43 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Albanese 2013" TYPE="JOURNAL_ARTICLE">
<AU>Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al</AU>
<TI>Phenomenology and classification of dystonia: a consensus update</TI>
<SO>Movement Disorders</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>7</NO>
<PG>863-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2002" MODIFIED="2016-04-21 19:46:28 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Deeks JJ</AU>
<TI>Meta-analysis, Simpson's paradox, and the number needed to treat</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Antonucci-2008" MODIFIED="2016-04-22 16:49:07 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Antonucci 2008" TYPE="JOURNAL_ARTICLE">
<AU>Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M</AU>
<TI>Long-distance retrograde effects of botulinum neurotoxin</TI>
<SO>Journal of Neuroscience</SO>
<YR>2008</YR>
<VL>28</VL>
<PG>3689&#8211;96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balint-2015" MODIFIED="2016-04-22 16:49:18 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Balint 2015" TYPE="JOURNAL_ARTICLE">
<AU>Balint B, Bhatia KP</AU>
<TI>Isolated and combined dystonia syndromes - an update on new genes and their phenotypes</TI>
<SO>European Journal of Neurology</SO>
<YR>2015</YR>
<VL>22</VL>
<NO>4</NO>
<PG>610-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benecke-2012" MODIFIED="2016-04-22 16:49:26 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Benecke 2012" TYPE="JOURNAL_ARTICLE">
<AU>Benecke R</AU>
<TI>Clinical relevance of Botulinum toxin immunogenicity</TI>
<SO>BioDrugs</SO>
<YR>2012 Apr</YR>
<VL>26</VL>
<NO>2</NO>
<PG>e1-e9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boroff-1975" MODIFIED="2016-02-17 10:48:23 +0000" MODIFIED_BY="[Empty name]" NAME="Boroff 1975" TYPE="JOURNAL_ARTICLE">
<AU>Boroff DA, Chen GS</AU>
<TI>On the question of permeability of the blood&#8211;brain barrier to botulinum toxin</TI>
<SO>Int Arch Allergy ApplImmunol.</SO>
<YR>1975</YR>
<VL>48</VL>
<PG>495&#8211;504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brashear-2008" MODIFIED="2016-04-22 16:49:36 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Brashear 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brashear A</AU>
<TI>Botulinum toxin serotype A for cervical dystonia &#8212; an assessment</TI>
<SO>US Neurol</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>2</NO>
<PG>58-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brin-2008" MODIFIED="2016-04-22 16:49:42 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Brin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group</AU>
<TI>Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay</TI>
<SO>Movement Disorders</SO>
<YR>2008 Jul</YR>
<VL>23</VL>
<NO>10</NO>
<PG>1353-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brozek-2006" MODIFIED="2016-02-17 10:48:50 +0000" MODIFIED_BY="[Empty name]" NAME="Brozek 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bro&#380;ek JL, Guyatt GH, Schünemann HJ</AU>
<TI>How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure</TI>
<SO>Health and Quality of Life Outcomes</SO>
<YR>2006</YR>
<VL>4</VL>
<PG>69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-1991" NAME="Chan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Chan J, Brin MF, Fanh S</AU>
<TI>Idiopathic cervical dystonia: clinical characteristics</TI>
<SO>Movement Disorders</SO>
<YR>1991</YR>
<VL>6</VL>
<PG>119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2016-04-20 18:32:12 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<TI>Statistical 
power 
analysis in the 
behavioral 
sciences</TI>
<SO>Statistical Power Analysis in the Behavioral Sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Hillsdale (NJ): Lawrence Erlbaum Associates, Inc.</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Comella-2015" MODIFIED="2016-04-22 16:49:53 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Comella 2015" TYPE="JOURNAL_ARTICLE">
<AU>Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, et al</AU>
<TI>Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology</TI>
<SO>Movement Disorders</SO>
<YR>2015</YR>
<VL>2</VL>
<NO>2</NO>
<PG>135-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Consky-1994" MODIFIED="2016-04-22 16:50:04 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Consky 1994" TYPE="BOOK_SECTION">
<AU>Consky ES, Lang AE</AU>
<TI>Clinical assessments of patients with cervical dystonia</TI>
<SO>Therapy with botulinum toxin</SO>
<YR>1994</YR>
<PG>211-37</PG>
<ED>Jankovic J, Hallett M</ED>
<PB>Marcel Dekker, Inc</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Paiva-1999" MODIFIED="2016-02-17 10:56:40 +0000" MODIFIED_BY="[Empty name]" NAME="de Paiva 1999" TYPE="JOURNAL_ARTICLE">
<AU>de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO</AU>
<TI>Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals</TI>
<SO>Proc Natl Acad Sci USA.</SO>
<YR>1999</YR>
<VL>96</VL>
<PG>3200&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Defazio-2013" MODIFIED="2016-04-22 16:50:12 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Defazio 2013" TYPE="JOURNAL_ARTICLE">
<AU>Defazio G, Jankovic J, Giel JL, Papapetropoulos S</AU>
<TI>Descriptive epidemiology of cervical dystonia</TI>
<SO>Tremor Other Hyperkinet Mov</SO>
<YR>2013</YR>
<VL>3</VL>
<PG>tre-03-193-4374-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duchen-1971" MODIFIED="2016-02-17 10:56:50 +0000" MODIFIED_BY="[Empty name]" NAME="Duchen 1971" TYPE="JOURNAL_ARTICLE">
<AU>Duchen LW</AU>
<TI>An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse</TI>
<SO>J Neurol Sci.</SO>
<YR>1971</YR>
<VL>14</VL>
<PG>47-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2000" MODIFIED="2016-04-20 18:29:34 +0100" MODIFIED_BY="[Empty name]" NAME="Edwards 2000" TYPE="JOURNAL_ARTICLE">
<AU>Edwards IR, Aronson JK
</AU>
<TI>Adverse drug reactions: definitions, diagnosis, and management</TI>
<SO>Lancet</SO>
<YR>2000 Oct 7</YR>
<VL>356</VL>
<NO>9237</NO>
<PG>1255-1259</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eleopra-1997" MODIFIED="2016-02-17 10:57:00 +0000" MODIFIED_BY="[Empty name]" NAME="Eleopra 1997" TYPE="JOURNAL_ARTICLE">
<AU>Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D</AU>
<TI>Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human</TI>
<SO>Neuroscience Letters</SO>
<YR>1997</YR>
<VL>224(2)</VL>
<PG>91-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESDE-2000" MODIFIED="2016-04-20 18:30:38 +0100" MODIFIED_BY="[Empty name]" NAME="ESDE 2000" TYPE="JOURNAL_ARTICLE">
<AU>Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group</AU>
<TI>A prevalence study of primary dystonia in eight European countries
</TI>
<SO>Journal of Neurology</SO>
<YR>2000</YR>
<VL>247</VL>
<PG>787-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fabbri-2015" MODIFIED="2016-04-22 16:50:27 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Fabbri 2015" TYPE="JOURNAL_ARTICLE">
<AU>Fabbri M, Leodori G, Fernandes RM, Bhidayasiri R, Marti MJ, Colosimo C, et al</AU>
<TI>Neutralizing antibody and Botulinum toxin therapy: a sSystematic review and meta-analysis</TI>
<SO>Neurotox Res</SO>
<YR>2015</YR>
<VL>29</VL>
<PG>105-117</PG>
<IDENTIFIERS MODIFIED="2016-02-19 23:44:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-19 23:44:29 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="26467676"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Filippi-1993" MODIFIED="2016-02-18 19:15:26 +0000" MODIFIED_BY="[Empty name]" NAME="Filippi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E</AU>
<TI>Botulinum A toxin effects on rat jaw muscle spindles</TI>
<SO>Acta Otolaryngol.</SO>
<YR>1993</YR>
<VL>113</VL>
<PG>400&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Follmann-1992" MODIFIED="2016-02-17 10:58:33 +0000" MODIFIED_BY="[Empty name]" NAME="Follmann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Follmann D, Elliott P, Suh I, Cutler J</AU>
<TI>Variance imputation for overviews of clinical trials with continuous response</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>769-773</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foltz-1959" MODIFIED="2016-04-22 16:50:38 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Foltz 1959" TYPE="JOURNAL_ARTICLE">
<AU>Foltz EL, Knopp LM, Ward AA</AU>
<TI>Experimental spasmodic torticollis</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1959</YR>
<VL>16</VL>
<PG>55-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frevert-2010" MODIFIED="2016-02-17 10:59:08 +0000" MODIFIED_BY="[Empty name]" NAME="Frevert 2010" TYPE="JOURNAL_ARTICLE">
<AU>Frevert J, Dressler D</AU>
<TI>Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?</TI>
<SO>Biologics: Targets &amp; Therapy</SO>
<YR>2010 Dec</YR>
<VL>4</VL>
<PG>325-332</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greene-1993" MODIFIED="2016-02-18 19:16:08 +0000" MODIFIED_BY="[Empty name]" NAME="Greene 1993" TYPE="JOURNAL_ARTICLE">
<AU>Greene PE, Fahn S</AU>
<TI>Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A</TI>
<SO>Movement Disorders</SO>
<YR>1993</YR>
<VL>8(4)</VL>
<PG>479-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hallett-1998" MODIFIED="2015-04-03 14:24:11 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Hallett 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hallett M</AU>
<TI>The neurophysiology of dystonia</TI>
<SO>Arch Neurol</SO>
<YR>1998 May</YR>
<VL>55</VL>
<NO>5</NO>
<PG>601-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hanna-1998" MODIFIED="2016-04-22 16:50:51 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Hanna 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hanna PA, Jankovic J</AU>
<TI>Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response</TI>
<SO>Neurology</SO>
<YR>1998 Jun</YR>
<VL>50</VL>
<NO>6</NO>
<PG>1624-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2016-04-22 16:51:02 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2016-04-22 16:51:12 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2016-04-22 16:51:19 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holland-1981" MODIFIED="2016-02-18 19:10:01 +0000" MODIFIED_BY="[Empty name]" NAME="Holland 1981" TYPE="JOURNAL_ARTICLE">
<AU>Holland RL, Brown MC</AU>
<TI>Nerve growth in botulinum toxin poisoned muscles</TI>
<SO>Neuroscience.</SO>
<YR>1981</YR>
<VL>6</VL>
<PG>1167&#8211;79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jahnanshani-1990" MODIFIED="2016-02-18 19:12:15 +0000" MODIFIED_BY="[Empty name]" NAME="Jahnanshani 1990" TYPE="JOURNAL_ARTICLE">
<AU>Jahnanshani M, Marion M-H, Marsden CD</AU>
<TI>Natural history of adult-onset idiopathic torticollis</TI>
<SO>Archives of Neurology</SO>
<YR>1990</YR>
<VL>47</VL>
<PG>548-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jankovic-2004" MODIFIED="2015-04-03 14:54:53 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Jankovic 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jankovic J</AU>
<TI>Botulinum toxin in clinical practice</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>7</NO>
<PG>951-957</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juzans-1996" MODIFIED="2016-01-02 08:47:55 +0000" MODIFIED_BY="[Empty name]" NAME="Juzans 1996" TYPE="JOURNAL_ARTICLE">
<AU>Juzans P, Comella J, Molgo J, Faille L, Angaut-Petit D</AU>
<TI>Nerve terminal sprouting inbotulinum type-A treated mouse levator auris longus muscle</TI>
<SO>Neuromuscul Disord.</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>3</NO>
<PG>177-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lange-2009" MODIFIED="2016-01-02 09:29:54 +0000" MODIFIED_BY="[Empty name]" NAME="Lange 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K</AU>
<TI>Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?</TI>
<SO>Clin Neuropharmacol</SO>
<YR>2009 Jul-Aug</YR>
<VL>32</VL>
<NO>4</NO>
<PG>213-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macefield-2014" MODIFIED="2016-04-22 16:51:28 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Macefield 2014" TYPE="JOURNAL_ARTICLE">
<AU>Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, Set al</AU>
<TI>Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs)</TI>
<SO>Trials</SO>
<YR>2014</YR>
<VL>15</VL>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matak-2014" MODIFIED="2016-01-02 09:12:59 +0000" MODIFIED_BY="[Empty name]" NAME="Matak 2014" TYPE="JOURNAL_ARTICLE">
<AU>Matak I, Lackovi&#263; Z</AU>
<TI>Botulinum toxin A, brain and pain</TI>
<SO>Prog Neurobiol.</SO>
<YR>2014 Aug-Sep</YR>
<VL>119-120</VL>
<PG>39&#8211;59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matak-2015" MODIFIED="2016-01-02 09:18:48 +0000" MODIFIED_BY="[Empty name]" NAME="Matak 2015" TYPE="JOURNAL_ARTICLE">
<AU>Matak I, Lackovi&#263; Z</AU>
<TI>Botulinum neurotoxin type A: Actions beyond SNAP-25?</TI>
<SO>Toxicology.</SO>
<YR>2015</YR>
<VL>335</VL>
<PG>79-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Michiels-2005" MODIFIED="2016-02-20 22:35:02 +0000" MODIFIED_BY="[Empty name]" NAME="Michiels 2005" TYPE="JOURNAL_ARTICLE">
<AU>Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP</AU>
<TI>Meta-analysis when only the median survival times are known: a comparison with individual patient data results</TI>
<SO>Int J Technol Assess Health Care</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>1</NO>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muller-2009" MODIFIED="2016-01-02 09:38:26 +0000" MODIFIED_BY="[Empty name]" NAME="Muller 2009" TYPE="JOURNAL_ARTICLE">
<AU>Müller K, Mix E, Adib Saberi F, Dressler D, Benecke R</AU>
<TI>Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity</TI>
<SO>J Neural Transm</SO>
<YR>2009 May</YR>
<VL>116</VL>
<NO>5</NO>
<PG>579-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palomar-2012" MODIFIED="2016-02-18 19:09:51 +0000" MODIFIED_BY="[Empty name]" NAME="Palomar 2012" TYPE="JOURNAL_ARTICLE">
<AU>Palomar FJ, Mir P</AU>
<TI>Neurophysiological changes after intramuscular injection of botulinum toxin</TI>
<SO>Clin Neurophysiol.</SO>
<YR>2012</YR>
<VL>123</VL>
<PG>23:54&#8211;60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pellizzari-1999" MODIFIED="2016-02-18 19:09:35 +0000" MODIFIED_BY="[Empty name]" NAME="Pellizzari 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pellizzari R, Rossetto O, Schiavo G, Montecucco C</AU>
<TI>Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses</TI>
<SO>Philos Trans R Soc Lond B Biol Sci.</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>259&#8211;68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-2006" MODIFIED="2016-04-22 16:51:39 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Peters 2006" TYPE="JOURNAL_ARTICLE">
<AU>Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L</AU>
<TI>Comparison of two methods to detect publication bias in meta-analysis</TI>
<SO>JAMA.</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>6</NO>
<PG>676-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-04-22 16:51:50 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosales-1996" MODIFIED="2016-02-18 19:09:29 +0000" MODIFIED_BY="[Empty name]" NAME="Rosales 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rosales RL, Arimura K, Takenaka S, Osame M</AU>
<TI>Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection</TI>
<SO>Muscle Nerve.</SO>
<YR>1996</YR>
<VL>19</VL>
<PG>488&#8211;96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosales-2010" MODIFIED="2016-02-18 19:09:24 +0000" MODIFIED_BY="[Empty name]" NAME="Rosales 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rosales RL, Dressler D</AU>
<TI>On muscle spindles, dystonia and botulinum toxin</TI>
<SO>Eur J Neurol.</SO>
<YR>2010</YR>
<VL>17</VL>
<PG>71&#8211;80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2004" MODIFIED="2016-02-18 19:09:19 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Simpson LL</AU>
<TI>Identification of the major steps in botulinum toxin action</TI>
<SO>Annu Rev Pharmacol Toxicol.</SO>
<YR>2004</YR>
<VL>44</VL>
<PG>167-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smeeth-1999" NAME="Smeeth 1999" TYPE="JOURNAL_ARTICLE">
<AU>Smeeth L, Haines A, Ebrahim S</AU>
<TI>Numbers needed to treat derived from meta-analysis - sometimes informative, usually misleading</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318(7197)</VL>
<PG>1548-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steeves-2012" MODIFIED="2016-01-02 08:10:06 +0000" MODIFIED_BY="[Empty name]" NAME="Steeves 2012" TYPE="JOURNAL_ARTICLE">
<AU>Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T</AU>
<TI>The prevalence of primary dystonia: A systematic review and meta&#8208;analysis</TI>
<SO>Movement Disorders.</SO>
<YR>2012 Dec</YR>
<VL>27</VL>
<NO>14</NO>
<PG>1789-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2016-01-02 08:10:43 +0000" MODIFIED_BY="[Empty name]" NAME="Sterne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis</TI>
<SO>J Clin Epidemiol.</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1046-1055</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2016-04-22 16:52:02 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Intervention.</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2007" MODIFIED="2016-02-04 21:47:57 +0000" MODIFIED_BY="[Empty name]" NAME="Tugwell 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L</AU>
<TI>OMERACT: an international initiative to improve outcome measurement in rheumatology</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker-2014" MODIFIED="2016-04-22 16:52:08 +0100" MODIFIED_BY="Ana Raquel Marques" NAME="Walker 2014" TYPE="JOURNAL_ARTICLE">
<AU>Walker TJ, Dayan SH</AU>
<TI>Comparison and overview of currently available neurotoxins</TI>
<SO>J Clin Aesthet Dermatol.</SO>
<YR>2014</YR>
<VL>7</VL>
<NO>2</NO>
<PG>31-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zoons-2012" MODIFIED="2016-04-21 23:28:36 +0100" MODIFIED_BY="[Empty name]" NAME="Zoons 2012" TYPE="JOURNAL_ARTICLE">
<AU>Zoons E, Dijkgraaf MGW, Dijk JM, vVan Schaik IN, Tijssen MA</AU>
<TI>Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value</TI>
<SO>Neurology</SO>
<YR>Dec 2012</YR>
<VL>259</VL>
<NO>12</NO>
<PG>2519&#8211;2526</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-01-02 08:30:51 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Costa-2004" MODIFIED="2016-01-02 08:30:48 +0000" MODIFIED_BY="[Empty name]" NAME="Costa 2004" TYPE="COCHRANE_REVIEW">
<AU>Costa J, Borges A, Espírito-Santo C, Ferreira J, Coelho M, Moore P, Sampaio C</AU>
<TI>Botulinum toxin type A versus botulinum toxin type B for cervical dystonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-01-02 08:30:36 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-02 08:30:36 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004314.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-04-22 16:42:28 +0100" MODIFIED_BY="Ana Raquel Marques">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-04-22 16:41:39 +0100" MODIFIED_BY="Ana Raquel Marques" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-04-22 16:39:04 +0100" MODIFIED_BY="Ana Raquel Marques" STUDY_ID="STD-Brashear-1999">
<CHAR_METHODS MODIFIED="2016-04-21 23:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, multi-centre, double-blind, three-arm, parallel, phase III study</P>
<P>Method of randomisation: master randomisation tables generated by an independent organisation</P>
<P>Data analysed on intention-to-treat basis</P>
<P>Location: multiple centres in the USA</P>
<P>Duration: 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-22 16:37:22 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>109 participants were enrolled</P>
<P>
<B>Placebo arm</B>: 36 participants (2 withdrawals: 5.5%), 21 participants were female and 15 were male, mean age was 54.3 ± 12.2 (SD) years, ethnicity: 32 white and 4 black, mean duration of symptoms not stated, mean TWSTRS-Total score at baseline: 43.6 ± 9 (SD)</P>
<P>
<B>BtB 5000 U arm</B>: 36 participants (1 withdrawal: 2.7%), 18 participants were female and 18 were male, mean age was 57.6 ± 12.3 (SD) years, ethnicity: 35 white and 1 black, mean duration of symptoms not stated, mean TWSTRS-Total score at baseline: 46.4 ± 10.4 (SD)</P>
<P>
<B>BtB 10,000 U arm</B>: 37 participants (1 withdrawal: 2.7%), 28 participants were female and 9 were male, mean age was 56.2 ± 11.8 (SD), ethnicity: 33 white and 4 black, mean duration of symptoms not stated, mean TWSTRS-Total score at baseline: 46.9 ± 9.6 (SD).</P>
<P>
<B>Inclusion criteria</B>: Cervical Dystonia (CD) for at least 1 year with involvement of two or more neck muscles and responsive to BtA treatment; TWSTRS-Total score at baseline of at least 20 with a TWSTRS-Severity score of at least 10, a TWSTRS-Disability score of at least 3, and a TWSTRS-Pain score of at least 1.</P>
<P>Age more than 17 years-old</P>
<P>Weight more than 45 Kg</P>
<P>Physical and neurological examinations and laboratory tests acceptable clinically </P>
<P>Informed consent.</P>
<P>
<B>Exclusion criteria:</B> Bt injections in the previous 4 months for CD; previous participation in BtB trial; neck contractures or cervical spine disease; pure retrocollis or anterocollis; use of drugs that could interfere with efficacy and security evaluations (e.g., narcotics, benzodiazepines); acute or chronic medical condition or known drug hypersensitivity to the study drug; history of myotomy or denervation surgery of the neck; previous tetanus toxoid in the last 4 months; history of clinically persistent neurological or neuromuscular disorder; and women of child-bearing potential who were pregnant or breast-feeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-22 16:37:50 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>The study drug (BtB) was provided by Athenas Neurociences, Inc in vials that contained placebo or 5000 U in a 1 ml sterile solution, buffered to a pH of 5.5, and refrigerated.</P>
<P>Each participant was randomly assigned to one of the three groups: placebo, 5000 U of BtB or 10,000 U BtB. A total of 2 ml of the study drug was injected into two to four involved CD muscles selected by the investigator with or without the use of electromyography. Based on the investigator's judgement, the proportionate volume per muscle was divided and injected into one to five sites. Each participant received only one treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-22 16:38:26 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>The primary efficacy outcome was the change in TWSTRS-Total score at week 4</P>
<P>Secondary efficacy outcomes included changes in two visual analogue scales (Patient Global Assessment of Change and Principal investigator Global Assessment of Change) at week 4, and change in TWSTRS-Total score at weeks 8 and 12</P>
<P>Tertiary efficacy outcomes included change in visual analogue scale Patient Analog Pain Assessment at week 4, and changes in the TWSTRS sub-scales scores at weeks 4 and 16. For all outcomes data were collected at treatment visit (day 1), and at weeks 2, 4, 8, 12, and 16 (termination). Adverse events data were collected at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-22 16:39:04 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>
<B>Reasons for withdrawal:</B> in the placebo group one discontinued the study because of lack of effect and one participant due to request related to a new job; in the 5000 U group one participant discontinued because of lack of effect; in the 10,000 U group one participant discontinued because of a serious adverse effect (death following coronary artery bypass surgery). Results were presented as variance of the means of the various outcome scales scores without individual data. An estimation of duration of treatment effect was made based on time to return to baseline TWSTRS-Total score</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-22 16:40:42 +0100" MODIFIED_BY="Ana Raquel Marques" STUDY_ID="STD-Brin-1999">
<CHAR_METHODS MODIFIED="2016-04-21 23:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, multicenter, placebo-controlled, double-blind, two-arm, parallel, phase III study</P>
<P>Method of randomisation: master randomisation tables generated by an independent organisation</P>
<P>Data analysed on an intention-to-treat basis</P>
<P>Location: seven centres in the USA</P>
<P>Duration: 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-22 16:40:42 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>77 participants were enrolled</P>
<P>
<B>Placebo arm</B>: 38 participants (1 withdrawal: 2.6%); 26 participants were female and 12 were male; mean age was 52.6 ± 13.3 (SD) years; ethnicity: all participants were White; mean duration of symptoms not stated; mean TWSTRS-Total score at baseline: 51.2 ± 9.5 (SD).</P>
<P>
<B>BtB 10,000 U arm</B>: 39 participants (0 withdrawals); 27 participants were female and 12 were male; mean age was 56.6 ± 11.7 (SD); ethnicity: all participants were White; mean duration of symptoms not stated; mean TWSTRS-Total score at baseline: 52.8 ± 8.6 (SD).</P>
<P>
<B>Inclusion criteria</B>: Cervical Dystonia (CD) for at least one year of duration with involvement of two or more neck muscles, and considered clinically non-responsive to BtA treatment with an appropriate frontalis-type A test result; TWSTRS-Total score at baseline of at least 20 with a TWSTRS-Severity score of at least 10, a TWSTRS-Disability score of at least 3, and a TWSTRS-Pain score of at least 1</P>
<P>Age more than 17 years-old</P>
<P>Weight more than 45 Kg</P>
<P>Physical and neurological examinations and laboratory tests acceptable clinically</P>
<P>Informed consent</P>
<P>
<B>Exclusion criteria</B>: Bt injections in the previous four months for CD; previous participation in a BtB trial; neck contractures or cervical spine disease that limit range of motion; pure retrocollis or anterocollis; use of drugs that could interfere with efficacy and security evaluations (e.g., narcotics, benzodiazepines); previous tetanus toxoid in the last 4 months; use of any investigational drug or device within 30 days of entry into the study; current acute or chronic medical condition or known drug hypersensitivity to the study drug that would preclude Bt injections; history of myotomy or denervation surgery of the neck; history of clinically persistent neurological or neuromuscular disorder; and women of child-bearing potential who were pregnant or breast-feeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-21 23:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>The study drug (BtB) was provided by Athenas Neurociences, Inc in vials that contained placebo or 5000 U of BtB in a 1 ml sterile solution. Each participant was randomly assigned to one of the 2 groups: placebo or 10,000 U BtB. A total of 2 ml of the study drug was injected into 2 to 4 involved CD muscles selected by the investigator with or without the use of electromyography. Based on the investigator judgement, the proportionate volume per muscle was divided and injected into one to five sites. Each participant received only one treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-21 23:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>The primary efficacy outcome was the change in TWSTRS-Total score at week 4</P>
<P>Secondary efficacy outcomes included changes in two visual analogue scales (Patient Global Assessment of Change and Principal investigator Global Assessment of Change) at week 4, and change in TWSTRS-Total score at weeks 8 and 12</P>
<P>Tertiary efficacy outcomes included change in visual analogue scale Patient Analog Pain Assessment at week 4, changes in the TWSTRS subscales scores at week 4, and change in TWSTRS-Total score at week 16</P>
<P>All outcomes data were collected at treatment visit (day 1), and at weeks 2, 4, 8, 12, and 16 (termination). The results of the primary outcome were used to assess the duration of clinical benefit. Adverse events data were collected at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-21 23:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>Reasons for withdrawal: in the placebo group 1 discontinued the study because of an adverse effect</P>
<P>Results are presented as variance of the means of the various outcome scales scores without individual data. An estimation of duration of treatment effect was made based on time to return to baseline TWSTRS-Total score</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-21 23:07:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaji-2013">
<CHAR_METHODS MODIFIED="2016-04-21 23:07:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, four-arm, parallel, study</P>
<P>Method of randomisation: random sequence was generated by independent organisation, but randomisation sequence was not described</P>
<P>Data analysed on an intention-to-treat basis</P>
<P>Location: Japan</P>
<P>Duration: 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-21 23:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>130 participants were administered Bt</P>
<P>
<B>Placebo arm</B>: 33 participants (4 withdrawals, 2 of them before the study medication: 12.1%), 12 participants were female and 21 were male, mean age was 49.7 ± 13.6 (SD) years, ethnicity not stated, mean duration of symptoms: 7.84 ± 7.1 (SD) years, mean TWSTRS-Total score at baseline: 44.0 ± 8.8 (SD)</P>
<P>
<B>BtB 2500 U arm</B>: 34 participants (1 withdrawal: 1.94%), 11 participants were female and 23 were male, mean age was 50.8 ± 14.7 (SD) years, ethnicity not stated, mean duration of symptoms: 8.53 ± 7.41 (SD) years, mean TWSTRS-Total score at baseline: 43.9 ± 7.5 (SD)</P>
<P>
<B>BtB 5000 U arm</B>: 32 participants (2 withdrawals, 1 of them before study medication: 6.25%), 15 participants were female and 17 were male, mean age was 46.8 ± 12.5 (SD) years, ethnicity not stated, mean duration of symptoms: 5.58 ± 5.90 (SD) years, mean TWSTRS-Total score at baseline: 43.2 ± 9.7 (SD)</P>
<P>
<B>BtB 10,000 U arm</B>: 31 participants (2 withdrawals: 6.45%), 14 participants were female and 17 were male, mean age was 50.0 ± 12.6 (SD) years, ethnicity not stated, mean duration of symptoms: 6.76 ± 5.10 (SD) years, mean TWSTRS-Total score at baseline: 42.4 ± 8.8 (SD)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-21 23:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Study drug (BtB) and placebo were prepared by mixing three unlabelled vials. Each participant was randomly assigned to one of the 4 groups: placebo, 2500 U of BtB, 5000 U of BtB, or 10,000 U BtB. Each participant received only one treatment</P>
<P>The provider of the study drug is not stated, though members of Eisai Co., Ltd were included as authors</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-21 23:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>The primary efficacy outcome was the change in TWSTRS-Total score from baseline at week 4</P>
<P>Secondary efficacy outcomes included changes in two visual analogue scales (Patient Global and Pain Assessment of Change, and Principal investigator Global Assessment of Change), and change in TWSTRS severity, disability and pain score at week 4. Adverse effects were collected</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-21 23:04:05 +0100" MODIFIED_BY="[Empty name]">
<P>Reasons for withdrawals: 3 of the 133 participants withdrew before the start of study medication (2 participants in placebo group and 1 participant in 5000 U group). Two of these withdrawals were due to participant request, and the other participant did not attend hospital</P>
<P>The motive of each participant was not reported</P>
<P>After medication, 2 participants in placebo group, 1 participant in 2500 U group and 1 participant in 5000 U group requested to discontinue the study; and 2 participants in 10,000 U group moved to another treatment because of lack of effect</P>
<P>There were no adverse events that led to death, serious disorders or study withdrawal. Results are presented as variance of the means of the various outcome scales scores without individual data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-22 16:41:39 +0100" MODIFIED_BY="Ana Raquel Marques" STUDY_ID="STD-Lew-1997">
<CHAR_METHODS MODIFIED="2016-04-22 16:41:39 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>Randomised, multicenter, placebo-controlled, double-blind, four-arm, parallel, phase II study</P>
<P>Method of randomisation: not described</P>
<P>Data analysed on an intention-to-treat basis</P>
<P>Location: multiple centres in the USA</P>
<P>Duration: 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-21 23:57:40 +0100" MODIFIED_BY="[Empty name]">
<P>122 participants aged 19 to 81 years were enrolled. 67% of the participants were female. 97% were White, 1.6% were Hispanic and 1.6% were Afro-American. 79% were responsive to BtA treatment and 21% were BtA-non-responsive.</P>
<P>
<B>Placebo arm</B>: 30 participants, mean duration of symptoms not stated, mean TWSTRS-Total score was 45.5</P>
<P>
<B>BtB 2500 U arm</B>: 31 participants, mean duration of symptoms not stated, mean TWSTRS-Total score at baseline was 45.6</P>
<P>
<B>BtB 5000 U arm</B>: 31 participants, mean duration of symptoms not stated, mean TWSTRS-Total score at baseline was 45.2.</P>
<P>
<B>BtB 10,000 U arm</B>: 30 participants, mean duration of symptoms not stated, mean TWSTRS-Total score at baseline was 47.5.</P>
<P>
<B>Inclusion criteria</B>: Idiopathic Cervical Dystonia (CD) of 1 to 10 years' duration with involvement of 2 or more neck muscles, either responsive or non--responsive to BtA treatment; TWSTRS-Total score at baseline of at least 20 with a TWSTRS-Severity score of at least 10, a TWSTRS-Disability score of at least 3, and a TWSTRS-Pain score of at least 1</P>
<P>Age more than 17 years-old</P>
<P>Weight more than 45 Kg</P>
<P>Physical and neurological examinations and laboratory tests acceptable clinically</P>
<P>Informed consent</P>
<P>
<B>Exclusion criteria</B>: Primary nonresponder to BtA injection; Bt injections in the previous 4 months for CD; no return to inter-treatment baseline clinical dystonia status; neck contractures or cervical spine disease that limit range of motion; pure retrocollis or anterocollis; use of drugs that could interfere with efficacy and security evaluations (e.g., narcotics, benzodiazepines); use of aminoglycosides or any investigational drug or device within 30 days of entry into the study; current acute or chronic medical condition or known drug hypersensitivity to the study drug that would preclude Bt injections; history of myotomy or denervation surgery of the neck; history of clinically persistent neurological or neuromuscular disorder; and women pregnant or nursing</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-21 23:57:40 +0100" MODIFIED_BY="[Empty name]">
<P>The study drug (BtB) was provided by Athenas Neurociences, Inc in vials that contained placebo, 2500 U or 5000 U of BtB in a 1 ml sterile solution. Each participant was randomly assigned to one of the 4 groups: placebo, 2500 U, 5000 U or 10,000 U BtB. A total of 2 ml of the study drug was injected into 2 to 4 involved CD muscles selected by the investigator with or without the use of electromyography. The study drug (in a volume of 2 ml) could be further diluted by adding 0.9% sterile normal saline without preservative up to a maximal final volume of 5 ml. Each participant received only one treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-21 23:57:29 +0100" MODIFIED_BY="[Empty name]">
<P>The primary efficacy outcome was the change in TWSTRS-Total score at week 4</P>
<P>Secondary efficacy outcomes included changes in three visual analogue scales (Patient Global Assessment of Change, Patient Analog Pain Assessment, and Principal investigator Global Assessment of Change) at week 4, changes in the TWSTRS subscales scores at week 4, change in TWSTRS-Total score at week 8, 12 and 16, and change in Sickness Impact Profile (SIP) at week 4. With the exception of SIP all outcomes data were collected at treatment visit (day 1), and at weeks 2, 4, 8, 12, and 16 (termination). The results of the primary outcome were used to assess the duration of clinical benefit. Adverse events data were either spontaneously reported by participants or elicited by the investigators at each visit. BtB antibodies were determined by ELISA at baseline and week 4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-21 23:57:30 +0100" MODIFIED_BY="[Empty name]">
<P>All participants completed the study per the protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>SD: Standard deviation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-04-22 16:42:28 +0100" MODIFIED_BY="Ana Raquel Marques" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-04-22 16:42:08 +0100" MODIFIED_BY="Ana Raquel Marques" STUDY_ID="STD-AN072_x002d_008-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-22 16:42:08 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>This is a randomised, multicentre (USA), double-blind, placebo-controlled, single dose, four-arm, dose-finding parallel group design study. The follow-up was 16 weeks. 85 participants were enrolled. Mean age was 53.2 years (18-80). 38% of the participants were male and 62% were female. 95% were White. The study included both BtA-responsive and -non-responsive participants. The study drug (BtB) was provided by Athenas Neurociences, Inc. Each participant was randomly assigned to one of the 4 groups: placebo, 400 U, 1200 U or 2400 U of BtB. The study drug was injected into 2 to 4 superficial neck and/or shoulder muscle groups. Each participant received only one treatment. The primary efficacy outcome was the change in TWSTRS-Total score (range 0 to 87). One participant in the placebo group withdrew because of an adverse effect. This study was excluded because data was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-22 16:42:13 +0100" MODIFIED_BY="Ana Raquel Marques" STUDY_ID="STD-Chinnapongse-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-22 16:42:13 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>This trial was a sequential dose-escalation, safety, and tolerability study of BtB in subjects with cervical dystonia. Participants were assigned to one of three doses of BtB: 10,000 U, 12,500 U, and 15,000 U. Efficacy was evaluated using TWSTRS total and subscale scores and three VAS. The study was excluded for being open-label and not having a placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-22 16:42:19 +0100" MODIFIED_BY="Ana Raquel Marques" STUDY_ID="STD-Cullis-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-22 16:42:19 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>145 participants with cervical dystonia were enrolled. The study was open-label and compared three different doses of BtB without a placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-21 16:13:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dressler-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-21 16:13:32 +0100" MODIFIED_BY="[Empty name]">
<P>This was a non-randomised, non-controlled study enrolling 9 participants with cervical dystonia aiming to test the immunogenicity of botulinum toxin type B in patients naïve to botulinum toxin treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-22 16:42:28 +0100" MODIFIED_BY="Ana Raquel Marques" STUDY_ID="STD-Jacob-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-22 16:42:28 +0100" MODIFIED_BY="Ana Raquel Marques">
<P>This was a double-blind study evaluating botulinum toxin type B diluted with preserved versus nonpreserved isotonic saline. Ten participants were treated on each half of the frontalis muscle with a total of 2400 units of botulinum toxin type B diluted either with preserved or nonpreserved saline. In addition to studying a different population, the study is not placebo-controlled as both arms are treated with BtB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-22 00:46:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jankovic-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-22 00:46:40 +0100" MODIFIED_BY="[Empty name]">
<P>This was a non-randomised, non-controlled, multicenter study enrolling 100 participants with cervical dystonia aiming to test the immunogenicity of botulinum toxin type B</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-22 00:46:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lew-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-22 00:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>This paper describes an analysis of a subset of efficacy data from two randomised, double blind, placebo-controlled clinical trials already included in this systematic review (<LINK REF="STD-Brashear-1999" TYPE="STUDY">Brashear 1999</LINK>; <LINK REF="STD-Brin-1999" TYPE="STUDY">Brin 1999</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-22 00:46:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Truong-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-22 00:46:50 +0100" MODIFIED_BY="[Empty name]">
<P>12 participants with cervical dystonia were enrolled. The study was open-label and compared different doses of BtB without a placebo group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-04-22 16:40:32 +0100" MODIFIED_BY="Ana Raquel Marques">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-04-22 16:39:24 +0100" MODIFIED_BY="Ana Raquel Marques" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 16:39:24 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="YES" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>"Master randomisation tables were generated by an independent organisation (Pharmaceutical Research Associates)."</P>
<P>Method of randomisation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-21 23:08:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>"Master randomisation tables were generated by an independent organisation (Pharmaceutical Research Associates)."<BR/>Method of randomisation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-21 16:16:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>Random sequence was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 00:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>Method of randomisation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-04-22 16:39:32 +0100" MODIFIED_BY="Ana Raquel Marques" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 16:39:32 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="YES" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>"Investigators, patients, and the sponsor were blinded to drug assignment until after the database was locked and analyzed."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-21 23:08:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>"Investigators, patients, and the sponsor were blinded to drug assignment until after the database was locked and analyzed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 00:12:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>Randomisation was generated by an independent organisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 00:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>Method of concealment not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-10-04 10:26:49 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-04-22 16:39:43 +0100" MODIFIED_BY="Ana Raquel Marques" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-22 16:39:43 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="YES" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>"The study drug was provided by Athena Neurosciences, Inc. in 3.5-mL vials containing either 5000U of NeurBloc or placebo (same solution without toxin)."</P>
<P>Study described as double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-21 23:08:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>"The study drug, provided by Athena Neurosciences, Inc. in 3.5-mL vials containing either 5000 U of NeurBloc or placebo (same solution without toxin)."<BR/>Study described as double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-22 00:12:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>Placebo and active drug were prepared by mixing three unlabelled vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-22 00:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>"The study drug was provided by Athena Neurosciences, Inc. in 5-mL vials containing either 2500U or 5000U of NeurBloc in 1-mL sterile solution. The same sterile solution (without toxin) was used as placebo."<BR/>Blinding not specified although study described as double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-04-22 16:40:13 +0100" MODIFIED_BY="Ana Raquel Marques" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Subjective Outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Objective Outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-22 16:40:13 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="YES" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>"The principal investigator (PI) completed all screening, day 1 activities, and subsequently completed only the TWSTRS and PI Global Assessment of Change. After study-drug injection, no other information about the patient was provided to or discussed with the PI."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-04-22 16:39:48 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="UNKNOWN" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>"The administrative investigator (...) conducted all other activities for weeks 1 to 12 and termination visit."<BR/>Although placebo was identical to intervention, the fact that all of the participants had previously been treated with botulinum toxins could have led to a degree of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-21 23:08:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>"The principal investigator (PI) performed all screening assessments, (...) and performed the injection, in addition to acquiring all TWSTRS scores and the PI Global Assessment of Change."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-04-21 23:08:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>"The administrative investigator (...) performed all other activities for each visit (including adverse events collection and assessment. Patients were instructed not to divulge any AE information to the principal investigator."<BR/>Although placebo was identical to intervention, the fact that all of the participants had previously been treated with botulinum toxins could have led to a degree of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-21 16:16:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>No description of the process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-04-21 16:16:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>No description of the process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-21 16:14:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>Blinding not specified although study described as double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-04-22 00:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>Blinding not specified although study described as double blind</P>
<P>Although placebo was identical to intervention, the fact that all of the participants had previously been treated with botulinum toxin could have led to a degree of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-04-22 16:40:19 +0100" MODIFIED_BY="Ana Raquel Marques" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-22 16:40:19 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="YES" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>Post-randomisation exclusions were low and distributed evenly between groups (BTB 5000 U group = 1; BTB 10,000 U group = 1; Placebo group = 2), and the reasons were described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-21 23:08:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>Post-randomisation exclusions were low (Placebo group = 1), and the reasons were described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-21 16:16:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>The missing data maximum ratio was 11% in placebo group and balanced across group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-22 00:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>"All patients completed the study per protocol."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-04-22 16:40:11 +0100" MODIFIED_BY="Ana Raquel Marques" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 16:40:11 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="YES" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>"The ITT dataset was used for all analyses."<BR/>The usual and more clinically relevant outcomes that are usually evaluated in intervention trials for this condition were reported in this study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-21 23:08:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>"The ITT dataset was used for all analyses."<BR/>The usual and more clinically relevant outcomes that are usually evaluated in intervention trials for this condition were reported in this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-21 16:16:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>All outcomes in methods were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 00:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>"The primary analyses included all patients who entered the study, received the study drug, and had at least one visit during which efficacy data were obtained."<BR/>The expected outcomes that are usually evaluated in intervention trials for this condition were reported in this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-10-04 10:35:44 +0100" MODIFIED_BY="Ana Raquel Marques" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2016-04-22 16:40:05 +0100" MODIFIED_BY="Ana Raquel Marques" NO="11">
<NAME>Enriched population &#8211; preferential enrolment of positive responders</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 16:40:05 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="NO" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>"Patients were eligible (...) if their CD continued to respond to BoNT/A treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-03 13:37:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>Trial in botulinum toxin type A-non-responsive CD</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-21 16:16:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>The study allowed the entrance of BtA-naive and -non-responsive patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 00:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>"Patients were excluded if they were a primary nonresponder to type A toxin injection."<BR/>Both BtA-responsive and BtA-non-responsive patients were enrolled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2016-04-22 16:40:24 +0100" MODIFIED_BY="Ana Raquel Marques" NO="12">
<NAME>Enriched population &#8211; exclusion of poor responders</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 16:40:24 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="NO" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>"Patients were excluded if they (...) had pure anterocollis or retrocollis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-21 23:07:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>"Patients were excluded if they (...) had pure anterocollis or retrocollis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-21 16:16:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>Enrolled participants were consistent with review protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 00:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>"Patients were excluded if they (...) had pure anterocollis or retrocollis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-04-22 16:40:32 +0100" MODIFIED_BY="Ana Raquel Marques" NO="10">
<NAME>Other issues</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 16:40:32 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="NO" STUDY_ID="STD-Brashear-1999">
<DESCRIPTION>
<P>"Supported by a grant from Athena Neurosciences, Inc."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-04 16:18:48 +0100" MODIFIED_BY="Ana Raquel Marques" RESULT="NO" STUDY_ID="STD-Brin-1999">
<DESCRIPTION>
<P>&#8220;Supported by a grant from Athena Neurosciences, Inc.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-21 16:16:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaji-2013">
<DESCRIPTION>
<P>No description of funding, but members of Eisai Co., Ltd were included as authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-22 00:47:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lew-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-04-23 01:02:43 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-04-23 01:02:43 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-04-21 16:12:36 +0100" MODIFIED_BY="[Empty name]">Botulinum neurotoxin B compared to placebo for cervical dystonia</TITLE>
<TABLE COLS="7" ROWS="18">
<TR>
<TD COLSPAN="7">
<P>
<B>Botulinum Neurotoxin B compared to placebo for cervical dystonia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>
adults with cervical dystonia<BR/>
<B>Settings: </B>
hospital-based, movement disorders clinics<BR/>
<B>Intervention: </B>
botulinum neurotoxin B<BR/>
<B>Comparison: </B>
placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Botulinum Neurotoxin B</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Overall cervical dystonia improvement as assessed with TWSTRS: change from baseline to week 4</P>
<P>(range, 0 to 85; more is worst)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-<SUP>7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-<SUP>7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change from baseline to week 4 in the BtB group was 6.78 TWSTRS units higher (4.54 higher to 9.01 higher) compared to the placebo group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>316<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Proportion of withdrawals due to adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.88<BR/>(0.19 to 4.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>440<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>14 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>13 per 1000<BR/>(3 to 58)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cervical dystonia associated pain: change from baseline to week 4 as assessed with TWSTRS</P>
<P>(range, 0 to 20; more is worst)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-<SUP>7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-<SUP>7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change from baseline to week 4 in the BtB group was 2.41 TWSTRS units higher (0.82 higher to 4.01 higher) compared to the placebo group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>207<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Subjective change as assessed by the patient at week 4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-<SUP>7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-<SUP>7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change at week 4 in the BtB group was 0.86 standard deviations higher (0.61 higher to 1.1 higher) compared to the placebo group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>316<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Proportion of participants with adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.09<BR/>(0.97 to 1.23)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>186<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW <SUP>3,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>838 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>930 per 1000<BR/>(796 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Adverse events: dry mouth</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 7.65<BR/>(2.75 to 21.32)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>438<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH <SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>22 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>168 per 1000<BR/>(60 to 467)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Adverse events: dysphagia</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 6.78<BR/>(2.42 to 19.05)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>438<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH <SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>22 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>148 per 1000<BR/>(53 to 417)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI: </B>Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Two of 3 studies enrolled an enriched population; none of the included studies had independent funding; blinding of outcome assessment was unclear in all studies</P>
<P>
<SUP>2</SUP>Three of 4 studies enrolled an enriched population; none of the studies had a clearly stated independent funding; blinding of outcome assessment was unclear in all studies; two out of 4 had an unclear random sequence generation</P>
<P>
<SUP>3</SUP>The total number of participants included was less than the number generated by a conventional sample size calculation for a single adequately powered trial</P>
<P>
<SUP>4</SUP>I-squared of 58% and small overlap between confidence intervals</P>
<P>
<SUP>5</SUP>Both studies had an enriched population and non-independent funding; blinding of outcome assessment was unclear in all studies</P>
<P>
<SUP>6</SUP>I-squared of 45% and there is a wide variance of point estimates between studies</P>
<P>
<SUP>7</SUP> Data were only available as the difference between the BtB and placebo groups</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-04-22 13:14:39 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-04-22 13:14:39 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-04-22 01:27:43 +0100" MODIFIED_BY="[Empty name]">Glossary of terms</TITLE>
<TABLE COLS="2" ROWS="8">
<TR>
<TD>
<P>
<B>Term</B>
</P>
</TD>
<TD>
<P>
<B>Definition</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>BtA-non-responsive</B>
</P>
</TD>
<TD>
<P>People who do not experience the expected benefit from treatment with botulinum toxin type A</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cervical dystonia or spasmodic toricollis</B>
</P>
</TD>
<TD>
<P>It is a common movement disorder in which people have abnormal movements or postures of the head and neck that they cannot control. It is frequently accompanied by social embarrassment and pain. </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Chemodenervation</B>
</P>
</TD>
<TD>
<P>It is the process by which botulinum toxin causes muscular paralysis. Altought all the anatomical elements necessary for muscular control are intact (i.e. nerve, synapse and muscle), there is a chemical process that disables the transmission of the transmission of the electrical signal from the nerve to the muscle.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Dysphagia</B>
</P>
</TD>
<TD>
<P>A discomfort or difficulty when swallowing.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Electromyography</B>
</P>
</TD>
<TD>
<P>It is an exam that displays the electrical activity of muscles using pieces of metal attached to the skin or inserted into the muscle.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Non-naive</B>
</P>
</TD>
<TD>
<P>People who have been treated in the past with botulinum toxin.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Voluntary action</B>
</P>
</TD>
<TD>
<P>Movements that we are able to control, start and stop when we want to.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-04-22 17:39:59 +0100" MODIFIED_BY="Ana Raquel Marques">
<COMPARISON ID="CMP-001" MODIFIED="2016-04-22 17:39:59 +0100" MODIFIED_BY="Ana Raquel Marques" NO="1">
<NAME>Botulinum toxin type B vs Placebo</NAME>
<IV_OUTCOME CHI2="1.225843090082956" CI_END="9.013486888219477" CI_START="4.540211104998864" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="6.7768489966091705" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.9548928313078869" LOG_CI_START="0.6570760466026161" LOG_DATA="NO" LOG_EFFECT_SIZE="0.8310278086929966" MODIFIED="2016-02-11 10:37:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5417660486818814" P_Q="1.0" P_Z="2.875586528317528E-9" Q="0.0" RANDOM="NO" SCALE="8.78980588307797" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="107" WEIGHT="100.0" Z="5.93854732222993">
<NAME>Overall cervical dystonia improvement as assessed with TWSTRS: change from baseline to week 4</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="10.598683473033107" CI_START="1.834116526966893" EFFECT_SIZE="6.2164" ESTIMABLE="YES" ESTIMATE="6.2164" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="402" SE="2.2359" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" WEIGHT="26.04896200959468">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="13.536728635014864" CI_START="4.463271364985136" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="400" SE="2.3147" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="24.305566676677">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="9.156857669361072" CI_START="2.8081423306389284" EFFECT_SIZE="5.9825" ESTIMABLE="YES" ESTIMATE="5.9825" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="401" SE="1.6196" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" WEIGHT="49.64547131372832">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="7.481804152529014" CI_END="9.002084448834006" CI_START="5.873018405853205" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="7.437551427343606" ESTIMABLE="YES" I2="0.0" I2_Q="6.888215411535975" ID="CMP-001.02" LOG_CI_END="0.954343082751603" LOG_CI_START="0.7688613619102066" LOG_DATA="NO" LOG_EFFECT_SIZE="0.8714299816992049" MODIFIED="2016-04-22 16:57:05 +0100" MODIFIED_BY="Ana Raquel Marques" NO="2" P_CHI2="0.4856497138586541" P_Q="0.3416469827559634" P_Z="1.1925981049726235E-20" Q="2.14795582410928" RANDOM="NO" SCALE="25.23" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="38" WEIGHT="300.0" Z="9.317369931170468">
<NAME>Overall cervical dystonia improvement as assessed with TWSTRS: change from baseline to week 4 - Doses subgroup analysis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.5132662062877906" CI_END="10.213010590600101" CI_START="3.6957334210446557" DF="1" EFFECT_SIZE="6.954372005822378" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.0091537822589078" LOG_CI_START="0.5677006373465898" LOG_EFFECT_SIZE="0.8422579184086003" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" NO="1" P_CHI2="0.473728410424052" P_Z="2.8790756086114494E-5" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="4.182826144076725">
<NAME>2500 units</NAME>
<IV_DATA CI_END="13.216373658820274" CI_START="3.3836263411797285" EFFECT_SIZE="8.3" ESTIMABLE="YES" ESTIMATE="8.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="237" SE="2.5084" STUDY_ID="STD-Lew-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="43.932166909265746">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="10.251904031272737" CI_START="1.5480959687272637" EFFECT_SIZE="5.9" ESTIMABLE="YES" ESTIMATE="5.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="236" SE="2.2204" STUDY_ID="STD-Kaji-2013" TOTAL_1="0" TOTAL_2="0" WEIGHT="56.06783309073426">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.227801276797106" CI_END="8.805874877453798" CI_START="3.398992433033422" DF="2" EFFECT_SIZE="6.10243365524361" ESTIMABLE="YES" I2="10.225385862271086" ID="CMP-001.02.02" LOG_CI_END="0.9447725102834622" LOG_CI_START="0.5313501977411981" LOG_EFFECT_SIZE="0.7855030665295001" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" NO="2" P_CHI2="0.3282762703061912" P_Z="9.680271406991528E-6" STUDIES="3" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="4.42419464646037">
<NAME>5000 units</NAME>
<IV_DATA CI_END="14.09422606579497" CI_START="4.305773934205029" EFFECT_SIZE="9.2" ESTIMABLE="YES" ESTIMATE="9.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="237" SE="2.4971" STUDY_ID="STD-Lew-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="30.51165829239454">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="10.43694009311411" CI_START="-0.436940093114111" EFFECT_SIZE="5.0" ESTIMABLE="YES" ESTIMATE="5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="235" SE="2.774" STUDY_ID="STD-Brashear-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="24.724343448365214">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="8.640661750527777" CI_START="0.5593382494722237" EFFECT_SIZE="4.6" ESTIMABLE="YES" ESTIMATE="4.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="236" SE="2.0616" STUDY_ID="STD-Kaji-2013" TOTAL_1="0" TOTAL_2="0" WEIGHT="44.76399825924026">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.5927808453348375" CI_END="11.096112697010074" CI_START="6.349490286836569" DF="3" EFFECT_SIZE="8.722801491923322" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="1.045170858973759" LOG_CI_START="0.8027388631661185" LOG_EFFECT_SIZE="0.940655989185301" MODIFIED="2016-04-22 16:57:05 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3" P_CHI2="0.45875660788799244" P_Z="5.864465592334131E-13" STUDIES="4" TAU2="0.0" TOTAL_1="39" TOTAL_2="38" WEIGHT="100.00000000000001" Z="7.203596701443556">
<NAME>10,000 units</NAME>
<IV_DATA CI_END="19.244291095134617" CI_START="6.955708904865383" EFFECT_SIZE="13.1" ESTIMABLE="YES" ESTIMATE="13.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="237" SE="3.1349" STUDY_ID="STD-Lew-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.9198966086587">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="13.536728635014864" CI_START="4.463271364985136" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="400" SE="2.3147" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="27.366784604390535">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="12.325781485946065" CI_START="2.474218514053936" EFFECT_SIZE="7.4" ESTIMABLE="YES" ESTIMATE="7.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="235" SE="2.5132" STUDY_ID="STD-Brashear-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.21448722742329">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="11.540661750527775" CI_START="3.459338249472224" EFFECT_SIZE="7.5" ESTIMABLE="YES" ESTIMATE="7.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="236" SE="2.0616" STUDY_ID="STD-Kaji-2013" TOTAL_1="0" TOTAL_2="0" WEIGHT="34.49883155952748">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.7481929673024614" CI_END="10.71167120024951" CI_START="4.408105145132501" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="7.559888172691005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.0298572333365832" LOG_CI_START="0.6442519450556696" LOG_DATA="NO" LOG_EFFECT_SIZE="0.8785153713818389" MODIFIED="2016-04-21 23:52:52 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3870489839049932" P_Q="0.3870489839049933" P_Z="2.5865867031399134E-6" Q="0.7481929673024619" RANDOM="NO" SCALE="21.94" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="4.701182922830386">
<NAME>Overall cervical dystonia improvement as assessed with TWSTRS: change from baseline to week 4 - BtA-responsive vs BtA-non-responsive subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="13.536728635014864" CI_START="4.463271364985136" DF="0" EFFECT_SIZE="9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.1315137228853762" LOG_CI_START="0.6496532925615397" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2016-04-21 23:48:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0099336824134463E-4" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="48.26441200930467" Z="3.888192854365576">
<NAME>BtA-responsive</NAME>
<IV_DATA CI_END="13.536728635014864" CI_START="4.463271364985136" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-04-21 23:48:40 +0100" MODIFIED_BY="[Empty name]" ORDER="243" SE="2.3147" STUDY_ID="STD-Brashear-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="48.26441200930467"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.5782412127816326E-31" CI_END="10.598291480236199" CI_START="1.8345085197637996" DF="0" EFFECT_SIZE="6.216399999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.03.02" LOG_CI_END="1.0252358595562499" LOG_CI_START="0.2635197330327208" LOG_EFFECT_SIZE="0.7935389517715621" MODIFIED="2016-04-21 23:49:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.005427255686501036" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="51.73558799069532" Z="2.780516169432392">
<NAME>BtA-non-responsive</NAME>
<IV_DATA CI_END="10.598291480236199" CI_START="1.8345085197638005" EFFECT_SIZE="6.2164" ESTIMABLE="YES" ESTIMATE="6.2164" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-04-21 23:49:15 +0100" MODIFIED_BY="[Empty name]" ORDER="244" SE="2.2357" STUDY_ID="STD-Brin-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="51.73558799069532"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="1.8027538499341609" CI_END="1.2271883904609928" CI_START="0.9749821173189894" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0938403609672398" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="62" I2="44.52930997559531" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.0889112380793375" LOG_CI_START="-0.011003349861368342" LOG_EFFECT_SIZE="0.038953944108984576" METHOD="MH" MODIFIED="2016-04-22 17:15:01 +0100" MODIFIED_BY="Ana Raquel Marques" NO="4" P_CHI2="0.17938007011917" P_Q="1.0" P_Z="0.12644504893801314" Q="0.0" RANDOM="NO" SCALE="3.0748144957102723" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="74" WEIGHT="100.0" Z="1.528271878671106">
<NAME>Proportion of participants with adverse events</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3693887730704777" CI_START="1.0254392526173641" EFFECT_SIZE="1.185" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" LOG_CI_END="0.13652676298396005" LOG_CI_START="0.01090993770828526" LOG_EFFECT_SIZE="0.07371835034612269" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="404" O_E="0.0" SE="0.07378794498024496" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="0.005444660824407657" WEIGHT="45.025579104572465"/>
<DICH_DATA CI_END="1.2142748727403485" CI_START="0.8554273719556984" EFFECT_SIZE="1.0191780821917809" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="30" LOG_CI_END="0.08431700815763252" LOG_CI_START="-0.06781685730678687" LOG_EFFECT_SIZE="0.008250075425422816" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="403" O_E="0.0" SE="0.08936418564857944" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" VAR="0.007985957676633772" WEIGHT="54.97442089542754"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.544966173743061" CI_END="1.234571956119158" CI_START="0.9402528332938251" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0774088266048958" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="92" I2="21.41349379671875" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.09151640754034954" LOG_CI_START="-0.026755349230189768" LOG_EFFECT_SIZE="0.03238052915507992" METHOD="MH" MODIFIED="2016-04-22 17:16:00 +0100" MODIFIED_BY="Ana Raquel Marques" NO="5" P_CHI2="0.28013526858768" P_Q="0.8771400962126278" P_Z="0.2831810560074107" Q="0.023899822544774213" RANDOM="YES" SCALE="4.52" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.002284875666024384" TOTALS="SUB" TOTAL_1="112" TOTAL_2="110" WEIGHT="200.0" Z="1.0732007822870926">
<NAME>Proportion of participants with adverse events - doses subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2850064681426578" CI_START="0.8854257204030391" DF="0" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.10890531371524691" LOG_CI_START="-0.05284786651475983" LOG_EFFECT_SIZE="0.028028723600243534" MODIFIED="2016-04-21 19:43:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49698053368977635" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="0.6792483302150762">
<NAME>5000 U</NAME>
<DICH_DATA CI_END="1.2850064681426578" CI_START="0.8854257204030391" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" LOG_CI_END="0.10890531371524691" LOG_CI_START="-0.05284786651475983" LOG_EFFECT_SIZE="0.028028723600243534" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="1079" O_E="0.0" SE="0.09501461875826148" STUDY_ID="STD-Brin-1999" TOTAL_1="36" TOTAL_2="36" VAR="0.009027777777777773" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4531816303216156" CI_END="1.3306597386955088" CI_START="0.8926745352981073" DF="1" EFFECT_SIZE="1.0898835093164378" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="62" I2="59.23660981152469" ID="CMP-001.05.02" LOG_CI_END="0.12406701678283756" LOG_CI_START="-0.049306853864262035" LOG_EFFECT_SIZE="0.03738008145928771" MODIFIED="2016-04-22 16:58:44 +0100" MODIFIED_BY="Ana Raquel Marques" NO="2" P_CHI2="0.11728715668282741" P_Z="0.3980261371048781" STUDIES="2" TAU2="0.01257476042621558" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="0.8451517304877463">
<NAME>10,000 U</NAME>
<DICH_DATA CI_END="1.2045005097501742" CI_START="0.785949361144078" EFFECT_SIZE="0.972972972972973" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.08080698812982998" LOG_CI_START="-0.1046054347292454" LOG_EFFECT_SIZE="-0.011899223299707707" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="1080" O_E="0.0" SE="0.10891217499371621" STUDY_ID="STD-Brashear-1999" TOTAL_1="37" TOTAL_2="36" VAR="0.011861861861861861" WEIGHT="42.44253526402593"/>
<DICH_DATA CI_END="1.3693887730704777" CI_START="1.0254392526173641" EFFECT_SIZE="1.185" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" LOG_CI_END="0.13652676298396005" LOG_CI_START="0.01090993770828526" LOG_EFFECT_SIZE="0.07371835034612269" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="404" O_E="0.0" SE="0.07378794498024496" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="0.005444660824407657" WEIGHT="57.55746473597407"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4531816303216156" CI_END="1.2553974514026727" CI_START="0.9880629074140316" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1137376961354457" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="62" I2="59.23660981152469" I2_Q="55.4700090788398" ID="CMP-001.06" LOG_CI_END="0.09878124264918343" LOG_CI_START="-0.005215404123851212" LOG_EFFECT_SIZE="0.04678291926266615" METHOD="MH" MODIFIED="2016-04-22 17:16:44 +0100" MODIFIED_BY="Ana Raquel Marques" NO="6" P_CHI2="0.11728715668282741" P_Q="0.1339883119995261" P_Z="0.07783631256771852" Q="2.245677529489031" RANDOM="YES" SCALE="4.52" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01257476042621558" TOTALS="SUB" TOTAL_1="76" TOTAL_2="74" WEIGHT="200.0" Z="1.7633806414274857">
<NAME>Proportion of participants with adverse events - BtA-responsive vs BtA-non-responsive subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2045005097501742" CI_START="0.785949361144078" DF="0" EFFECT_SIZE="0.972972972972973" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.08080698812982998" LOG_CI_START="-0.1046054347292454" LOG_EFFECT_SIZE="-0.011899223299707707" MODIFIED="2016-04-21 19:44:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8013738874840584" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0" Z="0.2515694337175362">
<NAME>BtA-responsive</NAME>
<DICH_DATA CI_END="1.2045005097501742" CI_START="0.785949361144078" EFFECT_SIZE="0.972972972972973" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.08080698812982998" LOG_CI_START="-0.1046054347292454" LOG_EFFECT_SIZE="-0.011899223299707707" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="1080" O_E="0.0" SE="0.10891217499371621" STUDY_ID="STD-Brashear-1999" TOTAL_1="37" TOTAL_2="36" VAR="0.011861861861861861" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3693887730704777" CI_START="1.0254392526173641" DF="0" EFFECT_SIZE="1.185" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.13652676298396005" LOG_CI_START="0.01090993770828526" LOG_EFFECT_SIZE="0.07371835034612269" MODIFIED="2016-04-21 19:44:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.021424812530690864" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="38" WEIGHT="100.0" Z="2.300413362000247">
<NAME>BtA-non-responsive</NAME>
<DICH_DATA CI_END="1.3693887730704777" CI_START="1.0254392526173641" EFFECT_SIZE="1.185" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" LOG_CI_END="0.13652676298396005" LOG_CI_START="0.01090993770828526" LOG_EFFECT_SIZE="0.07371835034612269" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="404" O_E="0.0" SE="0.07378794498024496" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="0.005444660824407657" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8950991722123759" CI_END="1.1035808862834335" CI_START="0.6078728552566792" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.8557268707700564" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2016-04-22 17:36:09 +0100" MODIFIED_BY="Ana Raquel Marques" NO="7" P_CHI2="0.6391925472420696" P_Q="1.0" P_Z="1.3160575619120843E-11" Q="0.0" RANDOM="NO" SCALE="2.54" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="107" UNITS="" WEIGHT="100.0" Z="6.766861710263277">
<NAME>Subjective change as assessed by the participant at week 4</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2954821802358683" CI_START="0.4625222244609945" EFFECT_SIZE="0.8790022023484314" ESTIMABLE="YES" MEAN_1="62.6274" MEAN_2="43.6" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="609" SD_1="21.3939" SD_2="21.7" SE="0.21249368925785259" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" WEIGHT="35.41633878027972">
<FOOTNOTE>PGAC, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.4924370968122722" CI_START="0.5400888976349889" EFFECT_SIZE="1.0162629972236306" ESTIMABLE="YES" MEAN_1="60.2" MEAN_2="39.5" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="607" SD_1="22.9" SD_2="16.9" SE="0.24295043344910527" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="27.09320482108514">
<FOOTNOTE>PGAC, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.1225201033615826" CI_START="0.3129292530315016" EFFECT_SIZE="0.7177246781965421" ESTIMABLE="YES" MEAN_1="11.6876" MEAN_2="-0.4" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="603" SD_1="16.1591" SD_2="18.3826" SE="0.20653207322074033" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" WEIGHT="37.49045639863514">
<FOOTNOTE>PGVAS, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8804667871204687" CI_END="1.0426493072258254" CI_START="0.5495731664258017" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.7961112368258135" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2016-04-22 17:36:12 +0100" MODIFIED_BY="Ana Raquel Marques" NO="8" P_CHI2="0.643886148351797" P_Q="1.0" P_Z="2.4669088270795445E-10" Q="0.0" RANDOM="NO" SCALE="4.133101347707424" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="107" UNITS="" WEIGHT="100.0" Z="6.329040173529959">
<NAME>Subjective change as assessed by the clinician at week 4</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1513400942640555" CI_START="0.32832908971052566" EFFECT_SIZE="0.7398345919872905" ESTIMABLE="YES" MEAN_1="64.7425" MEAN_2="52.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="278" SD_1="16.9058" SD_2="17.5" SE="0.20995564486014423" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" WEIGHT="35.893572990701585">
<FOOTNOTE>PIGAC, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.4638603793498643" CI_START="0.5145147510531474" EFFECT_SIZE="0.9891875652015059" ESTIMABLE="YES" MEAN_1="60.6" MEAN_2="47.9" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="279" SD_1="14.4" SD_2="10.7" SE="0.24218445741478775" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="26.97610645182706">
<FOOTNOTE>PIGAC, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.1148328127995122" CI_START="0.30564443051013307" EFFECT_SIZE="0.7102386216548227" ESTIMABLE="YES" MEAN_1="12.8113" MEAN_2="2.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="280" SD_1="15.8774" SD_2="12.638" SE="0.20642940091556627" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" WEIGHT="37.13032055747135">
<FOOTNOTE>IGVAS ,week 4</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.61242516278764" CI_END="16.09722213809296" CI_START="9.430527221639464" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="12.763874679866213" ESTIMABLE="YES" I2="0.0" I2_Q="2.622328266545643" ID="CMP-001.09" MODIFIED="2016-04-22 17:36:15 +0100" MODIFIED_BY="Ana Raquel Marques" NO="9" P_CHI2="0.46498373563638484" P_Q="0.3581049907161745" P_Z="6.143394693107747E-14" Q="2.053858923095298" RANDOM="NO" SCALE="31.07" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="209" TOTAL_2="209" UNITS="" WEIGHT="300.0" Z="7.504988600566928">
<NAME>Subjective change as assessed by the participant at week 4 - doses subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.394126380957175" CI_START="4.205873619042821" DF="0" EFFECT_SIZE="12.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" MODIFIED="2016-02-04 07:25:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0028975627970865957" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="33" WEIGHT="100.0" Z="2.9784013586147897">
<NAME>2500 U</NAME>
<CONT_DATA CI_END="20.394126380957175" CI_START="4.205873619042821" EFFECT_SIZE="12.299999999999997" ESTIMABLE="YES" MEAN_1="61.9" MEAN_2="49.6" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="603" SD_1="15.2" SD_2="18.4" SE="4.129732201613199" STUDY_ID="STD-Kaji-2013" TOTAL_1="34" TOTAL_2="33" WEIGHT="100.0">
<FOOTNOTE>IGVAS, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4103821481449176" CI_END="15.372100262112543" CI_START="4.054112806382986" DF="1" EFFECT_SIZE="9.713106534247764" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2016-02-04 07:26:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.521775620901133" P_Z="7.679773573355189E-4" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="69" WEIGHT="100.0" Z="3.364085542520888">
<NAME>5000 U</NAME>
<CONT_DATA CI_END="15.824399909615106" CI_START="-0.024399909615110182" EFFECT_SIZE="7.899999999999999" ESTIMABLE="YES" MEAN_1="59.9" MEAN_2="52.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="609" SD_1="16.8" SD_2="17.5" SE="4.04313547193814" STUDY_ID="STD-Brashear-1999" TOTAL_1="36" TOTAL_2="36" WEIGHT="50.99712069600637">
<FOOTNOTE>IGAC, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="19.68403924322979" CI_START="3.5159607567702125" EFFECT_SIZE="11.600000000000001" ESTIMABLE="YES" MEAN_1="61.2" MEAN_2="49.6" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="603" SD_1="14.7" SD_2="18.4" SE="4.124585608202834" STUDY_ID="STD-Kaji-2013" TOTAL_1="32" TOTAL_2="33" WEIGHT="49.00287930399362">
<FOOTNOTE>IGVAS, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.1481840915474253" CI_END="19.91026407430143" CI_START="10.322006894594647" DF="2" EFFECT_SIZE="15.116135484448039" ESTIMABLE="YES" I2="6.8981095303001805" ID="CMP-001.09.03" MODIFIED="2016-04-22 16:58:13 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3" P_CHI2="0.3416079917689938" P_Z="6.41552818844936E-10" STUDIES="3" TAU2="0.0" TOTAL_1="107" TOTAL_2="107" WEIGHT="100.0" Z="6.179867848695337">
<NAME>10,000 U</NAME>
<CONT_DATA CI_END="19.897910033510044" CI_START="4.502089966489962" EFFECT_SIZE="12.200000000000003" ESTIMABLE="YES" MEAN_1="64.2" MEAN_2="52.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="609" SD_1="16.0" SD_2="17.5" SE="3.9275772892921363" STUDY_ID="STD-Brashear-1999" TOTAL_1="37" TOTAL_2="36" WEIGHT="38.785884072168834">
<FOOTNOTE>IGAC, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="29.673652431676828" CI_START="11.726347568323177" EFFECT_SIZE="20.700000000000003" ESTIMABLE="YES" MEAN_1="60.2" MEAN_2="39.5" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="607" SD_1="22.9" SD_2="16.9" SE="4.578478228406159" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="28.541767793293854">
<FOOTNOTE>PGAC, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="22.087248385044468" CI_START="5.312751614955523" EFFECT_SIZE="13.699999999999996" ESTIMABLE="YES" MEAN_1="63.3" MEAN_2="49.6" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="603" SD_1="15.8" SD_2="18.4" SE="4.2792869926192605" STUDY_ID="STD-Kaji-2013" TOTAL_1="31" TOTAL_2="33" WEIGHT="32.67234813453731">
<FOOTNOTE>IGVAS, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.3231010848318636" CI_END="14.619251759207934" CI_START="8.958592362638672" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="11.788922060923303" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2016-04-22 17:36:18 +0100" MODIFIED_BY="Ana Raquel Marques" NO="10" P_CHI2="0.8028682001816227" P_Q="0.48890283218355335" P_Z="3.250102784566926E-16" Q="1.431183324811757" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="209" TOTAL_2="209" UNITS="" WEIGHT="300.0" Z="8.163664703077908">
<NAME>Subjective change as assessed by the clinician at week 4 - doses subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.738689556256862" CI_START="1.4613104437431401" DF="0" EFFECT_SIZE="8.600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" MODIFIED="2016-02-04 07:26:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.01821716649704893" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="33" WEIGHT="100.0" Z="2.361174293154537">
<NAME>2500 U</NAME>
<CONT_DATA CI_END="15.738689556256864" CI_START="1.4613104437431392" EFFECT_SIZE="8.600000000000001" ESTIMABLE="YES" MEAN_1="60.6" MEAN_2="52.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="603" SD_1="16.8" SD_2="12.8" SE="3.642255476409737" STUDY_ID="STD-Kaji-2013" TOTAL_1="34" TOTAL_2="33" WEIGHT="100.0">
<FOOTNOTE>IGVAS, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5752002380552468" CI_END="16.036676567587875" CI_START="5.651128987502636" DF="1" EFFECT_SIZE="10.843902777545257" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" MODIFIED="2016-02-04 07:26:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.44819997477010165" P_Z="4.2595659995489224E-5" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="69" WEIGHT="100.0" Z="4.092929858912287">
<NAME>5000 U</NAME>
<CONT_DATA CI_END="21.500744244244732" CI_START="5.099255755755262" EFFECT_SIZE="13.299999999999997" ESTIMABLE="YES" MEAN_1="65.3" MEAN_2="52.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="609" SD_1="18.0" SD_2="17.5" SE="4.184130070211064" STUDY_ID="STD-Brashear-1999" TOTAL_1="36" TOTAL_2="36" WEIGHT="40.09518969622574">
<FOOTNOTE>IGAC, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="15.909166278171206" CI_START="2.4908337218287997" EFFECT_SIZE="9.200000000000003" ESTIMABLE="YES" MEAN_1="61.2" MEAN_2="52.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="603" SD_1="14.7" SD_2="12.8" SE="3.4231069198680437" STUDY_ID="STD-Kaji-2013" TOTAL_1="32" TOTAL_2="33" WEIGHT="59.90481030377426">
<FOOTNOTE>IGVAS, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.31671752196486114" CI_END="17.05326868511916" CI_START="9.390594519394629" DF="2" EFFECT_SIZE="13.221931602256895" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.03" MODIFIED="2016-04-22 16:58:28 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3" P_CHI2="0.8535435280518939" P_Z="1.3439148162188329E-11" STUDIES="3" TAU2="0.0" TOTAL_1="107" TOTAL_2="107" WEIGHT="100.0" Z="6.763829228806881">
<NAME>10,000 U</NAME>
<CONT_DATA CI_END="19.897910033510044" CI_START="4.502089966489962" EFFECT_SIZE="12.200000000000003" ESTIMABLE="YES" MEAN_1="64.2" MEAN_2="52.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="609" SD_1="16.0" SD_2="17.5" SE="3.9275772892921363" STUDY_ID="STD-Brashear-1999" TOTAL_1="37" TOTAL_2="36" WEIGHT="24.771657342378827">
<FOOTNOTE>IGAC, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="21.97157387959014" CI_START="7.828426120409872" EFFECT_SIZE="14.900000000000006" ESTIMABLE="YES" MEAN_1="66.9" MEAN_2="52.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="603" SD_1="15.8" SD_2="12.8" SE="3.6080121550037685" STUDY_ID="STD-Kaji-2013" TOTAL_1="31" TOTAL_2="33" WEIGHT="29.354085862217417">
<FOOTNOTE>IGVAS, week 4</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="18.35673511095078" CI_START="7.043264889049224" EFFECT_SIZE="12.700000000000003" ESTIMABLE="YES" MEAN_1="60.6" MEAN_2="47.9" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="279" SD_1="14.4" SD_2="10.7" SE="2.8861423758652625" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="45.87425679540376">
<FOOTNOTE>PIGAC, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0693974463562944" CI_END="26.04739367476001" CI_START="13.613109262266128" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="19.83025146851307" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2016-04-22 17:36:21 +0100" MODIFIED_BY="Ana Raquel Marques" NO="11" P_CHI2="0.7922161306231417" P_Q="0.7922161306231417" P_Z="4.064812904247207E-10" Q="0.0693974463562944" RANDOM="NO" SCALE="47.68" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="74" UNITS="" WEIGHT="99.99999999999999" Z="6.251518365400308">
<NAME>Subjective change as assessed by the participant at week 4 - BtA-responsive vs BtA-non-responsive subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="27.64904219569801" CI_START="10.405757804301993" DF="0" EFFECT_SIZE="19.0274" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" MODIFIED="2016-04-21 17:34:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.5217782814362567E-5" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="36" WEIGHT="51.999792627461986" Z="4.325512225274873">
<NAME>BtA-responsive</NAME>
<CONT_DATA CI_END="27.64904219569801" CI_START="10.405757804301993" EFFECT_SIZE="19.0274" ESTIMABLE="YES" MEAN_1="62.6274" MEAN_2="43.6" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="609" SD_1="21.3939" SD_2="21.7" SE="4.398877869034544" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" WEIGHT="51.999792627461986">
<FOOTNOTE>PGAC, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="29.673652431676828" CI_START="11.726347568323177" DF="0" EFFECT_SIZE="20.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" MODIFIED="2016-04-21 17:34:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="6.150375018709735E-6" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="38" WEIGHT="48.000207372538" Z="4.52115287380235">
<NAME>BtA-non-responsive</NAME>
<CONT_DATA CI_END="29.673652431676828" CI_START="11.726347568323177" EFFECT_SIZE="20.700000000000003" ESTIMABLE="YES" MEAN_1="60.2" MEAN_2="39.5" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="607" SD_1="22.9" SD_2="16.9" SE="4.578478228406159" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="48.000207372538">
<FOOTNOTE>PGAC, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.704016430418184E-5" CI_END="17.09363279846593" CI_START="8.340486199705087" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="12.717059499085508" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2016-04-22 17:36:24 +0100" MODIFIED_BY="Ana Raquel Marques" NO="12" P_CHI2="0.9925562185760333" P_Q="0.9925562185760329" P_Z="1.2330689583874064E-8" Q="8.704016430418913E-5" RANDOM="NO" SCALE="43.04985235131227" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="112" TOTAL_2="74" UNITS="" WEIGHT="200.0" Z="5.6950899487937585">
<NAME>Subjective change as assessed by the clinician at week 4 - BtA-non-responsive vs -responsive subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.5401861214026484E-31" CI_END="19.650391920215622" CI_START="5.834608079784395" DF="0" EFFECT_SIZE="12.742500000000009" ESTIMABLE="YES" I2="100.0" ID="CMP-001.12.01" MODIFIED="2016-04-21 17:34:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="2.998760718627318E-4" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="36" WEIGHT="100.0" Z="3.6154070390004205">
<NAME>BtA-responsive</NAME>
<CONT_DATA CI_END="19.65039192021562" CI_START="5.8346080797843936" EFFECT_SIZE="12.742500000000007" ESTIMABLE="YES" MEAN_1="64.7425" MEAN_2="52.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="278" SD_1="16.9058" SD_2="17.5" SE="3.5244994166750936" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" WEIGHT="100.0">
<FOOTNOTE>PIGAC, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="18.35673511095078" CI_START="7.043264889049224" DF="0" EFFECT_SIZE="12.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" MODIFIED="2016-04-21 17:34:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0808273234954777E-5" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="38" WEIGHT="100.0" Z="4.400337317452178">
<NAME>BtA-non-responsive</NAME>
<CONT_DATA CI_END="18.35673511095078" CI_START="7.043264889049224" EFFECT_SIZE="12.700000000000003" ESTIMABLE="YES" MEAN_1="60.6" MEAN_2="47.9" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="279" SD_1="14.4" SD_2="10.7" SE="2.8861423758652625" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="100.0">
<FOOTNOTE>PIGAC, week 4</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="2.377779960319596" CI_END="3.1456419689193242" CI_START="1.25493878414628" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="2.200290376532802" ESTIMABLE="YES" I2="57.94396383651957" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.49770929051511464" LOG_CI_START="0.09862254146973438" LOG_DATA="NO" LOG_EFFECT_SIZE="0.3424799992786089" MODIFIED="2016-04-22 17:36:27 +0100" MODIFIED_BY="Ana Raquel Marques" NO="13" P_CHI2="0.12307251142299336" P_Q="1.0" P_Z="5.07207796119223E-6" Q="0.0" RANDOM="NO" SCALE="6.97" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="71" WEIGHT="99.99999999999999" Z="4.561784132237581">
<NAME>Cervical dystonia associated pain: change from baseline to week 4 as assessed with TWSTRS</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="5.194151031447966" CI_START="1.6058489685520343" EFFECT_SIZE="3.4" ESTIMABLE="YES" ESTIMATE="3.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="263" SE="0.9154" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="27.763148876011698">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="2.8514795612264807" CI_START="0.6269204387735192" EFFECT_SIZE="1.7392" ESTIMABLE="YES" ESTIMATE="1.7392" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="0.5675" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" WEIGHT="72.23685112398829">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="10.710618773159869" CI_END="3.2889602656480386" CI_START="1.934041474644094" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="2.6115008701460662" ESTIMABLE="YES" I2="43.980827559322535" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.5170586267468575" LOG_CI_START="0.2864657830954501" LOG_DATA="NO" LOG_EFFECT_SIZE="0.4168901748789562" MODIFIED="2016-04-22 17:36:29 +0100" MODIFIED_BY="Ana Raquel Marques" NO="14" P_CHI2="0.09774260962367498" P_Q="0.4710905156802967" P_Z="4.1771221941158703E-14" Q="1.505410513507693" RANDOM="NO" SCALE="13.47" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="227" WEIGHT="300.0" Z="7.555357096034847">
<NAME>Cervical dystonia associated pain: change from baseline to week 4 as assessed with TWSTRS - doses subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.9693441027195473" CI_END="3.8360337898487784" CI_START="1.3332483345001402" DF="1" EFFECT_SIZE="2.5846410621744593" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.5838824240148505" LOG_CI_START="0.12491104983261873" LOG_EFFECT_SIZE="0.412400239677313" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" NO="1" P_CHI2="0.3248440157366741" P_Z="5.1627949553966495E-5" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="4.048132359087587">
<NAME>2500 units</NAME>
<IV_DATA CI_END="3.680122964336192" CI_START="0.5198770356638083" EFFECT_SIZE="2.1" ESTIMABLE="YES" ESTIMATE="2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="0.8062" STUDY_ID="STD-Kaji-2013" TOTAL_1="34" TOTAL_2="33" WEIGHT="62.719918294272375">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="5.449534338633535" CI_START="1.350465661366465" EFFECT_SIZE="3.4" ESTIMABLE="YES" ESTIMATE="3.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="249" SE="1.0457" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" WEIGHT="37.28008170572763">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.748541303632766" CI_END="3.2694420418050276" CI_START="0.8319271181804195" DF="1" EFFECT_SIZE="2.0506845799927236" ESTIMABLE="YES" I2="63.617064852607704" ID="CMP-001.14.02" LOG_CI_END="0.5144736429230186" LOG_CI_START="-0.07991471885169758" LOG_EFFECT_SIZE="0.3118988657788553" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" NO="2" P_CHI2="0.09734327948079269" P_Z="9.743140480425336E-4" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.0" Z="3.2978406667235465">
<NAME>5000 units</NAME>
<IV_DATA CI_END="2.7801229643361918" CI_START="-0.38012296433619186" EFFECT_SIZE="1.2" ESTIMABLE="YES" ESTIMATE="1.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="0.8062" STUDY_ID="STD-Kaji-2013" TOTAL_1="32" TOTAL_2="33" WEIGHT="59.49121047653697">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="5.214884812895633" CI_START="1.3851151871043668" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="249" SE="0.977" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" WEIGHT="40.50878952346302">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="5.4873228532998635" CI_END="4.140646815691781" CI_START="1.9928037377849936" DF="2" EFFECT_SIZE="3.0667252767383872" ESTIMABLE="YES" I2="63.55235415395182" ID="CMP-001.14.03" LOG_CI_END="0.6170681881122204" LOG_CI_START="0.2994645291098807" LOG_EFFECT_SIZE="0.48667487277398963" MODIFIED="2016-04-22 16:57:25 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3" P_CHI2="0.06433439732385537" P_Z="2.1817206321440228E-8" STUDIES="3" TAU2="0.0" TOTAL_1="100" TOTAL_2="101" WEIGHT="100.0" Z="5.596936903550384">
<NAME>10,000 units</NAME>
<IV_DATA CI_END="5.194151031447966" CI_START="1.6058489685520343" EFFECT_SIZE="3.4" ESTIMABLE="YES" ESTIMATE="3.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="263" SE="0.9154" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="35.82837469484086">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.480122964336192" CI_START="0.3198770356638081" EFFECT_SIZE="1.9" ESTIMABLE="YES" ESTIMATE="1.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="0.8062" STUDY_ID="STD-Kaji-2013" TOTAL_1="31" TOTAL_2="33" WEIGHT="46.19163512470845">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="7.932665460822658" CI_START="2.8673345391773424" EFFECT_SIZE="5.4" ESTIMABLE="YES" ESTIMATE="5.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="249" SE="1.2922" STUDY_ID="STD-Lew-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="17.979990180450695"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.07451366463161262" CI_END="1.2730575325708964" CI_START="0.6450163904050983" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.9590369614879973" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.10484803092268181" LOG_CI_START="-0.19042924943907474" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.018164654705301805" MODIFIED="2016-04-22 17:36:31 +0100" MODIFIED_BY="Ana Raquel Marques" NO="15" P_CHI2="0.7848748139189752" P_Q="0.784874813918975" P_Z="2.1527166223185436E-9" Q="0.0745136646316128" RANDOM="NO" SCALE="4.51" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="5.985843213637686">
<NAME>Cervical dystonia associated pain: change from baseline to week 4 as assessed with validated scales - BtA-responsive vs BtA-non-responsive subgroup analysis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.7091855386331485E-31" CI_END="1.3386603179023935" CI_START="0.5025396820976062" DF="0" EFFECT_SIZE="0.9205999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.15.01" LOG_CI_END="0.12667038972619316" LOG_CI_START="-0.29882963930928663" LOG_EFFECT_SIZE="-0.03592902944204463" MODIFIED="2016-04-21 17:34:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="1.588914219177437E-5" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="56.420678585036924" Z="4.315986872948898">
<NAME>BtA-responsive</NAME>
<IV_DATA CI_END="1.3386603179023935" CI_START="0.5025396820976065" EFFECT_SIZE="0.9206" ESTIMABLE="YES" ESTIMATE="0.9206" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="293" SE="0.2133" STUDY_ID="STD-Brashear-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="56.420678585036924">
<FOOTNOTE>Patient analog pain assessment, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.4844832590478712" CI_START="0.5331167409521287" DF="0" EFFECT_SIZE="1.0088" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.17157530429371584" LOG_CI_START="-0.2731776795291051" LOG_EFFECT_SIZE="0.0038050735650251716" MODIFIED="2016-04-21 17:34:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.2305853348499106E-5" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="43.579321414963076" Z="4.156571899464359">
<NAME>BtA-non-responsive</NAME>
<IV_DATA CI_END="1.4844832590478712" CI_START="0.5331167409521287" EFFECT_SIZE="1.0088" ESTIMABLE="YES" ESTIMATE="1.0088" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="292" SE="0.2427" STUDY_ID="STD-Brin-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="43.579321414963076">
<FOOTNOTE>TWSTRS pain subscore, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.037700148011693455" CI_END="3.6258625096593695" CI_START="1.2405136530363492" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="2.4331880813478595" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.5594113319083196" LOG_CI_START="0.09360154845967329" LOG_DATA="NO" LOG_EFFECT_SIZE="0.3861756804616346" MODIFIED="2016-04-22 17:36:34 +0100" MODIFIED_BY="Ana Raquel Marques" NO="16" P_CHI2="0.8460465619561308" P_Q="1.0" P_Z="6.373337307507379E-5" Q="0.0" RANDOM="NO" SCALE="9.99256158241071" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="71" WEIGHT="100.0" Z="3.9985438555980615">
<NAME>Cervical dystonia severity: change from baseline to week 4 as assessed with TWSTRS</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="4.663450082923769" CI_START="0.5365499170762309" EFFECT_SIZE="2.6" ESTIMABLE="YES" ESTIMATE="2.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="255" SE="1.0528" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="33.408415707728416">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.811045143271518" CI_START="0.8879548567284814" EFFECT_SIZE="2.3495" ESTIMABLE="YES" ESTIMATE="2.3495" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="256" SE="0.7457" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" WEIGHT="66.59158429227158">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.9817349242011129" CI_END="3.2371714330428247" CI_START="1.828411678638302" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="2.5327915558405634" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.51016569923361" LOG_CI_START="0.2620739866010891" LOG_DATA="NO" LOG_EFFECT_SIZE="0.4035994496116316" MODIFIED="2016-04-22 17:38:16 +0100" MODIFIED_BY="Ana Raquel Marques" NO="17" P_CHI2="0.9213707546752009" P_Q="0.4881974448192721" P_Z="1.820437311566032E-12" Q="1.434071007150977" RANDOM="NO" SCALE="10.084144381106293" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="227" WEIGHT="300.0" Z="7.047589504561072">
<NAME>Cervical dystonia severity: change from baseline to week 4 as assessed with TWSTRS - doses subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="3.2530512613209663" CI_START="0.5469487386790335" DF="1" EFFECT_SIZE="1.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.5122909069134012" LOG_CI_START="-0.26205337485860863" LOG_EFFECT_SIZE="0.2787536009528289" MODIFIED="2016-04-21 19:44:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.005918782085028973" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="2.752247218623836">
<NAME>2500 units</NAME>
<IV_DATA CI_END="3.8599639845400544" CI_START="-0.05996398454005436" EFFECT_SIZE="1.9" ESTIMABLE="YES" ESTIMATE="1.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="1.0" STUDY_ID="STD-Kaji-2013" TOTAL_1="34" TOTAL_2="33" WEIGHT="47.65761657784618">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.77019763404812" CI_START="0.029802365951880017" EFFECT_SIZE="1.9" ESTIMABLE="YES" ESTIMATE="1.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="249" SE="0.9542" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" WEIGHT="52.342383422153816">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.3849796137353963" CI_END="3.7722962284707657" CI_START="1.245866296435836" DF="1" EFFECT_SIZE="2.509081262453301" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.5766057894043194" LOG_CI_START="0.09547143731848745" LOG_EFFECT_SIZE="0.3995147271829023" MODIFIED="2016-04-21 19:44:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5349505485376373" P_Z="9.90079357038747E-5" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.0" Z="3.8930103276062438">
<NAME>5000 units</NAME>
<IV_DATA CI_END="3.90708679374593" CI_START="0.29291320625407" EFFECT_SIZE="2.1" ESTIMABLE="YES" ESTIMATE="2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="0.922" STUDY_ID="STD-Kaji-2013" TOTAL_1="32" TOTAL_2="33" WEIGHT="48.864842193337374">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.6665155392659505" CI_START="1.133484460734049" EFFECT_SIZE="2.9" ESTIMABLE="YES" ESTIMATE="2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="249" SE="0.9013" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" WEIGHT="51.135157806662626">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.16268430331474049" CI_END="4.05003226404305" CI_START="1.8712369501686708" DF="2" EFFECT_SIZE="2.9606346071058605" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.03" LOG_CI_END="0.6074584829776433" LOG_CI_START="0.27212878463260604" LOG_EFFECT_SIZE="0.4713848113374042" MODIFIED="2016-04-22 16:57:47 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3" P_CHI2="0.92187824305045" P_Z="1.0009264548399738E-7" STUDIES="3" TAU2="0.0" TOTAL_1="100" TOTAL_2="101" WEIGHT="100.0" Z="5.326555610211802">
<NAME>10,000 units</NAME>
<IV_DATA CI_END="4.663450082923769" CI_START="0.5365499170762309" EFFECT_SIZE="2.6" ESTIMABLE="YES" ESTIMATE="2.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="255" SE="1.0528" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="27.873078578827972">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="5.059963984540055" CI_START="1.1400360154599458" EFFECT_SIZE="3.1" ESTIMABLE="YES" ESTIMATE="3.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="1.0" STUDY_ID="STD-Kaji-2013" TOTAL_1="31" TOTAL_2="33" WEIGHT="30.894181360137406">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.796544825017871" CI_START="1.4034551749821291" EFFECT_SIZE="3.1" ESTIMABLE="YES" ESTIMATE="3.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="249" SE="0.8656" STUDY_ID="STD-Lew-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="41.23274006103462">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.6938295230769289" CI_END="3.535134458308884" CI_START="1.0415164367517895" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="2.2883254475303367" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.5484059367725412" LOG_CI_START="0.01766612818129212" LOG_DATA="NO" LOG_EFFECT_SIZE="0.3595177902325895" MODIFIED="2016-04-22 17:38:19 +0100" MODIFIED_BY="Ana Raquel Marques" NO="18" P_CHI2="0.40486527089291424" P_Q="1.0" P_Z="3.216471868174496E-4" Q="0.0" RANDOM="NO" SCALE="13.96185410870371" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="71" WEIGHT="100.0" Z="3.597211299640321">
<NAME>Cervical dystonia associated disability: change from baseline to week 4 as assessed with TWSTRS</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="5.0877536363320655" CI_START="0.9122463636679345" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="259" SE="1.0652" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="35.664929265081994">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.448247436138717" CI_START="0.3393525638612829" EFFECT_SIZE="1.8938" ESTIMABLE="YES" ESTIMATE="1.8938" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="260" SE="0.7931" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" WEIGHT="64.335070734918">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.9105430467718865" CI_END="3.438432909097907" CI_START="1.9025361701388246" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="2.6704845396183656" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.5363605547816253" LOG_CI_START="0.2793329221271723" LOG_DATA="NO" LOG_EFFECT_SIZE="0.4265900680277295" MODIFIED="2016-04-22 17:38:22 +0100" MODIFIED_BY="Ana Raquel Marques" NO="19" P_CHI2="0.43328555213869135" P_Q="0.4126595727560546" P_Z="9.385022295282053E-12" Q="1.770264786745976" RANDOM="NO" SCALE="4.21" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="227" WEIGHT="300.0" Z="6.815632048897091">
<NAME>Cervical dystonia associated disability: change from baseline to week 4 as assessed with TWSTRS - doses subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.5931735609362258" CI_END="3.7769335580507617" CI_START="0.8634786975740889" DF="1" EFFECT_SIZE="2.3202061278124253" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.5771393450007514" LOG_CI_START="-0.06374837221365404" LOG_EFFECT_SIZE="0.3655265694576608" MODIFIED="2016-04-21 19:44:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4411946929339946" P_Z="0.0017978725004642857" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="3.1217373633703516">
<NAME>2500 units</NAME>
<IV_DATA CI_END="3.7070867937459298" CI_START="0.09291320625406985" EFFECT_SIZE="1.9" ESTIMABLE="YES" ESTIMATE="1.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="0.922" STUDY_ID="STD-Kaji-2013" TOTAL_1="34" TOTAL_2="33" WEIGHT="64.98282268229788">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="5.561714764582309" CI_START="0.6382852354176918" EFFECT_SIZE="3.1" ESTIMABLE="YES" ESTIMATE="3.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="249" SE="1.256" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" WEIGHT="35.017177317702114">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.0722481831005846" CI_END="3.5693164522231493" CI_START="0.545192556789331" DF="1" EFFECT_SIZE="2.0572545045062403" ESTIMABLE="YES" I2="6.738009375000001" ID="CMP-001.19.02" LOG_CI_END="0.5525850538009279" LOG_CI_START="-0.2634500819778394" LOG_EFFECT_SIZE="0.31328802191617705" MODIFIED="2016-04-21 19:44:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.30043860065904626" P_Z="0.007661069513544961" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.0" Z="2.6666531367668083">
<NAME>5000 units</NAME>
<IV_DATA CI_END="3.383441715566078" CI_START="-0.7834417155660776" EFFECT_SIZE="1.3" ESTIMABLE="YES" ESTIMATE="1.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="1.063" STUDY_ID="STD-Kaji-2013" TOTAL_1="32" TOTAL_2="33" WEIGHT="52.67159346835998">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="5.097903612263217" CI_START="0.7020963877367832" EFFECT_SIZE="2.9" ESTIMABLE="YES" ESTIMATE="2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="249" SE="1.1214" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" WEIGHT="47.32840653164001">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.474856515989099" CI_END="4.348226576193408" CI_START="2.093802888857928" DF="2" EFFECT_SIZE="3.221014732525668" ESTIMABLE="YES" I2="19.1872342061543" ID="CMP-001.19.03" LOG_CI_END="0.6383121661011848" LOG_CI_START="0.3209357946730042" LOG_EFFECT_SIZE="0.507992711233839" MODIFIED="2016-04-22 16:57:59 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3" P_CHI2="0.290129481614272" P_Z="2.135999649952323E-8" STUDIES="3" TAU2="0.0" TOTAL_1="100" TOTAL_2="101" WEIGHT="99.99999999999999" Z="5.600609064647199">
<NAME>10,000 units</NAME>
<IV_DATA CI_END="5.0877536363320655" CI_START="0.9122463636679345" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="259" SE="1.0652" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" WEIGHT="29.15094170617557">
<FOOTNOTE>TWSTRS, week 4, pooled SD</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.185961019501354" CI_START="0.8140389804986454" EFFECT_SIZE="2.5" ESTIMABLE="YES" ESTIMATE="2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="264" SE="0.8602" STUDY_ID="STD-Kaji-2013" TOTAL_1="31" TOTAL_2="33" WEIGHT="44.7008753849703">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="6.904371493412199" CI_START="2.495628506587801" EFFECT_SIZE="4.7" ESTIMABLE="YES" ESTIMATE="4.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="249" SE="1.1247" STUDY_ID="STD-Lew-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="26.148182908854114">
<FOOTNOTE>TWSTRS, week 4</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.593723289981013" CI_END="4.059584570216499" CI_START="0.19117070200592834" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8809504141214323" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.6084815931600299" LOG_CI_START="-0.7185786650521554" LOG_EFFECT_SIZE="-0.05504853594606272" METHOD="MH" MODIFIED="2016-04-22 17:38:22 +0100" MODIFIED_BY="Ana Raquel Marques" NO="20" P_CHI2="0.7431468544435353" P_Q="1.0" P_Z="0.870829650319241" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="139" WEIGHT="100.00000000000001" Z="0.16260474562216948">
<NAME>Proportion of withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-27 11:00:58 +0000" MODIFIED_BY="[Empty name]" ORDER="524" O_E="0.0" SE="0.0" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>No withdrawals</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.737987442424938" CI_START="0.013650190154211364" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8886280205920004" LOG_CI_START="-1.8648612986342514" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="405" O_E="0.0" SE="1.6174132561054522" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="2.616025641025641" WEIGHT="42.46864198604379">
<FOOTNOTE>1 patients withdraw treatment due to adverse event</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="11.117224889975173" CI_START="0.09749561277724661" EFFECT_SIZE="1.0410958904109588" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0459963910785604" LOG_CI_START="-1.0110149267578894" LOG_EFFECT_SIZE="0.017490732160335427" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="232" O_E="0.0" SE="1.208298630467373" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="38" VAR="1.4599855803893294" WEIGHT="36.77427302305023">
<FOOTNOTE>2 patients (1 BtB and 1 placebo) withdraw treatment due to lack of effect, 1 patient (BtB) withdraw treatment due to serious adverse event</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="35.23464426115391" CI_START="0.08540352576031503" EFFECT_SIZE="1.7346938775510203" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.546969891096583" LOG_CI_START="-1.068524199725025" LOG_EFFECT_SIZE="0.23922284568577906" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="523" O_E="0.0" SE="1.5363541758531671" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" VAR="2.3603841536614647" WEIGHT="20.757084990905998">
<FOOTNOTE>2 patients withdraw treatment due to lack of effect</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.230528052986315" CI_END="21.317494793786572" CI_START="2.7479262188002904" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="7.653685573825517" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="1.328736165590835" LOG_CI_START="0.439005067835086" LOG_EFFECT_SIZE="0.8838706167129606" METHOD="MH" MODIFIED="2016-04-22 16:58:55 +0100" MODIFIED_BY="Ana Raquel Marques" NO="21" P_CHI2="0.7456921959794831" P_Q="1.0" P_Z="9.856065792049515E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="137" WEIGHT="100.0" Z="3.8941081864403464">
<NAME>Adverse events: dry mouth</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="50.461810894764085" CI_START="0.9446099609246307" EFFECT_SIZE="6.904109589041096" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.70296283174421" LOG_CI_START="-0.024747479094071198" LOG_EFFECT_SIZE="0.8391076763250694" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="298" O_E="0.0" SE="1.0148655888903748" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" VAR="1.0299521635138074" WEIGHT="29.09912674444073"/>
<DICH_DATA CI_END="118.38234356956944" CI_START="2.3176555344410055" EFFECT_SIZE="16.564102564102566" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="2.0732869332811923" LOG_CI_START="0.3650488886559776" LOG_EFFECT_SIZE="1.219167910968585" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="299" O_E="0.0" SE="1.0034274833275472" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="1.0068667142970549" WEIGHT="22.006829352538254"/>
<DICH_DATA CI_END="56.49765730329629" CI_START="0.17256799831212227" EFFECT_SIZE="3.122448979591837" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7520304400080269" LOG_CI_START="-0.7630397384298568" LOG_EFFECT_SIZE="0.4944953507890852" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="300" O_E="0.0" SE="1.477364672612584" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" VAR="2.182606375883687" WEIGHT="16.12893689726629"/>
<DICH_DATA CI_END="33.279168109548756" CI_START="0.6262539304246527" EFFECT_SIZE="4.565217391304348" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.5221724615505352" LOG_CI_START="-0.2032495354458449" LOG_EFFECT_SIZE="0.6594614630523452" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="301" O_E="0.0" SE="1.0135214220123059" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="1.0272256728778466" WEIGHT="32.76510700575473"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2497607900053841" CI_END="19.0456183797275" CI_START="2.4167880695236224" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="6.784484009622635" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="1.2797950780493932" LOG_CI_START="0.38323856837543335" LOG_EFFECT_SIZE="0.8315168232124132" METHOD="MH" MODIFIED="2016-04-22 17:39:59 +0100" MODIFIED_BY="Ana Raquel Marques" NO="22" P_CHI2="0.9691825060746632" P_Q="1.0" P_Z="2.77376141064373E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="137" WEIGHT="99.99999999999999" Z="3.6355611909575205">
<NAME>Adverse events: dysphagia</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="178.01519722010724" CI_START="0.6797172482436389" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.2504570797645105" LOG_CI_START="-0.16767170944806045" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="305" O_E="0.0" SE="1.4204208207140194" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="2.0175953079178885" WEIGHT="15.438935705336391"/>
<DICH_DATA CI_END="22.593182453265406" CI_START="1.27111823398717" EFFECT_SIZE="5.358974358974359" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3539774095190948" LOG_CI_START="0.10418594865001479" LOG_EFFECT_SIZE="0.7290816790845548" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="303" O_E="0.0" SE="0.7341336906820045" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="0.5389522757943811" WEIGHT="41.70517697025934"/>
<DICH_DATA CI_END="43.75162202596382" CI_START="0.8004378465829044" EFFECT_SIZE="5.917808219178082" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.6409941584753025" LOG_CI_START="-0.0966723850863903" LOG_EFFECT_SIZE="0.7721608866944562" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="302" O_E="0.0" SE="1.0207139292762537" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" VAR="1.0418569254185692" WEIGHT="27.572900464576307"/>
<DICH_DATA CI_END="131.8029311163835" CI_START="0.483099164347553" EFFECT_SIZE="7.979591836734694" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.1199250684789055" LOG_CI_START="-0.31596371374419935" LOG_EFFECT_SIZE="0.9019806773673532" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="304" O_E="0.0" SE="1.4308531285217905" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" VAR="2.047340675400595" WEIGHT="15.282986859827943"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.780376637189769" CI_END="16.690376847795182" CI_START="3.390053251911292" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="7.522052001182455" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="6" I2="0.0" I2_Q="40.95078317132012" ID="CMP-001.23" LOG_CI_END="1.2224661426151544" LOG_CI_START="0.5302065202767049" LOG_EFFECT_SIZE="0.8763363314459296" METHOD="MH" MODIFIED="2016-04-22 17:39:59 +0100" MODIFIED_BY="Ana Raquel Marques" NO="23" P_CHI2="0.7063686290460631" P_Q="0.18387460860908444" P_Z="6.967604950801093E-7" Q="3.3870051245601123" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="301" TOTAL_2="299" WEIGHT="300.0" Z="4.9622644237893745">
<NAME>Adverse events: dry mouth - doses subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.778704322459019" CI_START="0.06336986201630977" DF="0" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="1.1696363602920683" LOG_CI_START="-1.1981172385212888" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2016-02-04 07:27:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9811910394990938" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="0.02357571987444934">
<NAME>2500 U</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="300" O_E="0.0" SE="0.0" STUDY_ID="STD-Kaji-2013" TOTAL_1="34" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.778704322459014" CI_START="0.0633698620163098" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.169636360292068" LOG_CI_START="-1.1981172385212886" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="301" O_E="0.0" SE="1.3908301845123068" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" VAR="1.9344086021505376" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12320502311321715" CI_END="17.861534591829937" CI_START="0.8704713573234754" DF="1" EFFECT_SIZE="3.9430894308943096" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-001.23.02" LOG_CI_END="1.2519187690056575" LOG_CI_START="-0.06024551467992575" LOG_EFFECT_SIZE="0.5958366271628658" MODIFIED="2016-02-04 07:27:28 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7255841139257501" P_Z="0.07507792697649224" STUDIES="3" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.00000000000001" Z="1.779987985389894">
<NAME>5000 U</NAME>
<DICH_DATA CI_END="40.69812832327722" CI_START="0.6142788631805778" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6095744368035072" LOG_CI_START="-0.21163442813146952" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="298" O_E="0.0" SE="1.0697871023920809" STUDY_ID="STD-Brashear-1999" TOTAL_1="36" TOTAL_2="36" VAR="1.1444444444444446" WEIGHT="49.59349593495936"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="300" O_E="0.0" SE="0.0" STUDY_ID="STD-Kaji-2013" TOTAL_1="32" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="26.38050340998278" CI_START="0.3195056573506123" EFFECT_SIZE="2.903225806451613" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4212830787801585" LOG_CI_START="-0.4955214475700541" LOG_EFFECT_SIZE="0.46288081560505223" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="301" O_E="0.0" SE="1.1259404671135462" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" VAR="1.2677419354838708" WEIGHT="50.40650406504066"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2366936720585368" CI_END="33.30014878700358" CI_START="3.953703401908162" DF="3" EFFECT_SIZE="11.474271721692142" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="3" I2="0.0" ID="CMP-001.23.03" LOG_CI_END="1.5224461739636854" LOG_CI_START="0.5970040863873494" LOG_EFFECT_SIZE="1.0597251301755173" MODIFIED="2016-04-22 16:59:23 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3" P_CHI2="0.9714589967716559" P_Z="7.165393912726528E-6" STUDIES="4" TAU2="0.0" TOTAL_1="137" TOTAL_2="137" WEIGHT="100.00000000000001" Z="4.488715429175267">
<NAME>10,000 U</NAME>
<DICH_DATA CI_END="65.64183013428077" CI_START="1.168169576322634" EFFECT_SIZE="8.756756756756756" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.8171806809450286" LOG_CI_START="0.06750589133420558" LOG_EFFECT_SIZE="0.9423432861396172" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="298" O_E="0.0" SE="1.0277676324472893" STUDY_ID="STD-Brashear-1999" TOTAL_1="37" TOTAL_2="36" VAR="1.0563063063063065" WEIGHT="28.86768555264714"/>
<DICH_DATA CI_END="118.38234356956944" CI_START="2.3176555344410055" EFFECT_SIZE="16.564102564102566" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="2.0732869332811923" LOG_CI_START="0.3650488886559776" LOG_EFFECT_SIZE="1.219167910968585" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="299" O_E="0.0" SE="1.0034274833275472" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="1.0068667142970549" WEIGHT="28.84742041712404"/>
<DICH_DATA CI_END="170.61960044736696" CI_START="0.5359372897969482" EFFECT_SIZE="9.5625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.232028920601572" LOG_CI_START="-0.27088602427822384" LOG_EFFECT_SIZE="0.9805714481616741" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="300" O_E="0.0" SE="1.4702246282511866" STUDY_ID="STD-Kaji-2013" TOTAL_1="31" TOTAL_2="33" VAR="2.16156045751634" WEIGHT="13.807312336401251"/>
<DICH_DATA CI_END="73.32835516809254" CI_START="1.363728939109126" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8652719434241838" LOG_CI_START="0.13472805657581635" LOG_EFFECT_SIZE="1.0" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="301" O_E="0.0" SE="1.016530045465127" STUDY_ID="STD-Lew-1997" TOTAL_1="30" TOTAL_2="30" VAR="1.0333333333333332" WEIGHT="28.47758169382758"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7918585665761637" CI_END="16.783623768462256" CI_START="3.6182427613586308" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="7.792767493619018" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="1.2248857355591984" LOG_CI_START="0.5584977019327366" LOG_EFFECT_SIZE="0.8916917187459676" METHOD="MH" MODIFIED="2016-04-22 17:00:00 +0100" MODIFIED_BY="Ana Raquel Marques" NO="24" P_CHI2="0.9867414147698187" P_Q="0.8467921642239357" P_Z="1.560763035173167E-7" Q="0.33260004650257907" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="301" TOTAL_2="299" WEIGHT="300.0" Z="5.245243209257162">
<NAME>Adverse events: dysphagia - doses subgroup analysis</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3700683053793473" CI_END="53.62795128442538" CI_START="0.8591709547054377" DF="1" EFFECT_SIZE="6.787899388171311" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="1.729391206195512" LOG_CI_START="-0.06592041323712955" LOG_EFFECT_SIZE="0.8317353964791913" MODIFIED="2016-02-04 07:27:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5429673154167283" P_Z="0.06936550688380547" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="1.816031717414638">
<NAME>2500 U</NAME>
<DICH_DATA CI_END="184.70493429888194" CI_START="0.6147949674086615" EFFECT_SIZE="10.65625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2664784975525993" LOG_CI_START="-0.21126969620741534" LOG_EFFECT_SIZE="1.0276044006725917" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="305" O_E="0.0" SE="1.4554415540659997" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" VAR="2.1183101173020527" WEIGHT="50.03399048266485"/>
<DICH_DATA CI_END="69.07858546156456" CI_START="0.1229478161392773" EFFECT_SIZE="2.914285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8393434358362613" LOG_CI_START="-0.9102791810129777" LOG_EFFECT_SIZE="0.4645321274116419" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="304" O_E="0.0" SE="1.6151419359887094" STUDY_ID="STD-Kaji-2013" TOTAL_1="34" TOTAL_2="33" VAR="2.608683473389356" WEIGHT="49.966009517335145"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13758015565645815" CI_END="24.17199063641899" CI_START="1.2501014797084389" DF="2" EFFECT_SIZE="5.497039317858834" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-001.24.02" LOG_CI_END="1.3833124173424145" LOG_CI_START="0.0969452692388791" LOG_EFFECT_SIZE="0.7401288432906469" MODIFIED="2016-02-04 07:28:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9335226387298404" P_Z="0.02410924251623068" STUDIES="3" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="2.2553838986133705">
<NAME>5000 U</NAME>
<DICH_DATA CI_END="125.9509737107974" CI_START="0.36510516915962377" EFFECT_SIZE="6.78125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1002015293219576" LOG_CI_START="-0.43758201826471055" LOG_EFFECT_SIZE="0.8313097555286235" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="305" O_E="0.0" SE="1.4907066180835706" STUDY_ID="STD-Lew-1997" TOTAL_1="31" TOTAL_2="30" VAR="2.2222062211981566" WEIGHT="25.390810042633824"/>
<DICH_DATA CI_END="34.06776346393617" CI_START="0.46965219824123333" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5323436232316976" LOG_CI_START="-0.32822364057577297" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="302" O_E="0.0" SE="1.0929064207170003" STUDY_ID="STD-Brashear-1999" TOTAL_1="36" TOTAL_2="36" VAR="1.1944444444444446" WEIGHT="49.98815727143534"/>
<DICH_DATA CI_END="134.28803467492696" CI_START="0.3873367608978824" EFFECT_SIZE="7.212121212121212" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1280373179095604" LOG_CI_START="-0.4119112835523115" LOG_EFFECT_SIZE="0.8580630171786244" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="304" O_E="0.0" SE="1.4919783814470546" STUDY_ID="STD-Kaji-2013" TOTAL_1="32" TOTAL_2="33" VAR="2.225999490705373" WEIGHT="24.62103268593084"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0477827502387034" CI_END="25.007665227766605" CI_START="3.375287083909999" DF="3" EFFECT_SIZE="9.187385343068277" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="3" I2="0.0" ID="CMP-001.24.03" LOG_CI_END="1.3980731469072452" LOG_CI_START="0.5283107175094266" LOG_EFFECT_SIZE="0.9631919322083359" MODIFIED="2016-04-22 17:00:00 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3" P_CHI2="0.7896921001845238" P_Z="1.4183254013957222E-5" STUDIES="4" TAU2="0.0" TOTAL_1="137" TOTAL_2="137" WEIGHT="100.00000000000001" Z="4.341004930817533">
<NAME>10,000 U</NAME>
<DICH_DATA CI_END="342.93392811309036" CI_START="1.2859619998128908" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.5352104540953477" LOG_CI_START="0.10922813537249075" LOG_EFFECT_SIZE="1.3222192947339193" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="305" O_E="0.0" SE="1.4250340228239595" STUDY_ID="STD-Lew-1997" TOTAL_1="30" TOTAL_2="30" VAR="2.0307219662058373" WEIGHT="12.423838327279695"/>
<DICH_DATA CI_END="22.593182453265406" CI_START="1.27111823398717" EFFECT_SIZE="5.358974358974359" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3539774095190948" LOG_CI_START="0.10418594865001479" LOG_EFFECT_SIZE="0.7290816790845548" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="303" O_E="0.0" SE="0.7341336906820045" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="0.5389522757943811" WEIGHT="50.340747507938495"/>
<DICH_DATA CI_END="59.12358972386191" CI_START="1.0247566204229097" EFFECT_SIZE="7.783783783783784" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7717607946346736" LOG_CI_START="0.010620732749798108" LOG_EFFECT_SIZE="0.8911907636922359" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="302" O_E="0.0" SE="1.034502390135081" STUDY_ID="STD-Brashear-1999" TOTAL_1="37" TOTAL_2="36" VAR="1.0701951951951953" WEIGHT="25.188055786813628"/>
<DICH_DATA CI_END="267.8403388437017" CI_START="0.9483407441409488" EFFECT_SIZE="15.9375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.427875985737661" LOG_CI_START="-0.023035590181600462" LOG_EFFECT_SIZE="1.2024201977780304" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="304" O_E="0.0" SE="1.439677591902941" STUDY_ID="STD-Kaji-2013" TOTAL_1="31" TOTAL_2="33" VAR="2.072671568627451" WEIGHT="12.04735837796819"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.0797343693414385" CI_END="3.377218012376762" CI_START="0.381925749473335" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.135714101573033" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" I2="60.627862510470415" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.5285590969149849" LOG_CI_START="-0.41802106046093657" LOG_EFFECT_SIZE="0.055269018227024146" METHOD="MH" MODIFIED="2016-04-22 17:00:19 +0100" MODIFIED_BY="Ana Raquel Marques" NO="25" P_CHI2="0.07887695964521346" P_Q="1.0" P_Z="0.8189643996315845" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5163403904451166" TOTALS="YES" TOTAL_1="204" TOTAL_2="104" WEIGHT="100.0" Z="0.22887715180117654">
<NAME>Adverse events: infection</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2381024198232118" CI_START="0.28285587329659057" EFFECT_SIZE="0.5917808219178082" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.09275657240964691" LOG_CI_START="-0.5484347990207347" LOG_EFFECT_SIZE="-0.2278391133055438" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="310" O_E="0.0" SE="0.37663898552668346" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" VAR="0.14185692541856926" WEIGHT="46.971441657068496"/>
<DICH_DATA CI_END="3.391622222620542" CI_START="0.49763163392273807" EFFECT_SIZE="1.2991452991452992" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.53040747219073" LOG_CI_START="-0.30309201979350825" LOG_EFFECT_SIZE="0.11365772619861092" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="311" O_E="0.0" SE="0.4896017274805684" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="0.23970985155195676" WEIGHT="40.89209301655097"/>
<DICH_DATA CI_END="147.00618718365615" CI_START="0.5509972168641177" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.167335613681327" LOG_CI_START="-0.25885059480267714" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="313" O_E="0.0" SE="1.4251537886789278" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="2.031063321385902" WEIGHT="12.136465326380524"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08897401188777779" CI_END="1.7276231950092853" CI_START="0.6691478094620826" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0751908093526226" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="0.23744902623730219" LOG_CI_START="-0.17447793941694714" LOG_EFFECT_SIZE="0.0314855434101775" METHOD="MH" MODIFIED="2016-04-22 17:00:33 +0100" MODIFIED_BY="Ana Raquel Marques" NO="26" P_CHI2="0.9564880300712278" P_Q="1.0" P_Z="0.7644679443925835" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="204" TOTAL_2="104" WEIGHT="100.0" Z="0.29961879781095485">
<NAME>Adverse events: neck pain secondary to CD</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2512706535050633" CI_START="0.5881459919247974" EFFECT_SIZE="1.1506849315068493" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.352427710130593" LOG_CI_START="-0.2305148582477415" LOG_EFFECT_SIZE="0.06095642594142573" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="322" O_E="0.0" SE="0.3424233502776857" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" VAR="0.11725375081539464" WEIGHT="46.02615556870382"/>
<DICH_DATA CI_END="2.3308861861576338" CI_START="0.40730234558508294" EFFECT_SIZE="0.9743589743589743" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3675210680592077" LOG_CI_START="-0.3900830888785857" LOG_EFFECT_SIZE="-0.011281010409689058" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="323" O_E="0.0" SE="0.4450204319863192" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="0.19804318488529016" WEIGHT="30.940668892061108"/>
<DICH_DATA CI_END="3.0047814282466736" CI_START="0.3737839854625057" EFFECT_SIZE="1.059782608695652" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.4778128863358457" LOG_CI_START="-0.4273793096298826" LOG_EFFECT_SIZE="0.02521678835298152" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="325" O_E="0.0" SE="0.5317143766839038" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="0.2827201783723523" WEIGHT="23.033175539235067"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.237160611878653" CI_END="2.6612803780018166" CI_START="0.7272140064949834" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3911579227726754" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.42509063186235346" LOG_CI_START="-0.13833776498286912" LOG_EFFECT_SIZE="0.1433764334397422" METHOD="MH" MODIFIED="2016-04-22 17:00:42 +0100" MODIFIED_BY="Ana Raquel Marques" NO="27" P_CHI2="0.524666124725948" P_Q="1.0" P_Z="0.3185171807859405" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="137" WEIGHT="100.00000000000001" Z="0.9975097007788728">
<NAME>Adverse events: injection site pain</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7187364425074274" CI_START="0.2615916473870182" EFFECT_SIZE="0.9863013698630136" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5703953997570091" LOG_CI_START="-0.582376127135384" LOG_EFFECT_SIZE="-0.005990363689187465" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="314" O_E="0.0" SE="0.6771437012076801" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" VAR="0.4585235920852359" WEIGHT="27.586204150724388"/>
<DICH_DATA CI_END="8.149120990861803" CI_START="0.6342796588047185" EFFECT_SIZE="2.2735042735042734" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9111107658680395" LOG_CI_START="-0.19771921609822882" LOG_EFFECT_SIZE="0.35669577488490534" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="315" O_E="0.0" SE="0.6513322202039189" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="0.4242336610757663" WEIGHT="20.862649678834615"/>
<DICH_DATA CI_END="2.922131499877043" CI_START="0.08911835746665803" EFFECT_SIZE="0.5103092783505154" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.46569975587820445" LOG_CI_START="-1.0500328265435566" LOG_EFFECT_SIZE="-0.29216653533267617" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="316" O_E="0.0" SE="0.8903488219118323" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" VAR="0.7927210246797876" WEIGHT="20.489563504433363"/>
<DICH_DATA CI_END="5.5600839109210085" CI_START="0.5439800401656412" EFFECT_SIZE="1.7391304347826086" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="0.7450813458581327" LOG_CI_START="-0.26441703523739374" LOG_EFFECT_SIZE="0.2403321553103695" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="317" O_E="0.0" SE="0.5929843461530908" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="0.3516304347826087" WEIGHT="31.06158266600765"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.016451589077560363" CI_END="6.277062664505273" CI_START="0.6756959426940281" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.059462496488435" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.7977564642748953" LOG_CI_START="-0.17024868884605535" LOG_EFFECT_SIZE="0.31375388771442" METHOD="MH" MODIFIED="2016-04-22 17:00:54 +0100" MODIFIED_BY="Ana Raquel Marques" NO="28" P_CHI2="0.8979402572263997" P_Q="1.0" P_Z="0.2038911290691371" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="68" WEIGHT="100.00000000000001" Z="1.2705434840858763">
<NAME>Adverse events: nausea</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.236182123401312" CI_START="0.5247935415244226" EFFECT_SIZE="1.9487179487179487" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8595094888390828" LOG_CI_START="-0.2800115183304985" LOG_EFFECT_SIZE="0.28974898525429216" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="319" O_E="0.0" SE="0.66936028033137" STUDY_ID="STD-Brin-1999" TOTAL_1="39" TOTAL_2="38" VAR="0.44804318488529016" WEIGHT="66.83210038393109"/>
<DICH_DATA CI_END="17.808728385947656" CI_START="0.2925701568663497" EFFECT_SIZE="2.282608695652174" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.2506329102166307" LOG_CI_START="-0.5337699754399026" LOG_EFFECT_SIZE="0.358431467388364" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="321" O_E="0.0" SE="1.0481670879713874" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="1.098654244306418" WEIGHT="33.16789961606892"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2294446643110793" CI_END="4.409045346284291" CI_START="0.819883837121901" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9012903556679672" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.644344565494449" LOG_CI_START="-0.08624767501950877" LOG_EFFECT_SIZE="0.2790484452374701" METHOD="MH" MODIFIED="2016-04-22 17:00:59 +0100" MODIFIED_BY="Ana Raquel Marques" NO="29" P_CHI2="0.8916136848578049" P_Q="1.0" P_Z="0.13433869650536648" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="262" TOTAL_2="99" WEIGHT="100.00000000000001" Z="1.4972097218623284">
<NAME>Adverse events: headache</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.499504516676777" CI_START="0.7062204222439239" EFFECT_SIZE="2.3013698630136985" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.8750325710208301" LOG_CI_START="-0.15105972781001636" LOG_EFFECT_SIZE="0.36198642160540695" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="326" O_E="0.0" SE="0.6027316955720353" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" VAR="0.3632854968471407" WEIGHT="47.124723527194675"/>
<DICH_DATA CI_END="14.035966943945606" CI_START="0.20614940381428346" EFFECT_SIZE="1.7010309278350515" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.1472423367392277" LOG_CI_START="-0.6858179168439047" LOG_EFFECT_SIZE="0.23071220994766142" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="334" O_E="0.0" SE="1.0767486667493276" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" VAR="1.1593876913464543" WEIGHT="17.500867644995758"/>
<DICH_DATA CI_END="6.418650591855854" CI_START="0.3354657196650798" EFFECT_SIZE="1.4673913043478262" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8074437349054786" LOG_CI_START="-0.4743518526065769" LOG_EFFECT_SIZE="0.16654594114945087" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="327" O_E="0.0" SE="0.7529330730950703" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="0.5669082125603865" WEIGHT="35.374408827809575"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.06669993815899" CI_END="8.919232145045862" CI_START="0.23118551414401675" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4359656225767625" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="10" I2="67.03314783346738" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="0.9503274676582444" LOG_CI_START="-0.6360393818622913" LOG_EFFECT_SIZE="0.15714404289797654" METHOD="MH" MODIFIED="2016-04-22 17:01:05 +0100" MODIFIED_BY="Ana Raquel Marques" NO="30" P_CHI2="0.04815419660030662" P_Q="1.0" P_Z="0.6977907351704016" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.7137880922256366" TOTALS="YES" TOTAL_1="262" TOTAL_2="99" WEIGHT="100.0" Z="0.3883044638232833">
<NAME>Adverse events: flu syndrome</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="23.661529052450646" CI_START="0.37001469813448684" EFFECT_SIZE="2.958904109589041" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3740428061239074" LOG_CI_START="-0.43178102406295743" LOG_EFFECT_SIZE="0.47113089103047495" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="333" O_E="0.0" SE="1.0607498568238898" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" VAR="1.1251902587519027" WEIGHT="30.58583736079444"/>
<DICH_DATA CI_END="0.9784405543469367" CI_START="0.21029427001542378" EFFECT_SIZE="0.4536082474226804" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="-0.009465554986401776" LOG_CI_START="-0.6771725605737131" LOG_EFFECT_SIZE="-0.34331905778005745" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="525" O_E="0.0" SE="0.39221440028496996" STUDY_ID="STD-Kaji-2013" TOTAL_1="97" TOTAL_2="33" VAR="0.15383213579089866" WEIGHT="46.493676182782615"/>
<DICH_DATA CI_END="95.3595377582692" CI_START="0.3367372773189284" EFFECT_SIZE="5.666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="1.9793641372208304" LOG_CI_START="-0.47270880390360737" LOG_EFFECT_SIZE="0.7533276666586115" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="329" O_E="0.0" SE="1.4403597835733117" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="2.0746363061353574" WEIGHT="22.920486456422946"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04103962851490624" CI_END="2.6173148193892706" CI_START="0.5079878136480046" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1530672281918681" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="0.41785596417614274" LOG_CI_START="-0.29414670608007154" LOG_EFFECT_SIZE="0.06185462904803561" METHOD="MH" MODIFIED="2016-04-22 17:01:11 +0100" MODIFIED_BY="Ana Raquel Marques" NO="31" P_CHI2="0.8394615527777847" P_Q="1.0" P_Z="0.7334495873413376" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="66" WEIGHT="100.0" Z="0.34054042288242886">
<NAME>Adverse events: pain</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8874862025957793" CI_START="0.40764744555183074" EFFECT_SIZE="1.084931506849315" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.46051991769644873" LOG_CI_START="-0.38971527475837353" LOG_EFFECT_SIZE="0.035402321469037594" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="332" O_E="0.0" SE="0.49943236078004277" STUDY_ID="STD-Brashear-1999" TOTAL_1="73" TOTAL_2="36" VAR="0.2494326829943268" WEIGHT="68.94683058247918"/>
<DICH_DATA CI_END="5.8089080353862865" CI_START="0.2928817672880637" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.7640945009313121" LOG_CI_START="-0.533307663527173" LOG_EFFECT_SIZE="0.11539341870206957" MODIFIED="2015-12-17 12:33:09 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="331" O_E="0.0" SE="0.7621004536472048" STUDY_ID="STD-Lew-1997" TOTAL_1="92" TOTAL_2="30" VAR="0.5807971014492753" WEIGHT="31.053169417520824"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-04-22 17:01:40 +0100" MODIFIED_BY="Ana Raquel Marques">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-04-22 17:01:40 +0100" MODIFIED_BY="Ana Raquel Marques" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAaYAAARPCAYAAABUAkXuAABzqUlEQVR42uydD2RW7///vySTzMTM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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-04-22 16:40:33 +0100" MODIFIED_BY="Ana Raquel Marques" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAAFLCAMAAAApq17iAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-04-22 16:40:33 +0100" MODIFIED_BY="Ana Raquel Marques" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZcAAAIZCAIAAADlVuVvAAAfYklEQVR42u3dsY4USdaG4ZKQEEYb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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-04-21 19:33:26 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-04-21 19:33:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-12-15 12:57:07 +0000" MODIFIED_BY="Ana Raquel Marques">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-04-21 19:33:16 +0100" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor: [Botulinum Toxins] explode all trees</P>
<P>#2 MeSH descriptor: [Botulinum Toxins, Type A] explode all trees</P>
<P>#3 (botul* near/2 tox*):ti,ab</P>
<P>#4 (botox or dysport or xeomin or myobloc or rimabotulinum* or abobotuli* or onabotulinum* or oculinum or</P>
<P>purtox or CNBTX or Neuronox):ti,ab</P>
<P>#5 {or #1-#4}</P>
<P>#6 MeSH descriptor: [Animals] explode all trees</P>
<P>#7 MeSH descriptor: [Humans] explode all trees</P>
<P>#8#6 not #7</P>
<P>#9#5 not #8</P>
<P>#10 (cervic* near/2 dysto*):ti,ab</P>
<P>#11 blepharosp*:ti,ab</P>
<P>#12 (hem* near/2 spasm*):ti,ab</P>
<P>#13 (meige and (dysto* or syndrom*)):ti,ab</P>
<P>#14 (crani* near/2 dysto*):ti,ab</P>
<P>#15 (foca* near/2 dysto*):ti,ab</P>
<P>#16 (write* and (cramp* or dysto*)):ti,ab</P>
<P>#17 torticol*:ti,ab</P>
<P>#18 MeSH descriptor: [Dystonic Disorders] explode all trees</P>
<P>#19 MeSH descriptor: [Dystonia] explode all trees</P>
<P>#20 MeSH descriptor: [Torticollis] explode all trees</P>
<P>#21 MeSH descriptor: [Blepharospasm] explode all trees</P>
<P>#22 MeSH descriptor: [Meige Syndrome] explode all trees</P>
<P>#23 MeSH descriptor: [Hemifacial Spasm] explode all trees</P>
<P>#24 {or #10-#23}</P>
<P>#25 MeSH descriptor: [Animals] explode all trees</P>
<P>#26 MeSH descriptor: [Humans] explode all trees</P>
<P>#27#25 not #26</P>
<P>#28#24 not #27</P>
<P>#29#9 and #28, in Trials</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-04-21 19:33:26 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-12-15 12:56:07 +0000" MODIFIED_BY="Ana Raquel Marques">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-04-21 19:33:15 +0100" MODIFIED_BY="[Empty name]">
<P>#1 randomized controlled trial.pt.</P>
<P>#2 controlled clinical trial.pt.</P>
<P>#3 randomized.ab.</P>
<P>#4 placebo.ab.</P>
<P>#5 clinical trials as topic.sh.</P>
<P>#6 randomly.ab.</P>
<P>#7 trial.ti.</P>
<P>#8 1 or 2 or 3 or 4 or 5 or 6 or 7</P>
<P>#9 exp animals/ not humans.sh.</P>
<P>#10 ((randomized controlled trial or controlled clinical trial or randomized or placebo or clinical trials as topic or</P>
<P>randomly or trial) not (animals not humans)).af,pt.</P>
<P>#11 exp botulinum toxins/</P>
<P>#12 exp botulinum toxins, type A/</P>
<P>#13 (botul$ adj2 tox$).ti,ab.</P>
<P>#14 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or</P>
<P>purtox or CNBTX or Neuronox).ti,ab.</P>
<P>#15 11 or 12 or 13 or 14</P>
<P>#16 exp animals/ not humans/</P>
<P>#17 ((botulinum toxins or botulinum toxins, type A or (botul$ adj2 tox$) or (botox or dysport or xeomin or</P>
<P>myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or purtox or CNBTX or Neuronox)) not</P>
<P>(animals not humans)).af.</P>
<P>#18 (cervic$ adj2 dysto$).ti,ab.</P>
<P>#19 blepharosp$.ti,ab.</P>
<P>#20 (hem$ adj2 spasm$).ti,ab.</P>
<P>#21 (meige and (dysto$ or syndrom$)).ti,ab.</P>
<P>#22 (crani$ adj2 dysto$).ti,ab.</P>
<P>#23 (foca$ adj2 dysto$).ti,ab.</P>
<P>#24 (write$ and (cramp$ or dysto$)).ti,ab.</P>
<P>#25 torticol$.ti,ab.</P>
<P>#26 exp dystonic disorders/</P>
<P>#27 exp dystonia/</P>
<P>#28 exp torticollis/</P>
<P>#29 exp blepharospasm/</P>
<P>#30 exp meige syndrome/</P>
<P>#31 exp hemifacial spasm/</P>
<P>#32 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31</P>
<P>#33 exp animals/ not humans/</P>
<P>#34 (((cervic$ adj2 dysto$) or blepharosp$ or (hem$ adj2 spasm$) or (meige and (dysto$ or syndrom$)) or</P>
<P>(crani$ adj2 dysto$) or (foca$ adj2 dysto$) or (write$ and (cramp$ or dysto$)) or torticol$ or dystonic disorders or</P>
<P>dystonia or torticollis or blepharospasm or meige syndrome or hemifacial spasm) not (animals not humans)).af.</P>
<P>#35 10 and 17 and 34</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-04-21 19:33:22 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-12-15 12:56:44 +0000" MODIFIED_BY="Ana Raquel Marques">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-02-10 07:47:42 +0000" MODIFIED_BY="[Empty name]">
<P>#1 random$.tw.</P>
<P>#2 clinical trial:.mp.</P>
<P>#3 placebo$.mp.</P>
<P>#4 double-blind$.tw.</P>
<P>#5 1 or 2 or 3 or 4</P>
<P>#6 5</P>
<P>#7 limit 6 to human</P>
<P>#8 (cervic$ adj2 dysto$).ti,ab.</P>
<P>#9 blepharosp$.ti,ab.</P>
<P>#10 (hem$ adj2 spasm$).ti,ab.</P>
<P>#11 (meige and (dysto$ or syndrom$)).ti,ab.</P>
<P>#12 (crani$ adj2 dysto$).ti,ab.</P>
<P>#13 (foca$ adj2 dysto$).ti,ab.</P>
<P>#14 (write$ and (cramp$ or dysto$)).ti,ab.</P>
<P>#15 torticol$.ti,ab.</P>
<P>#16 exp Dystonic Disorders/</P>
<P>#17 exp Dystonia/</P>
<P>#18 exp torticollis/</P>
<P>#19 exp blepharospasm/</P>
<P>#20 exp Meige Syndrome/</P>
<P>#21 exp Hemifacial Spasm/</P>
<P>#22 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21</P>
<P>#23 22</P>
<P>#24 limit 23 to human</P>
<P>#25 (botul$ adj2 tox$).ti,ab.</P>
<P>#26 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or</P>
<P>purtox or CNBTX or Neuronox).ti,ab.</P>
<P>#27 exp Botulinum Toxins/</P>
<P>#28 exp Botulinum Toxins, Type A/</P>
<P>#29 25 or 26 or 27 or 28</P>
<P>#30 29</P>
<P>#31 limit 30 to human</P>
<P>#32 7 and 24 and 31</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_z1309131047147899672215461982225_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1309131047147899672215461982225">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1408111518211702342261129499685_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1408111518211702342261129499685">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_6005_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="6005">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_FDF5556E82E26AA201D6C2758D661DA8_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="FDF5556E82E26AA201D6C2758D661DA8">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1307091141448665579807736261374_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1307091141448665579807736261374">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1309131050199323179683584225320_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1309131050199323179683584225320">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies (1 new study) included in qualitative and quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1450 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1450 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1667 records identified in total&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;189 records identified through CENTRAL database search&lt;/p&gt;&lt;p&gt;436 records identified through MEDLINE database search&lt;/p&gt;&lt;p&gt;1042 records identified through EMBASE database search&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1438 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;8 full-text articles excluded:&lt;/p&gt;&lt;p&gt;- 2 non-randomized non-controlled&lt;/p&gt;&lt;p&gt;- 2 non-blinded, non-controlled&lt;/p&gt;&lt;p&gt;- 1 wrong population&lt;/p&gt;&lt;p&gt;- 1 non-blinded&lt;/p&gt;&lt;p&gt;- 1 analysed two other trials&lt;/p&gt;&lt;p&gt;- 1 data not available&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>